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Abstract.
The first section of this thesis presents a review of the literature on
endocrine hormones, synthetic steroids, and synthetic steroid receptor
antagonists. Particular emphasis is placed upon the estrogen, progesterone
and glucocorticoid activity of these compounds. The structure, activity and
preparation of some progesterone/glucocorticoid receptor antagonists is
also reviewed.
The second section of this thesis presents a route for the synthesis of
19-aryl substituted androstanes. These compounds have been designed to
explore their potential antiprogestational and antiglucocorticoid activity. It
is demonstrated that a bulky aromatic functionality may be introduced at
the sterically hindered C-19 methyl group, by the nucleophilic attack of an
organometallic nucleophile on a 10~-formyl-19-norandrostane, which is
suitably protected at positions C-3 and C-17. The subsequent careful
manipulation of the C-3 and C-17 functionalities has led to a succesful 11
step synthesis (scheme 4.19) of 17~-hydroxy-17a-(prop-l-yne)-19-(p-N,N-
dimethylaminophenyl)androst-5-en-3-one (3.1), which should be of interest
for biological evaluation.
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Section 1; Literature Reyiew
Chapter I.
Hormones and the Endocrine System.
LL Structure and nomenclature of steroids.
Steroids are a class of widely occurring compounds. In the vast majority
of steroids, the junctions of rings B, C and C, D are trans'!
(fig. 1.1).
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3
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Figure 1.1 The basic ring system of steroids
The methyl groups attached at the positions C-I0 and C-13 of the ring
junctions are called angular methyl groups) By convention, other groups that
lie on the same side of the molecule as these two methyl groups, are designated
as P-substituents, whilst groups on the opposite side are designated as (X-
substituents.! In systematic nomenclature, the nature of the alkyl group at
position C-17 determines the base name of the individual steroid: e.g.
androstanes have no C-17 alkyl group, whilst pregnanes carry a 2-carbon side
chain.l
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U Nature of hormones.
Hormones are specialised chemical messengers which help to co-ordinate
the activities of cells in a multicellular organism.V' They are secreted by the
cells of endocrine glands, usually directly into the blood stream, in response to
some external stimuli (fig. 1.2).2-4 They can then be carried by the circulatory
system to most of the tissues in the body. Despite the wide distribution of the
hormone, only certain cells are capable of responding to this chemical
messenger, because they contain a specific receptor protein which will bind with
the molecule.Z-' In different target cells a hormone may give rise to different
responses+ and is effective at very low levels of blood concentrations.e+
Target cells
Capillary
network
Figure 1.2 Hormones are carried through the
circulatory system to target cells
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Figure 1.3 Locations of endocrine
glands in the human body.
The endocrine cells, hormones and target cells integrate to form one of
the most important communication systems of the body, known as the Endocrine
System (fig. 1.3).2-4 This system is responsible for the control and regulation of
a diverse number of physiological processes; it regulates blood pressure, water
and electrolyte balance, reproduction, growth, metabolic rate and responses to
stress.2-4
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At the highest level of control of the endocrine system is the
hypothalamus, which is located at the base of the brain within a boney structure
called the sella turcica (fig. 1.4).3 For the most part the endocrine system is
arranged in a hierarchical manner, consisting of 3 tiers (fig. 1.5). Immediately
below the hypothalamus lies the pituitary gland (second tier), to which it is
connected by a hypothalamic extension called the pituitary stalk) At the third
tier are the various endocrine glands.
Third Ventricle Pineal Gland
Figure 1.4 The locations of the pituitary gland and the
hypothalamus at the base of the brain.
It is at the hypothalamus that both the endocrine system and nervous
systems are linked physically and by fuucrion.J The bridging function is
mediated by cells that have properties of both nerve cells and endocrine cells.
They possess nerve processes that carry electrical impulses but release their
signalling molecules into the blood (fig. 1.6),3 For this reason the endocrine
cells of the hypothalamus are sometimes called neurosecretary cells and the
chemical messengers that they release are called neurohormones.t
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Figure 1.5 The three tier endocrine system.
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Nerves to Primary Capillaries
Superior Pituitary Artery
Inferior Pituitary Artery
Figure 1.6 The anterior pituitary, posterior pituitary
and hypothalamus.
When each of the hypothalamic neurosecretary cells (and its extension,
the posterior pituitary) is stimulated by other nerve cells from higher regions of
the brain, it begins to secrete specific peptide neurohormones into the blood
vessels of the pituitary stalk.2 The neurohormones are then carried to the
anterior pituitary gland by the circulatory system, where they specifically
stimulate or suppress the secretion of a second hormone from the pituitary
gland.2-4 The pituitary hormones then modify the secretary rates of the
endocrine gland into the blood.2-4 Consequently, the hypothalamus serves as the
main regulator of the endocrine sysrem.I+
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L.J Structural diversity of hormones.
Chemically, hormones are diverse, but they generally fall into four
different chemical groups: (1) amines, (2) peptides and proteins, (3) steroids and
(4) prostaglandins.2-4
Noradrenaline (1.1) and adrenaline (1.2) are hormones derived from the
amino acid residue tyrosine and produced by the medulla of the adrenal gland.2-4
The thyroid hormones thyroxine (T4) (1.3) and triiodothyronine (T3) (l.4) are
produced by the thyroid gland.2-4
The majority of hormones are peptides or proteins ranging in size from 3
to 200 amino acids. Oxytocin (1.5) and antidiuretic hormone (ADH) (1.6),
produced by neurosecretary cells in the hypothalamus, are both nona-peptides.
Seven of these amino acids are identical in the two hormones, but the actions of
these hormones are quite different.? The hormones glucagon (produced in the
islets of Langerhans), adrenocorticotrophic hormone (ACTH, produced in the
anterior pituitary) and calcitonin (produced in the thyroid gland), are
polypeptides with about 30 amino acid residues in the chain. Insulin (1.7)
(secreted by the islets of the Langerhans in the pancreas) is a protein consisting
of two peptide chains joined by disulphide bonds.?
The third class are the steroid hormones, derived from cholesterol (1.8),
secreted by the testes, ovaries, placenta and adrenal cortex.I-' The fourth group,
the prostaglandins, are closely related to lipids (fatty acids, each with a 5
membered ring in its structure) synthesised and released by many different
tissues in the body.? Although they are present in very small quantities,
prostaglandins exert a wide range of physiological effects on many tissues.
They are often referred to as local hormones, because they act on cells in their
immediate vicinity.
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Id Cellular Mechanisms of Action.
When a hormone is secreted by an endocrine gland into the blood stream,
it will be carried throughout the body along with 30-40 other hormones+ It then
diffuses through the walls of the capillaries and enters the interstitial spaces.s
The ability of a cell to respond to a hormone depends upon the presence
of a specific receptor which will recognise the hormone and be able to activate a
cascade of activities within the cell. 2 The receptor is a protein or glycoprotein
molecule, which folds into a specific conformation. It is this shape and chemical
composition of a receptor which allows it to bind strongly to the hormone (rather
like a lock and key).S This binding usually occurs through H-bonding,
electrostatic and Van der Waals interactions.s
When the hormone and receptor bind together, they both undergo a
conformational change so that they may form an 'induced fit'. This gives rise to
a tightly bound hormone-receptor complex. The change in conformation of the
receptor protein in this adduct causes the activation of a cascade of reactions
within the cell. This cascade mechanism gives rise to the amplification of the
hormonal signal within the cell.J
The link between hormone receptor binding and physiological response is
mediated by two alternative mechanisms of action, 1,2 depending on the types of
hormones and the receptors to which the hormones bind to: 1) membrane bound
receptors (fig. 1.8) and 2) intracellular receptors. Those hormones which are
soluble in water or which have a high molecular weight (e.g. proteins,
glycoproteins and polypeptides), will not easily be able to pass through the lipid
plasma membrane of the cell and so must bind to membrane bound receptors.
These receptors send a signal into the cell by altering the intracellular
concentration of ions, or by increasing the intracellular concentration of
chemical secondary messengers.
The opening of membrane-bound receptors which are gated ion channels,
has the effect of altering the position of the electrochemical equilibrium that
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exists across the membrane.f In nerve axons, this change may depolarise the
membrane.s which may cause the opening and shutting of voltage dependant
ion channels in the local vicinity of the membrane. In this manner an electrical
signal may be transmitted along the length of a nerve cell axon and hence cause
a physiological response.?
Calmodulin
ION
Membrane
Depolarisation
Ca2+ -Calmodulin
complex +
-------t~'rotein Kinase
~ Physiological
Protein Phosphoralated protein -----t ..~ Response
(inactive) (active)
Figure 1.8 The cellular mechanisms of action of secondary messengers.
Alternatively, a membrane bound receptor may indirectly effect a
physiological response through a secondary messenger. A number of species
have been identified as secondary messengers; cyclic adenosine monophosphate
(cAMP), calcium ions (Ca2+), diacyl glycerol (DO) and inositol trisphosphate
(IP3».6 The secondary messengers directly (cAMP, DO) or indirectly (IP3,
Ca2+), activate protein kinases. These activated protein kinases then activate
inactive proteins by phosphorylation. The phosphorylated proteins give rise to a
physiological response.f
Lipid soluble hormones (e.g. steroids, vitamin D3 and thyroid hormones)
are able to freely diffuse across the lipid soluble plasma membrane and so enter
the cel1.2,6 Intracellular receptors are present in target cells, which exist as a
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heterocomplex of a number of proteins? (receptor protein, heat shock proteins
(hsp) and association proteins)." Each hormone binds with high specificity and
affinity to a region of the receptor protein known as the hormone binding
domain (HBD).8 The binding of hormone and receptor, gives rise to a
conformational change in the receptor protein which activates 'transcription
activation factors' (TAFs) in the receptor protein and the dissociation of the
heterocomplex. The dissociation of one of the heat shock proteins (hsp 90) from
the receptor protein unmasks a region of the receptor protein, termed the DNA
binding domain (DBD).7,8 This region exists as two 'zinc fingers' each
containing a zinc ion tetrahedrally surrounded by four cysteine amino acid
residues from the primary amino acid sequence of the receptor protein.Zf
The DBD binds to a region of the DNA termed the hormone response
element (HRE)8 by insertion of the zinc fingers into the clefts of the DNA
double helix. The binding of DBD to HRE is not sufficient for the activation of
transcription: activated TAFs are also required.f
U Intra cellular receptors.
There are a number of different types of intracellular receptors that exist
in cell systems.f Each receptor is capable of specifically binding to one of the
classes of hormonal thyroid hormones (fig. 1.7), steroids (fig. 1.10), or vitamin
D3 (1.16). All of these receptors belong to a 'super family' of ligand inducible
transcription factors and show a high degree of molecular similarity.x? It has
been postulated that the members of this 'super family' have evolved (e.g. by
point mutations) from a single ancestral receptor gene.f
Due to the evolutionary conservation of essential amino acid sequences,
the primary amino acid sequence can be classified in seven regions; AlB to F.
The receptor proteins all possess a variable N-terminal region (AlB), a centrally
located DNA binding domain (C), a hinge region (D), a hormone binding
domain (E) and a short C-terminal region (F).
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The HBD comprises approximately 250 amino acid residues.S Of the
various domains, the DNA binding domain is the most highly conserved,
comprising approximately 70 amino acid residues with a high content of basic
amino acid residues due to the presence of the cysteine residues in the zinc
fingers.7-9
1.& Steroids and other intracellular hormones.
There are five classes of hormonal steroids that are currently recognised
to exist in mammalian systems; androgens, glucocorticoids, mineralcorticoids,
estrogens (1.14) and progestins.? Vitamin D (1.16), which is derived from
cholesterol (1.8), binds to an intracellular receptor which belongs to the 'super
family' of ligand inducible transcription factors." Androgens (e.g. testosterone
(1.11); synthesised in the testes) regulate male secondary sexual characteristics,
Glucocorticoids (e.g. cortisol (1.12); synthesised in the adrenal cortex) promote
gluconogenisis, formation of glycogen and degradation of fats and proteins.e+
Mineralcorticoids (e.g. aldosterone (l.13)) raise blood pressure and volume by
increasing the net reabsorption of Na+, CI- and HC03- by the kidneys. Estrogens
(e.g. estradiol (1.14); synthesised in the ovary), are responsible for the
development of female secondary sexual characteristics. Progestins (e.g.
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progesterone (1.15); synthesised in the corpus luteum), are responsible for the
maintenance of pregnancy. 2-4
OH OH
o
o 0
Dihydroxytestosterone. Cortisol.
(androgenic). (1.11) (glucocorticoid). (1.12)
o
Aldosterone.
(mineralcorticoid). (1.13)
HO
Estradiol
(estrogenic). (1.14)
o
Progesterone.
(progestational) (1.15)
HO
Dihydroxycalciferol.
(calcium activator). (1.16)
Figure 1.10 Some examples of naturally occurring
ligands that bind to each class of intracellular receptor.
L1 Sex hormones; reKulation and secretion.
The sex steroids (testosterone (1.11), estrogen (1.14) and progesterone
(1.15)) are responsible for the regulation of reproduction in the male and
female.c+ Testosterone is responsible in the male for the control and
development of the testes, spermatogenesis and the development of secondary
male sexual characteristics.2-4,6 Estrogens (1.14) and progesterone (l.15) are
responsible for the development and control of the female genital tract,
secondary female sexual characteristics and the development and function of
the ovaries.e+
There is a common mechanism by which the secretion of the male and
female sex steroids is regulated.2,3 The neurosecretary cells in the hypothalamus
rhythmically release a small peptide hormone called gonadotrophin-releasing
hormone (GnRH) into the hypothalamohypophyseal portal vein, which then
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carries the hormone through the pituitary stalk directly to the pituitary gland,
where it stimulates the pituitary gland to secrete two gonadotrophin hormones;
luteinizing hormone (LH) and follicle stimulating hormone (FSH).2-4,6 These
gonadotrophins are then carried via the circulatory system to the gonads where
they elicit the secretion of the sex steroids.e+
LB.. Male reproductive function.
The male reproductive structures consist of the testes, scrotum,
epididymis, vas deferens, seminal vesicles, prostate gland, urethra and the
penis.e+ At the beginning of puberty, the hypothalamus becomes less sensitive
to the inhibitory effects of testosterone and so levels of GnRH secreted in each
periodic pulse are increased.2,6 This then raises the levels of LH and FSH
secreted by the anterior pituitary and therefore raises the level of testicular
stimulation.?
1
.. - - - - J contain germ cell and Sertoli"'- ___~
cells.2,4.6 Interspersed between the
Hypothalamus ------
1,
GnRH
'- - - - - Anterior pituitarygland
FSH LH
Sertoli cells , Leydig cells
J
1- __ Inhibin
,
Ii --- .r,,,J,,,,",_ -spermatogenesis and
catabolic effects.
Spermatogenesis (production
of sperm) occurs in the seminiferous
tubules of the testes.? these tubules
seminiferous tubules are groups of
Leydig cells.2.6 The germ cells,
which are found close to the basement
membrane of the tubules, divide and
differentiate to produce immature
sperm cells, each containing 23
chromosomes.o The Leydig cells are stimulated by periodic pulses of LH to
Figure 1.11 Hormonal control
mechanism in male
secrete testosterone.e+ The Sertoli cells are stimulated by both testosterone and
FSH to secrete a protein hormone called inhibin and most importantly to
facilitate spermatogenisis by secreting a luminal fluid which nourishes the germ
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cells and developing sperm attached to it.2 The function of inhibin is to down-
regulate the anterior pituitary's secretion of FSH, (it is also thought to down
regulate the hypothalimic secretion of GnRH).6 After ten weeks of development
within the seminiferous tubules.? the sperm cells are released into the lumen of
the seminiferous tubules. The immature sperm are then carried by the luminal
fluid and pass through a network of highly coiled ducts which lead to the
epididymis.v+ The final maturation of the sperm cells occurs during their
twelve day passage through the epididymis.s The pressure of the luminal flow
from the Sertoli cells carries the mature sperm cells into the vas deferens, were
they are stored.? When ejaculation occurs the contents of the vas deferens, pass
through the urethra and acquire the bulk of the ejaculatory fluid from the
seminal vesicles and prostate gland.?
1..2 Female reproductive function.
The female reproductive structures consist of the ovaries, the uterinal
tubes, the uterus, the vagina and the breasts.c+ The physiology of the female
reproductive function is more complicated than that of the male due to the
number of functions it has to perform.e+
Oogenesis (production of ova) occurs In the ovanes, unlike
spermatogenesis in the male, the production of ova in the female is not
continuous, but occurs in two stages.2-4 At the beginning of puberty, the level of
GnRH secretion by the hypothalamus begins to increase+ This stimulates an
increase in the levels of LH and FSH secreted by the anterior pituitary gland, so
raising the levels of estrogens (1.14) and progesterone (1.15) being secreted by
the ovaries+ With the alteration in the hormonal pattern of secretion comes the
beginning of menstrual bleeding and the menstrual cycle.J
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Figure 1.12 The developmental stages that occur
during formation and release of ova.
The menstrual cycle (fig. l.13) prepares the female reproductive
structures for pregnancy. 6 The menstrual cycle is taken as beginning from the
first day of menstruation, which lasts for 3-6 days.2-4 During this time the
superficial layer of the endometrium is shed.2-4 When the menstrual flow stops,
the endometrium is regenerated.? In the first part of the cycle, GnRH secreted
by the hypothalamus stimulates the anterior pituitary gland to secrete increasing
quantities of follicle stimulating hormone (FSH), along with smaller amounts of
luteinizing hormone (LH).6 Both of these hormones cause the development of
small groups of primary follicles in the ovaries.? One of these follicles develops
faster than the others and the remainder degenerate.I The increasing level of
FSH stimulates the granulosa cells to multiply, to secrete a fluid into the centre
of the follicle and to secrete estrogen (1.14).2 The increasing numbers of
granulosa cells form a thicker layer of cells around the oocyte.t+ A fluid-filled
chamber develops within the follicle and a thin capsule of theca cells forms
around it.2-4
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Figure 1.13 The hormonal changes that occur during the
menstrual cycle stimulate follicular development and gives rise
to endometrial changes.
The granulosa cells begin to secrete estrogens (1.14) under the influence
of FSH.2 This has a negative feedback effect on the hypothalamus and the
anterior pituitary gland and so causes their secretary rates to fall to a low ebb at
about the tenth day of the cycle.s During this phase, the endometrium, under the
influence of estrogen, increases in thickness and vascularity.? Then, suddenly,
the anterior pituitary begins to secrete large amount of both FSH and LH, but
especially LH.2-4,6 This surge of secretion is called the LH surge and it is
believed to result from a transient second action of estrogens (1.14)6; a positive
feedback effect. It is this surge that causes the very rapid swelling and rupture
of the main follicle, resulting in ovulation.J The burst follicle then develops into
the corpus luteum, which begins to secrete large amounts of progesterone (1.15)
and continues to secrete estrogens (1.14).2 Both of these hormones have a
negative feedback effect on the hypothalamus and the anterior pituitary.2-4.6
17
Once again FSH and LH secretion diminish and this prevents the development
of a new follicle or ovum.I+ Beside the negative feedback effect, progesterone
(1.15) causes further thickening of the endometrium, initiates secretion of a
nutrient fluid by the endometrial glands, promotes an increase in the blood flow
to endometrial cells, inhibits contractility of uterine smooth muscle, firms the
cervix and inhibits dilatation and prepares the mammary glands for secretion of
milk+
;- .j Hypothalamus ~ _
~G"RH
t---- ... Anterior pituitary r-gland
FSH ~ LHr
Ovary
+ t ~
- - - E"Wg~" \ T IProgesterone - -
I Placenta I
Endometrium
Figure 1.14 Hormonal control
mechanism in male
If implantation of a fertilised
ovum does not occur, then the
corpus luteum will degenerate
because the low levels of FSH
and LH are not able to maintain
it. 6 As a result, the negative
feedback of progesterone (1.15)
and estrogens (1.14) on the
hypothalamus and anterior
pituitary is removed and so the
cycle begins again.f If a
fertilised ovum does implant
itself into the endometrium, then
the early developing foetal tissue and placenta begin to secrete human chorionic
gonadotrophin (HCG). 4 This substance is similar to LH and therefore maintains
the secretion of progesterone (1.15) and estrogen by the corpus luteum. As the
placenta develops, it begins to secrete large amounts of progesterone (1.15) and
estrogens (1.14) and its secretion of HCG diminishes.V' The placenta takes over
from the corpus luteum in the secretion of these two hormones.e+
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.lJJl Adrenall:lands and the adrenal steroids.
The adrenal glands are situated directly above the kidneys.2-4,6
Structurally each of the two glands consists of an inner medulla and an outer
cortex." The adrenal cortex secretes three types of corticosteroid hormones;
minera1corticoids, glucocorticoids and androgens.2-4,6 Minera1corticoids are
secreted by zona glomerulosa cells situated in the outer region of the cortex-
and are responsible for the regulation of water and electrolyte balance. The
principal mineral corticoid secreted by the adrenal cortex is aldosterone.? The
glucocorticoids are secreted by zona fasciculata cells situated in the middle
region of the cortex.? This group of hormones are responsible for the regulation
of increased glycogenesis, protein metabolism, fat metabolism, anti
inflammatory and immunosupressive action.26 These are involved in the body's
response to stress.f Cortisol accounts for 95% of the glucocorticoid activity of
the adrenal cortex.I Glucocorticoid secretion is regulated by the hypothalamus
which secretes corticotrophin releasing hormone (CRF). This hypothalamic
hormone stimulates the anterior pituitary to release adrenocorticotrophin
hormone (ACTH), which has a negative feed back effect on the hypothalamus.2
ACTH stimulates the secretion of glucocorticoids by the adrenal cortex.2-4 The
glucocorticoids have a negative feed back effect on the hypothalamus and
pituitary glands.2-4
Hypothalamus
Abdominal
aorta CRF
~~~~+I_ Middle
artery I~---- Anterior pituitarygland
r~"':::'~____;I--Inferior
'~~_-"_L_artery
ACTH - - - - - - - _
Renal
artery
Adrenal cortex
~
Figure 1.15 The adrenal glands and hormonal - - - - - - - -Glucocorticoids
control mechanism of glucocorticoids.
19
Ll1 References.
(1) T.W.G. Solomons, Organic chemistry; John Wiley and Sons, New York,
1984,976.
(2) E.P. Solomon, R.R. Scmidt, PJ. Andagna, Human anatomy and
physiology, Saunders College Publishing, New York, 1990,564.
(3) L. Crapo, Hormones the messengers of life, W.H. Freeman and Company,
New York, 1985.
(4) A.C. Guyton, Phisiology of the human body, Saunders College
Publishing Holt-Saunders, New York, 1984.
(5) L. Stryer, Biochemistry, W.H. Freeman and Company, New York, 1975,
103.
(6) H.P. Rang, M.M. Dale, Pharmacology, Churchill Livingstone, London,
1987, l.
(7) E-E. Baulieu, Science, 1989, 245, 1351.
(8) H. Gronemeyer, B. Benhamou, M. Berry, M.T. Bocquel, D. Gofflo, T.
Garcia, T. Lerouge, D. Metzger, M.E. Meyer, L. Tora, A Vergezac, P.
Chambon,l. Steroid Biochem. Molec. Bioi., 1992,41,217.
(9) J.W. Funder, Steroid hormone action, (Edited by M.G. Parker), IRL
Press, Oxford, 1993,26.
20
Chapter 2
Steroid Receptor Anta20nists
2.1 Introduction
Steroid receptor antagonists are those compounds which show a
high binding affinity for steroid receptor proteins, without themselves
triggering the normal physiological response controlled by those
receptors.I-? The receptor antagonist will compete with the natural
hormone agonist for binding to the steroid receptor site. Consequently, the
level of physiological response that a given tissue will produce in response
to a given concentration of a hormone will be reduced.6-10
There are a number of important clinical applications for steroid
receptor antagonists. They are clinically used to control fertility 1-3,7-9.1I;
for the treatment of testosterone (1.11),1,4,5 progesterone (1.15)9 and
estrogen (1.14) 1,13 dependant cancers; for treatment of Cushings
syndrome''; and to facilitate fertility.1,3-S,13
U Cellular mechanism of antaKonism.
The mechanism by which steroid receptor antagonists interfere with
their intracellular receptors has not been fully elucidated. The availability of
a number of synthetic steroid receptor antagonists (e.g. RU 38486 (2.40),
tamoxifen (2.15)) with strong antagonist properties and little or no agonist
action has made possible detailed studies of their receptor binding and of
the subsequent effects on DNA activation and terminarion.I+ Such studies
are complicated by the species specific nature of many of the effects.l> e.g.
RU 38486 (2.40) has been shown to bind to and antagonise the
progesterone receptor in humans.s but not in the chick or hamster.I>
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Steroid receptor antagonists may interrupt the process of
transcription activation at three distinct steps (fig. 2.l ).14
1) They may slow down or even inhibit the dissociation of the steroid
receptor heterocomplex (composed of steroid receptor, heat shock proteins
and association proteinsj.l+
2) They may not induce the association of the steroid receptor to the
corresponding response element in DNA.14
3) Interfere with the processes of TAFs of steroid receptors that
normally activate the transcriptional machinery of DNA.14
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The mechanism by which different steroid receptor antagonists
interact and interfere with the transcription activation of DNA varies. The
different steroid receptor antagonists may be classified on the basis of the
mechanism of antagonism into two classes ; Type I and Type II
antagonisrs.I+
Hydroxytamoxifen (2.16), RU 38486 (2.40) and ret 164,384 (2.20)
are all Type I antagonists.P These compounds are able to bind to steroid
receptors and induce the dissociation of the heterocomplex.l The DBD is
then able to bind to the HRE of DNA.1.l4 The binding of the antagonist to
the receptor does not activate TAF-2 which is essential for the activation of
DNA transcription.I-J't As a result the steroid receptor binding to DNA does
not give rise to transcription.I"
Although RU 38486 (2.40) binds with a high affinity to both the
human progesterone and glucocorticoid receptors,16-18 it does not bind to
the corresponding chicken and hamster receptors. IS Substitution of the
cysteine amino acid residue at position 575 for a glycine residue in the HBD
of the chicken progesterone receptor generates a mutated chicken
progesterone receptor that possesses an affinity for the progesterone
receptor antagonist RU 38486 (2.40) which has increased by more than
1000 fold, up to 20% of that for progesterone.!" In fact all receptors that
bind RU 38486 (2.40) posses a glycine at the corresponding position. IS
Type II antagonists (e.g. ZK 98,299 (2.41))1 abolish or severely
decrease the DNA binding capability of steroid receptors.I+ It is not yet
entirely clear by what mechanism this type of antagonism occurs.I+
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U Antiandroeens.
Cypristone acetate (2.1) was the first anti androgen to be
discovered.1,2,4,5,13 It showed progestational activity and also suppressed
the secretion of gonadotrophins. I,2,4 Pure antiandrogens were
subsequently developed that lacked the undesirable side effects.l
Flutamide (2.3) was the first to be developed.l-? In vivo, flutamide (2.3) is
metabolised by the liver to 4-hydroxy flutamide (2.4) which shows a
dramatic 100 fold increase in the affinity for the androgen receptor.1,3,13
Unfortunately this antiandrogen possesses a short half life of approximately
8 hrs.2 Additional antiandrogens with longer half lives were subsequently
developed e.g. Anandron (2.2) (RU 23,908) and Casodex (lCI 176324)
(2.5).1
Cl
Cypristone acetate (2.1)
~N--A-H->=' r~
F3C 0
Anandron
RV 23,908 (2.2)
R
H Flutamide (2.3)
OH 4-Hydroxyflutamide (2.4)
Figure 2.2 Some anti androgens
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2.4 Antiestrol:ens.
MER 25 (2.13) was the first triphenyl synthetic antiestrogen to be
described.t-' Unfortunately this compound was not suitable as a drug due
to its toxicity.L? This compound did however lead to the synthesis of
clomiphene (2.14).1-3 Although these compounds were first developed as
potential contraceptive agents, they were used to aid fertility.l.2.13 The
antagonist effectively removes the negative feedback effect of estrogen
(1.14) on the hypothalamo-pituitary axis.2 This has the effect of increasing
the levels of LH and FSH being secreted by the anterior pituitary gland and
so stimulating fertility.? Many estrogen receptor antagonists (fig. 2.4) were
synthesised in an attempt to asses their contraceptive activity.2
Unfortunately these compounds were not suitable for this purpose and
have instead been used to treat advanced estrogen dependant breast
cancers.1.2.13
To date, tamoxifen (2.15) is the most widely used antiestrogen which
is used for the treatment of estrogen dependant breast cancers. I,2,4 This
compound possesses a triphenylethylene structure. The liver metabolises
tamoxifen and converts it to 4-hydroxytamoxifen (2.16),1.2 and this
conversion increases its affinity for the estrogen receptor site by
approximately 100 fold.? The antiestrogenic activity of tamoxifen is
associated with the alkylamide side chain of the trans configuration of
tamoxifen (2.15) (Zeisomerj.t? The cis configuration (E-isomer) has been
reported to posses estrogenic activity.I?
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Figure 2.4 Antiestrogenic compounds
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~ Pro2estins.
For many years progesterone has been known to inhibit the
development and release of an ovum from the ovaries.20 In this regard
progesterone has been considered as a contraceptive agent'? ,20
Unfortunately progesterone is not orally active due to its rapid metabolism
by the liver.22-28 With this draw back came the pharmaceutical drive for the
discovery of an orally active progestin.20
The first orally active progestin was synthesised by researchers at
Schering who introduced the ethynyl functionality at position 17a in the
testosterone series to afford 17a-ethynyltestosterone (2.22) (ethisterone).21
Later literature reported the synthesis of 19-norprogesterone (2.23)22.23 and
14-iso-17-iso-19-norprogesterone (2.24).24,25 Surprisingly these synthetic
steroids exhibited a pharmaceutical level of activity which was 4-8 times
greater than that of the natural hormone progesterone (1.15).23-25
With the discovery that the removal of the 19-methyl functionality
from progesterone augmented its biological activity,23-25 the researchers at
Syntex applied this methodology to the Schering compound ethisterone
thus affording 19-nor-17a-ethynylethisterone (2.25) (norethisterone ),26
which exhibited a remarkable improvement in activity.26
Since the discovery of norethisterone (2.25),26 additional 19-
norsteroids have been synthesised,27 the first of these was norethindrone
acetate (2.27) which was synthesised at Schering.s? A more interesting
variant is that of lynesterol (2.28) which is devoid of the 3-keto
functionality and was synthesised by Organon.I? Interestingly an of these
synthetic steroids are metabolised by the body into norethisterone (2.25).27
The compound levonorgestrel (2.26) exhibits a lower level of biological
activity than norethisterone (2.25).27
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Figure 2.5 Progesterone receptor agonists
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Other orally active progestins are megestrol acetate (2.29) and
medroxyprogesterone acetate (2.30),7 these compounds both possess a 6-
methyl functionality'? The I7a-acetoxy group of these compound makes
the C-I7a ethan-l-one group on the pregnane skeleton more resistant to
metabolism?
~ Glucocorticoids.
Corticosterone (1.9) and cortisol (1.12) are two hormones secreted by
the adrenal cortex of the adrenal glands.4.13 These naturally occurring
steroids exhibit strong glucocorticoid activity and weak mineralcorticoid
activity.s-U The most important pharmacological actions of glucocorticoids
are their antiinflammatory and antirheumatic activity.f
Commercially a number of potent semisynthetic glucocorticoids have
been developed by structural variation of the natural hormones.4.13.28
Prednisolone (2.31) is an analogue of corticosterone (1.9) which possesses a
double bond at C-I,28 which alters the A-ring geometry and augments
glucocorticoid activity.t The introduction of a 9a-fluoro group and a 160.
or I6~ methyl group gives dexamethasone (2.35) and betamethasone (2.36)
which are amongst the most potent commercially available semisynthetic
glucocorticoids.28
These synthetic glucocorticoids are clinically used to suppress
inflammatory and allergic reactions.4,28 They are also useful in replacement
therapy where patients are suffering from Addisons disease (due to low
level of circulating glucocorticoidsl.P' In patients who suffer from Cushings
syndrome with high levels of circulating glucocorticoids, an antagonist of
the hormone (e.g. RU 38486 (2.40» is useful for controlling the disease."
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Figure 2.6 Synthetic glucocorticoids.
2. 7 Antiproeestins ± Antielucocorticoids.
By the 1970s a number of structurally interesting non-steroidal
estrogens (e.g. trans-diethylstilbestrol (2.10), hexestrol (2.12) and non-
steroidal antiestrogens (MER25 (2.13), clomiphene (2.14), tamoxifen (2.15»
had been discovered.I-3,19
At that time researchers at Roussel-Uclaf were involved in the total
synthesis of cortisone-? and methods for the purification of the estradiol
teceptor.w In the course of studying how small structural alterations affect
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the ability of novel corticosteroids31-34 steroids to bind to and activate their
receptors, the researchers developed a general synthetic strategy by which
alkyl and aryl functionalities could stereospecifically be introduced at the
II ~-position of I 9-norsteroids.16-18,35-37
The strategy primarily relies on two key features, the first involved
the stereospecific synthesis of 5a,IOa-epoxy-9(lI)-ene steroids (2.38»)6-
18,35-37The second key stage involved the treatment of the 5a,IOa-epoxy-
9(ll)-ene steroids (2.39) with lithium organocuprates or copper catalysed
Grignard reagents to give exclusive 11~-substituted-I9-norsteroids with an
excellent yield.16-18,35-37 The researchers at Roussel-Uclaf synthesised a
number of 11~-substituted steroids16-18,35-37which led to the discovery of
RV 38486 (2.40) (mifepristone) possessing antiprogestational and
antiglucocorticoid activity,38,39 The 17a substitution of RV 38486 (2.40)
imparts a higher binding affinity for the receptor and the l lp-ar yl
substitution is responsible for its antagonistic action.16,17,37
R
Scheme 2.1
Following the discovery of RV 38486 (2.40), a great many
analogues were synthesised by Roussel-Vclaf,16-18,35-37 Schering,40-44 and
Organon45 in order to improve their level of activity and receptor
specificity. Although there is some structural variation between these
analogues, the vast majority of antiprogestins, antiglucocorticoids and
antiestrogen analogues'f of RU 38486 (2.40) utilise the synthetic strategy
that was originally developed at Roussel-Uclaf to stereospecifically
introduce 11~ substituents into the steroid ske1eton.I6-18,35-37
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Figure 2.7 Progesterone and glucocorticoid receptor antagonists
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1.1 The synthesis of 5a.lOa-epoxides.
In the course of the synthesis of novel 19-norsteroids, L. Nedelec et
al reported45,46 the synthesis of 9(1l)-en-5a,IOa-epoxides of the general
structural formulae (fig. 2.8).
OR
R
H (2.48)
Bz (2.49)
Figure 2.8 General structure of 9(11)en-5,lOa-epoxides.
The epoxide (2.49) was synthesised in five steps via Birch reduction
of the readily available estradiol methyl ether (2.48) (scheme 2.2, 2.3).45
Hydrolysis of the methyl ether (2.51) led to the deconjugated enone (2.52),
which was converted to the corresponding dieneone (2.53) by a
bromination-dehydrobromination procedure.t'' Ketalization of the dienone
(2.53) afforded the conjugated diene (2.54) with a double bond shift to
5(10),9(11)-diene in 73% yieJd.46
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OBz OBz
MeO MeO
OBz OBz
o o
OBz
73%
p-Toluenesulphonic acid,
CHCI3, ethylene glycol
Scheme 2.2 Synthetic pathway to 5(lO),9(1l)-ketals.
The conjugated diene ketal (2.54) was oxidised with m-chloro
perbenzoic acid in chloroform at OOC (scheme 2.3).46 Under these
conditions the epoxidation occurred regiospecifically to afford a mixture of
3 epoxides which were purified by chromatography to give (2.49), (2.55)
and (2.56) in 41%, 12% and 0.5% yields respectively.w
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OBz
OBz
m-chlorperbenzoic acid,
(2.54) ------~
p-nitroperbenzoic acid.
OBz
Scheme 2.3 Epoxidation of conjugated diene ketal
Although the epoxidation reaction occurred regiospecifically, it did
not proceed in a stereospecific manner and afforded a low yield of the
5a,IOa-epoxide (2.49).46
The researchers at Roussel-Uclaf were able to improve upon the
stereospecificity of the epoxidation procedure when hydrogen peroxide
and hexachloroacetone was used as the oxidant.32,33 This improved the
stereoselectivity and yield of the 5a, lOc-epoxide (2.49) from 41% to 65%
and that of the 5~, 10~-epoxide (2.55) from 12% to 35%.32,33
Workers at Schering were able to improve upon the stereoselectivity
by employing iron(II)phthalocyanine as catalyst and iodosyl benzene as the
oxygen source (scheme 2.4).40 This gave a product mixture of 5a,10a-
epoxide (2.61) (91.6%) and the 5~,10~-epoxide (2.62) (8.4%).
36
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o
OH
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+ OH
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o
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Scheme 2.4
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U RinK openinK of 5a,lOa-epoxides in the synthesis of
106 substituted steroids.
At Roussel-Uclaf the epoxides (2.49, 2.55) were considered to be
intermediates that could potentially lead to novel steroids.lf Nedelec
demonstrated that reduction the of 9(11)-en-5(10)-epoxides (2.49) and
(2.55) with LiAIH4 in THF occurred regiospecifically and
stereospecifically.sv The introduction of the hydride nueleophile at position
C-IO occurred with an orientation that was opposite to that of the original
oxirane (fig. 2.5).46
OBz
(2.49)-------.
LiAIH4/THF
OBz
LiAIH4/THF
OH
(2.59)------.
Scheme 2.5
V sing this methodology the researchers at Roussel- Uclaf embarked
Upon the synthesis of novel lOa and 10~ substituted steroids.31-34.46
Nedelec and Gasc reported the introduction of methyl, ethyl and ethynyl
substituents at the 10~ position and methyl at the lOa position of steroids in
the testosterone series (scheme 2.6).46
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(2.49) -- .. ...
OHOH
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R
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o
OH
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OH
Scheme 2.6
The researchers at Roussel-Uclaf further reported the introduction of
lOp-methyl group in the corticoid series '! (scheme 2.7) and the IOp-ethynyl
group in the hydrocortisone series 32,33 (scheme 2.8).
o
eN
R
H (2.69)
Si(CH3h (2.70)
(2.71)
Scheme 2.7
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o
(2.72) (2.73)
Scheme 2.8
Unfortunately the 10~-ethynyl analogue (2.73) showed a reduced
level of biological activity to that of hydrocortisone.If In spite of this result,
the researchers continued to attempt ring openings of the 50.,1On-epoxide
using various nueleophiles such as azide, thiocyanate and mercaptides
(scheme 2.9).18
OR OR
(2.74) (2.75)
Scheme 2.9
In early 1975, a project had been initiated at Roussel-Uclaf on " New
steroids with anti-allergic or anti-stress activities't.lf The main thrust for this
research was to be directed towards agonists.lf In the original project, the
replacement of the 10~-methyl group by other substituents and the
bioisosteric relationships of a number of chemical modifications at position
C-17 were also to be investigated.If
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0R
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R = H or CH3
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0 OH
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"J (2.78) ~ R = H or CH3(2.79)
Scheme 2.10
It was well known at the time that for progestational steroids, the
17J3-acetyl side chain could be replaced by the 17a-ethynyl-17J3-hydroxy
system without altering the biological activity of the steroid (scheme
2.10).21,26 Similarly it was postulated that 17J3-hydroxy-17a-propionolates
should be used in the corticoid series.If To test this hypothesis, a number of
analogues were synthesised (fig. 2.9).18
-==--R
o
RV 24450 (2.80)
RV 25101 (2.81)
RV 200 (2.82)
RV 25458 (2.83)
Figure 2.9
The carboxylic methyl ester (2.80) exhibited anti-inflammatory
activity but its corresponding acid RV 25101 (2.81) was shown to be
inactive.18,48 To assess whether the ester significantly contributed to
biological activity, the compounds RV 200 (2.82) and RV 25458 (2.83)
were synthesised.18,48 RV 200 (2.82) showed no activity but surprisingly
RV 25458 (2.83) displayed an activity that was four times that of cortisol
( 1.12).18.48
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L.l.ll The discovery of the stereospecific introduction at
C-116·
Meanwhile, Teutsch attempted to synthesise 1O~-phenyl steroids, by
cleavage of the oxirane (2.49) (scheme 2.11 ).36 When the epoxide (2.49)
was reacted with phenyl magnesium bromide, the product was found to be
a mixture of two steroids in a ratio of 4: 1; (2.84) and (2.85).18,36
OBz
Ph Mg Br
(2.49) (2.84) Major 80%
+
(2.85) Minor 20%
Scheme 2.11
The epoxide (2.49) was reacted with diphenyl copper lithium, in the
hope that it would shift the reaction pathway entirely to the 11~-substituted
steroid (2.85), which it did (scheme 2.11).18,36 Later it was demonstrated
that Grignard reagents in the presence of catalytic amounts of copper salts
could also achieve the same 11~-transformation.36
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Scheme 2.12
When benzyl magnesium bromide was used, addition of the benzyl
group went entirely to the 10~-position, but in the presence of cuprous
chloride the group was introduced at the 11~ position (2.88)36 (scheme
2.12). This elegant stereospecific method for the introduction of 11~-
substituents into a sterically hindered environment was the second key
stage in the synthetic methodology,35,36
It was proposed that the mechanism involves the nucleophilic attack
on the epoxide (2.89) from the ~ -face at position 10 by the
organocuprate,35 This causes the opening of the vinyl oxirane (2.89) to
produce an unstable intermediate (2.90) which undergoes an intramolecular
allylic rearrangement (scheme 2.l3).35 Since the organocopper substituent
is attached to the ~ face at position 10, the nucleophilic attack by the alkyl
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functionality upon the sp2 hybridised position at C-l1 in the allylic
rearrangement may only occur stereospecifically from the f3-face to give the
I1f3-steroid (2.91) (scheme 2.l3).38
Scheme 2.13
Although conjugate openmg of an unsaturated epoxide by
Copper(II) modified Grignard reagents or cuprates is not an unusual
procedure,49-52 it is surprising that a large number of bulky groups are able
to overcome the unfavourable sterically hindered situation of position C-
11P which is also in a 1,3-diaxial relationship with the angular C-13 methyl
group_}6
44
2. 11 II-Keto Pathway.
Before the advent of the Roussel-Uelaf strategy, the synthesis of
11p, 19-norsteroids had already been reported for 11p-methylestra-I ,3,5( 10)-
trienes (2.96) which were further transformed to the estra-4-ene series
(2.97).53
x
MeO MeO
x x
MeO
x
R
Methyl
Ethyl
n-propyl
n-butyl
Scheme 2.14
The strategy reported by Kirk and Petrow=' involved the action of
organometallic reagents on an II-keto steroid followed by dehydration and
a catalytic hydrogenation procedure. This methodology was further utilised
in the synthesis of 11p-ethyl estrone and 11p-ethyl, n-propyl and n-butyl
estrenes.54 Unfortunately this scheme is impractical as a general synthetic
strategy for 11P-substituted steroids as it gives a poor yield of the adduct
(2.94) due to competing reduction of the ketone by Grignard
reagent. 16,17,37
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2.12 The Discovery of RV 38486 (2.40).
Researchers at Roussel-Uclaf devised a general strategy that utilised
the stereospecific method of introducing Ilf3-substituents, whilst affording a
flexible choice of 17a substituents.lf The 5(10), 9(ll)-diene ketal (2.104)
was oxidised and reacted with Me3SiCN to form the 17f3-cyano-17-a-
trimethyl silyl ester (2.105).36 This cyanohydrin side chain was chosen as a
protecting group for position C-17 as it could easily be transformed into a
variety of functionalities at an appropriate step (scheme 2.15). 36
Epoxidation of the cyanohydrin (2.105) followed by a nucleophilic
addition with a copper-catalysed Grignard reagent gives the 1113-
substituted 5a-hydroxy-9(10)-ene ketal (2.107).36 Functionalisation of
(2.107) at the position C-17 and reflux of the 17a-ethynylproduct (2.108)
in aqueous ethanol in the presence of sulphonic resin (Redex Cf.) gave the
Ilf3-substituted dienone (2.109).36
CN OH
"'--MeM-gB-' Ct)·O_SiM:_3
aBH4
- {j)
(2.98) (2.99) (2.lO0)
HC-C-Li
OHtb-=
(2.lO2)
Scheme 2.15 The accessibility of a variety of 17
functionalities from 17-cyano-17 -trimethylsilyl ether.
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Scheme 2.16 1) Cr03/Me3SiCN, 2) H202/CI3CCOCCI3, 3) R2CuLi or
RMgX, CuCI4) R-, THF 5) H3Q+
Having established this general strategy for the synthesis of 11f3-
substituted 19-norsteroids, the researchers investigated how chemical
modifications of 11f3-functionalities affect the relative binding affinity
(RBA) of steroids in the 19-nortestosterone (2.11 0) and 19-norpregnane
series (2.112).16-18 Some were 17a-benzoates and others had 17a-hydroxy
progesterone (2.111) type substituents which had been known to be
damaging to progesterone receptor binding.16-18,35-37 The binding affinities
of the compounds synthesised were assessed by Philibert.Je Further 11f3-
substituted 19-norsteroids were synthesised for the three classes of sex
hormones: progesterone, estrogen and androgen. IS
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Figure 2.10
A wide range of analogues were synthesised with substituents
including alkyl groups (ethyl, n-propyl, i-propyl, t-butyl, n-decyl),36 alkenyls
(vinyl, isopropenyl and allyl),36 aromatics and hetero aromatics (phenyl,
substituted phenyl, benzyl and thienyl).36 Some nitrogen containing
substituents (e.g. pyrazole, pyridine) could not be introduced.ts It was
found that unsaturated 11~-substituents (vinyl, isopropenyl, phenyl. p-
substituted phenyl rings) of the 17a-ethynyl series (2.112) displayed a high
affinity for the progesterone receptor.36.55 This remarkable discovery
indicatedl8 :-
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1) The presence of a hydrophobic pocket in the progesterone receptor,
which was able to accommodate large unsaturated substituents.
2) The remarkable binding specificity of unsaturated substituents;
(vinyl = 535) as opposed to saturated substituents (ethyl = 25) for
the progesterone receptor.
One of the compounds RV 25055 (2.115)16-18,36 which exhibited the
highest RBA for the glucocorticoid receptor was chosen to be tested for its
antiinflammatory action in rat thymus tissue.If The researchers were
working on the assumption that a high binding affinity for the steroid
receptor would relate directly to the agonistic activity at that receptor.l6-18
Surprisingly the compound showed no antiinflammatory activity, which for
the first time suggested the possibility of antagonism.tf
--== R R
(2.115) H
(2.116) C02Me
(2.117) Me
RU25055
RU25402
RU28289o
OH
_--_
RU 25375 (2.118) RU 25593
(2.119)
Figure 2.11
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Since the researchers were also concerned with the bioisosteric
relationships of the 17u-substituents, compounds RU 25402 (2.116) and
RU 25375 (2.118) were synthesised.If Both molecules were tested for
antiinflammatory activity in rat thymus tissue but were shown to be inactive
and to have poor binding affinity.If
With the possibility of antagonism, some of the molecules including
RV 25055 (2.115) and RV 25593 (2.119) were then tested for their ability
to antagonise the effects of dexamethasone (2.35).9,16-18,56 The results
confirmed the antagonistic activity but the results were not clear cut, as
there were problems with the low level of RBA for the glucocorticoid
receptor.te
In order to increase the RBA, there was a switch from the 17u-
ethynyl to the 17u-propynyl substituent, as it conferred an increase in the
RBA for the 11~-hydroxy substituent steroid RV 200 (5 %) (2.82) to RV
25458 (68 %) (2.83) (table 2.1). This alteration had a profound effect as
there was a significant improvement for RBA of the glucocorticoid
receptor.16-18,55
Table 2.1 Relative binding affinity (RBA)
for rabbit uterus progesterone receptor
determined after 2h and 24h of incubation
at O'C in a rabbit uterus preparation. Value
for progesterone is 100.
Code 4hrs 24hrs
RV 200
RV 25458
RU 25055
RV 28289
Cortisol
(2.82)
(2.83)
(2.115)
(2.117)
(1.12)
5
68
135
270
31
55
300
Alongside the glucocorticoid research, an 11~-substituted estradiol
bearing the tamoxifen side chain, as a potential antiestrogen RV 39411
(2.21) was synthesised.ts-t?
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Since the 11P substituted p-fluorophenyl and p-methoxyphenyl
derivatives of the 17a-ethynyl series showed high binding affinity for the
progesterone receptor,16-18,36 the researchers synthesised 17a-propynyl
analogues bearing 11P-(p-fluorophenyl), 11P-(p-methoxyphenyl), 11P_(p_
methylthiophenyl) and I1P-(p-dimethylaminophenYl) analogues (fig.
2.12).16-18 In order to progress quickly, the researchers chose to synthesise
these molecules from the 17a-hydroxy-17P-propynyl-9(ll)-ene_5a,IOa_
epoxide (2.120).16-18 The 17a-ethynyl analogue bearing the llP-p-
dimethylaminophenyl substituent RV 38473 (2.122) was also synthesised.
OH
>
(2.120) 0
I
......N
R
p-F-phenyl
p-MeO-phenyl
p-MeS-phenyl
p-MezN-phenyl
RV 38140
RV
RV
RV 38486
(2.123)
(2.124)
(2.125)
(2.40)
o
RV 38473 (2.122)
Figure 2.12
51
Table 2.2 Relative binding affinity (RBA) for rat thymic
glucocorticoid receptor determined after 4h and 24h of incubation at
O°C in a rat thymus preparation. Value for dexamethasone (2.35) is
100
RBACode R' R" 4h 24hRV 25055 (2.115) 2-thienyl H 136 54RV 28289 (2.117) 2-thienyl Me 268 299RV (2.126) p-MeO-phenyl H 237 87RV (2.124) p-MeO-phenyl Me 279 299RV 25593 (2.119) p-F-phenyl H 45 23RV 38140 (2.123) p-F-phenyl Me 216 283RV 38473 (2.122) P-Me2N-phenyl H 279 235RV 38486 (2.40) 12-Me2N-Ehen~I Me 283 302
OH
- R "--
o
When the RBA of these molecules was evaluated for rat thymus
glucocorticoid receptor, it became clear that the propynyl functionality
significantly enhanced the RBA for the glucocorticoid receptor (table
2.2).16-18,55. The RBA of RV 38486 (2.40) and RV 38473 (2.122) were
most potent (table 2.2).16-18,55
Table 2.3 Antiglucocorticoid activity on hepatic trypsin pyrolase in
adrenalectomysed rats.
Code Dose (mg/kg)
"
10
1
2.5
10
100
% inhibition of the effect
of dexamethasone (2.35)
100
18
65
94
100
RV 38473 (2.122)
RV 38486 (2.40)
"
"
The antiglucocorticoid activity was not the only outstanding feature
of RV 38486 (2.40), as when the RBA of this compound was evaluated for
the five classes of steroid receptors it exhibited an affinity for rabbit uterus
progesterone receptor which was more than five times greater than that for
the natural hormone progesterone (1.15) (table 2.4).16-18,39,55
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In vivo, RV 38486 (2.40) was completely able to antagonise the
abili ty of progesterone (1.15) to cause endometrial growth of estradiol (1.14)
treated immature female rabbitss? and interrupt pregnancy in both female
rats and monkeys (Macaca fasciculariss.s-s» This in vivo result confirmed
that RV 38486 (2.40) acts as a progesterone receptor antagonist.
Table 2.4 Relative binding affinity (RBA) for rabbit uterus
progesterone receptor determined after 2h and 24h of incubation
at O°C in a rabbit uterus preparation. Value for progesterone is
100.
Code R' RIO
RBA
RV 25055
RV 28289
RV
RV
RV 25593
RV 38140
RV 38473
RV 38486
(2.115)
(2.117)
(2.126)
(2.124)
(2.119)
(2.123)
(2.122)
(2.40)
2-thienyl H
2-thienyl Me
p-MeO-phenyl H
p-MeO-phenyl Me
p-F-phenyJ H
p-F-phenyl Me
p-Me2N-phenyl H
p-Me2N-phenyJ Me
4h 24h
70 85
230 438
130 335
136 506
38 36
46 85
81 350
78 530
Clinical trials of RV 38486 (2.40) in human volunteers showed that it
was possible to bring about the termination of early pregnancy (up to a
week after menstruation had been expected) in 80% of patients.I-3,7-9,11
When a prostaglandin was administered 36-48 hrs after the administration
of RV 38486 (2.40), the success rate dramatically improved to 96%.9 This
synergistic combination of RV 38486 (2.40) and prostaglandins was also
shown to be successful in 96% of patients for up to three weeks passed the
missed period.2,3,9,11,18,39
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lJ.J Potent anaIo2ues of RV 38486 (2.40),
Researchers at Schering similarly discovered that ZK 98.299 (2.41)
and ZK 98.734 (2.43) also displayed antiglucocorticoid effects.l-3.40-42
These compounds were also tested for their ability to bind to other steroid
receptors. As with RU 38486 (2.40), these compounds were shown to
exhibit antiprogestational and antiglucocorticoid activity in vitro.Vs
Researchers at Organon (Oss, Netherlands) reported that some 18-
dimethylaminophenyl-19-norsteroids are equipotent to RU 38486 (2.40) as
regards to the termination of early pregnancy in rat after oral administration,
but surprisingly display no glucocorticoid activity in vitro+» The most
potent of their series of compounds were Org 31343 (2.42) and Org 31167
(2.45).45 Organon reported that their compounds were far more active
when administered orally as opposed to subcutaneously.45 This was an
interesting finding as it indicated that the compounds were being
metabolised by the liver into biologically active intermediates. This idea
was further supported by the fact that these synthetic compounds also
showed a low binding affinity for the progesterone receptor in vitro and
that no glucocorticoid activity was exhibited in vivo in a test system for
termination of early pregnancy in rat.45 Unfortunately little
pharmacological data has been reported by Organon and their synthetic
route to 18-dimethylaminophenyl 19-norsteroids has not been published at
all.
The Schering strategy (scheme 2.17, 2.18) for the synthesis of their
related compounds ZK 98.299 (2.41) and ZK 98.734 (2.43),40.42,58.59 is
similar to that for RU 38486 (2.40) discussed above. The 17f3-hydroxy
dienone (2.127) was ketalised using 2,2-dimethyl-l,3-dihydroxypropane to
give the 5(lO),9(l1)-diene ketal (2.57) product with shifted double bonds.w
Epoxidation of (2.57) produced the vinyl epoxy ketal (2.58).40 The 11f3-
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substituent was introduced using copper catalysed Grignard reagents to
give the llf3-aryl-5a,17f3-dihydroxy-9(lO)-ene ketal (2.128).40 Oppenauer
oxidation of this intermediate gave the 9(lO)-en-17-one (2.129), which was
then treated with the litho derivative of propargyl tetrahydropyranyl ether
to afford (2.130).40 Hydrogenation and deprotective dehydration using
acid-catalysed conditions led to the compound ZK 98.734 (2.43).40
In the preparation of ZK 98.299 (2.41),40,42 following the Oppenauer
oxidation, the next step involved the photolysis of the intermediate (2.129)
in dioxane using a mercury high pressure lamp. Ring opening by a Norrish-
type I cleavage and subsequent recombination of the radical sites afforded
the l Irz-methyl gonane (2.132) in good yield.40 Treatment of (2.132) with
the litho derivative of propargyl tetrahydropyranyl ether 'afforded the 1713-
substituted product (2.133).40 Hydrogenation of the 1713 adduct (3.133)
followed by deprotective dehydrogenation under acid catalysed conditions
led to the desired conjugate dienone ZK 98.299 (2.41).40
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Schering employed a stereospecific and regiospecific 6-endo-trig
cyclisation of aryl radicals to gain entry to a series of 1113,19- bridged
steroids (scheme 2.19).41,43 The introduction of the llf3,19-bridged
structural element was accomplished surprisingly easily in two steps from
5a, 1Oa-epox y-3,3-(2,2-dimethylpropylenedioxy )-9( 11)-estren-17f3-01 (2.58).
The protocol leading to the methylene or sulphur bridged compounds
(scheme 2.19),41,43 involved SN2 opening of the 5a,10a-epoxide (2.58) by
(2-haloaryl)methyl magnesium halides, or by the corresponding
thiophenolate, to furnish 10f3-substituted steroids (2.135). The second step
involved the regiospecific radical initiated intramolecular cyclisation of the
19-(2-haloaryl)-9(l1 )-androstene derivatives (2.135).41,43 The phenyl
radical was generated by the action of lithium or tributylstannane, on the
aryl halide (2.135). Intramolecular ring closure of the aryl radical (2.136)
with the 9( 11) double bond can theoretically occur by a 6-endo trig or a 5-
exo trig cyclisation.w Both of these processes are favoured according to
Baldwin's rules, but investigations carried out by Beckwith et a160.61
suggest that the 6-endo trig cyclisation has a lower relative energy for the
transition state than does the 5-exo trig cyclisation transition state.
Schering later developed the synthesis of C-19 oxygen bridged
steroids (scheme 2.20).44 The intermolecular epoxide opening by the weak
nucleophile phenolate/phenol was not succesful even when assisted by
base or lewis acid condltions+' Instead the strategy of cyclisation was
reversed, by utilising the procedure presented by Teutsch et al,35 to
introduce an (orthomethoxy)arene into the l lji-position (2.143). The
formation of the bond between the aryl oxygen and C-IO carbon atom by
the nucleophilic attack of a phenolate/phenol on a new 5a,1 Oa-epoxide
(2.145) would become an en tropically favoured intramolecular process+'
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R
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Section 2 Synthetic approach to 19-aryl steroids
Chapter 3
Strate&y for Desi&n and Synthesis of 19-aryl steroids.
U Introduction.
Historically, natural chemical products have provided the oldest and
richest source for new drugs! (e.g. penicillin, morphine). These natural
chemicals have evolved for a specific function in biological systems.' The
activity of such compounds can therefore be exploited for a
pharmacological effect. Modern pharmacological random screening
methods have meant that natural products have continued to be a rich
source for drug leads.2,3 This rather expensive random method does not
make any assumption about structure activity relationships and may
uncover biological activity in novel structures.? Alternatively in cases
where lead compounds exist, a vast number of structural analogues may be
synthesised for biological screening, in order to discover drugs which
exhibit improved activity.' This method requires large chemical and
financial resources.
U Desien by Receptor Fit.
The biological activity of a drug is related to its ability to bind to the
active site of a receptor molecule. The nature of this binding is dependant
on the topology and electronic architecture of the ligand and receptor site.
A more rational approach to drug discovery is to design a ligand which best
fits the atomic constraints of the active site in the receptcr.e-' A variety of
methods can be used to gain access to the structural and electronic detail of
an active site. The most informative method is to obtain an X-ray
crystallographic structure of the crystallised receptor protein) This method
is only useful for relatively small proteins as most can not be crystallised.
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Alternatively a vague 3-dimensional map of the active site may be generated
by the use of molecular probes to explore the shape, size and polar
characteristics of the active site'
U Receptor Specificity.
Since the late 1970s, there has been intense research activity in the
design and synthesis of novel antiprogestational and antiglucocorticoid
agents.f This has culminated in the discovery of the potent steroid receptor
antagonist RU 38486 (2.40).5 Unfortunately no receptor specific
antagonist has been reported in the literature for the progesterone or
glucocorticoid receptors. In this work it is proposed to synthesise a steroid
receptor antagonist which may possess an enhanced receptor specificity.
M Receptor Fit and RHA.
In the absence of any crystallographic data for the crystallised pure
progesterone, glucocorticoid receptor protein, or receptor steroid complex,
the only way to determine the electronic and steric environment of the
active site is through molecular comparisons of the steric and electronic
features of molecular probes which exhibit a good RBA for the receptor.
The RBA of a ligand is considered to be a good method of evaluating the
degree to which a ligand may fit an active site.6
From the structures of molecules which exhibit a good RBA for the
progesterone and glucocorticoid receptors (fig. 2.7),6 it can be deduced that
the features of a C-3 carbonyl functionality conjugated to a C-4 double
bond, with a 17~-hydroxy functionality are condusive to the binding of
steroids to the progesterone and glucocorticoid receptors. Notable
exceptions to this general rule are the 17a-hydroxy functionality of ZK
98.299 (2.41), the 17~-(ethan-l-one) functionality in progesterone (1.15)
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and natural occurring glucocorticoids (1.12). Most of the antagonists of
these two receptors (fig. 2.7) possess an aryl functionality located on the ~-
face of a steroid. The aryl functionality is also observed in a number of
receptor antagonists of estrogen, (e.g. tamoxifen (2.15), clomiphene (2.14)).
For the vast majority of the antagonists (fig 2.7) there is a high degree
of structural similarity in the steroid skeleton with some difference of
hybridisation states of carbons at positions C-I, C-2, C-9 and C-IO. The
polar functions at positions C-3 and C-17 are responsible for a good RBA
and the substituted aryl functionalities are responsible for antagonistic
activity. The aryl functionalities are located at a number of different
position in the steroid skeleton
U StrateKies for the synthesis of 19 substituted steroids.
Steroids which possess a good RBA and a substituted aryl
functionality on the ~-face of the steroid (position 9, 10, II, 18, 19) which are
able to reach into the hydrophobic pocket of the receptor are of
pharmaceutical interest. The objective of this work is the synthesis of 170.-
propynyl-17~-hydroxy-19(p-dimethylaminophenyl)androst-4-en-3-one
(3.1). Retro-synthetic analysis (scheme 3.1) suggests that this type of
structure should be obtained by using a carbanion or organometallic reagent
to displace a C-I9 leaving group from a steroid whose A and Dring
functionalities are suitably protected. This strategy requires the preparation
of an intermediate steroid bearing a C-19 functionality which can be
converted into a good leaving group.
A number of 19-hydroxy steroids occur on the biosynthetic pathway
to estradiol from testosterone," unfortunately these naturally occurring
steroids are not available in large quantities and are extremely expensive to
purchase commercially. Naturally occurring 19-hydroxy steroids therefore
do not appear to be suitable starting materials.
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(3.1) P = Protecting group
L = Leaving group
Scheme 3.1
(3.2)
In principle, enzymatic oxygenation methods offer a promising
approach for the C-19 hydroxylation of non active C-19 methyl steroids
(adrenal incubation and microbiological hydroxylation methods). However,
such reactions have been reported to be characterised by low and
unpredictable yields.f Fortunately, chemical methods have been developed
and reported in the literature for the functionalisation of position C-19.4.9.10
One of the strategies relies upon free radical intramolecular attack on a
suitably located non-active group.P-!" A second strategy was reported by
researchers at Roussel-Uclaf.f they reported that a benzyl group could be
introduced into the IO~ position of a 19-norsteroid epoxide (3.3), by the
action of benzyl magnesium bromide as the nucleophile (scheme 3.2).4 This
method could be used to synthesis the target molecule (3.1) (scheme 3.3).
eN
- ·OSiMc3
OH
Scheme 3.2
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MeO
OH OH
OH OH
o OH
OH
Scheme 3.3 A synthetic route to 19-substituted steroids via a 5a, lOa-epoxide
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In principle this route could be used in achieving our own objectives
via the synthesis of the epoxide intermediate (3.9). In developing the
strategy for a multistep synthesis, one must evaluate the choice of starting
materials and number of stages involved as the overall yield exponentially
diminishes during the course of such a synthesis. Commercially
dehydroisoandrosterone is available at a fifth of the cost of the methyl ether
of estradiol (3.5). With these considerations it was chosen to explore a
route based on the funtionalisation of position C-19 in an androstane.
OH
3, 17~-estradiol 3-methyl ether
Sigma g = £62.70
MeO
o
Dehydroisoandrosterone-5-ene
3~-acetate.
Sigma 5g = £16.80
25g = £61.20
Dehydroisoandrosterone- 5-ene.
Sigma 5g = £12.00
25g = £44.50
250g =£315.30
Figure 3.1 relative cost of proposed stating materials
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l.:.i 19-Norsteroids froID 19-fuoctiooalised steroids.
With the synthesis of 14-iso-17 -iso-19-norprogeseterone came the
discovery that the removal of the 19-methyl functionality did not reduce,
but raised the level of biological activity of the steroid as a progestin,7,12,13
Ehrenstein et al reported that 19-norsteroids could be synthesised from 19-
oxygenated steroids since the 19-hydroxy, carbonyl and carboxylic
functionalities underwent conversion with base to the 19-norsteroid.13-15
With the realisation of the importance of 19-oxygenated steroids, a method
to functionalise the 19-methyl position was developed.9-11,16-18 A method
of intra-molecular transannulation of the C-18 and C-19 methyl
functionalities has been developed by researchers at Syntex9,10 and by
Barton et al.I6
OH
oHO
Scheme 3.4 The first reported synthesis of 19-norsteroids.
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la1 Transannular oxn:enation of saturated carbon atoms
via an intramolecular attack by a cationic or radical
oXYl:enation species.
The earliest reported example of an intramolecular transannular
oxygenation of a saturated carbon atom is for the conversion of 1,3,3-
trimethylcyclohexylperoxide (3.17) into the corresponding bicyclic ether
(3.18) by treatment with benzenesulphonyl chloride in pyridine.I?
··tr~
(3.17)
Para-nitro benzene
sulphonyl chloride
~
Pyridine ··e--
, (3.18)
Scheme 3.5
It was suggested in the Iiterarure!? that since the oxygen-oxygen
bond cleavage of the p-nitrobenzene sulphonyl derivative is unlikely to
Occur homolytically under these reaction conditions, the reaction must
therefore proceed via a cationic transition state such as (3.19).
H" -.e "$\ArSO~tj_·
(3.19)
Figure 3.2
Shortly after this report, the first example of a transannular reaction in
a steroid system was published.If 3p,20-Dihydroxypregnane 3-acetate
(3.20) was treated with lead tetraacetate in benzene solution under reflux
(scheme 3.6).18
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Benzene
I
H
(3.21)
Lead tetraacetate
AeO
H (3.20)
Scheme 3.6
Under these reaction conditions, a free radical intramolecular
transannular reaction gave rise to 3~-hydroxy-18,20-oxido-5a-pregnane 3-
acetate (3.21).18 This breakthrough was seen as a potential method that
could be utilised for a partial synthesis of aldosterone as it offered a solution
to the C-18 oxygenation. I I It was against this background that attempts
were made to functionalise the C-19 and C-18 positions from an 11~-
hydroxy group. A benzene solution of 3~, 11~,17~-trihydroxyandrostane-
3,17-diacetate (3.22) was refluxed with lead tetraacerate.U
OAe
x
I
H
(3.23)
I
H (3.22)
AeO
+
OAe OAe
I
H
(3.25)
AeO
H (3.24)
Scheme 3.7
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Although the 11~-hydroxy group is 1,3 diaxially oriented to both the
C-I8 and C-I9 positions, it was reported that there was no trace of the
expected 11~,I8-oxidoandrostane (3.23) or 11~,I9-oxidoandrostane (3.25).
Instead the attempts at a transannular reaction from a 11~-hydroxy group
afforded the l l-keto steroid (3.24). It was reported that the gain in energy
associated with the ketone formation due to the release of steric
compression in the C-ring was probably the governing factor.Jf
OAe OAe
Lead tetraacetate,
benzene,
reflux 18 hrs.
AeO AeO
H (3.27)
68% yield.OH
Scheme 3.8
With the failure to oxygenate the C-I9 position via an intramolecular
transannulation reaction from readily available C-II ~ hydroxy steroids, the
literature methods then focused on oxygenation procedures of the methyl
group from suitable 6~-functionalities, which are 1,3 diaxially oriented to the
C-19 methyl group.9-11,I6,18
The first reported intramolecular oxygenation of the C-I9 position of
a steroid system involved 3~,6~,17~-trihydroxyandrostane 3,I7-diacetate
(3.26).10 This 6P-hydroxy steroid (3.26) was refluxed with lead tetraacetate
in benzene and the reaction afforded 3~, 17~-dihydroxy-6~, 19-oxido
androstane 3,I7-diacetate (3.27).10
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In this reaction the action of lead tetraacetate on a 6f3-hydroxy
steroid gives rise to an alkyl lead intermediate which homolytic ally cleaves
to generated a 6f3-alkoxy radical.'? The 1,3 diaxial arrangement of the 6f3-
alkoxy radical and the C-19 methyl functionality enables the direct ring
closure at C-19 methyl or an abstraction of a C-19 hydrogen generating a
C-19 alkyl radical. Both of these processes occur through a cyclic 6-
membered transition state. The C-19 alkyl radical is oxidised to a C-19
carbonium ion which may then ring close at C-19 (scheme 3.9»)9
RO-H + Pb(OAc)4 -- ..... RO-Pb(OAch + HOAc
RO-Pb(OAch -- .......- RO· + ·Pb(OAch
H
.... AcO
(3.29)
AcO
(3.28) I
I
Br Br
(3.28) .... AcO
(3.30)
I
Br
+
~ H
·Pb(OAch 0'.. \ ,... (3.29)AcO (3.31 )
Br
Scheme 3.9
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In the literature, the stereospecific introduction of a 6p-hydroxy
functionality was reported to occur in four steps from 3p, 17p-
dihydroxyandrost-5-ene diacetate (3.32) (scheme 3.10).10 The action of
hypobromous acid on the androst-5-ene steroid (3.32) in dioxane, afforded
5a-bromo-6p-hydroxy androstane (3.33), oxidation of which gave the 6-
keto steroid (3.34). The 5a-bromo functionality in the 6-keto steroid (3.34)
was removed by reflux with zinc dust in acetic acid to give the 5a- H
androstane (3.35), reduction of which gave the product 3p,6p,17P-
trihydroxyandrostane diacetate (3.36). This compound could then undergo
an intramolecular oxygenation of the C-19 methyl group by treatment with
lead tetraacetate to give 3p,17P-dihydroxy-6p,19-oxidoandrostane diacetate
(3.37) (scheme 3.9).
Treatment of the 6p,19-oxido steroid (3.37) with acetic anhydride
and boron trifluoride led to the cleavage of the oxide bridge to give
3p,6p,17p,19-tetrahydroxyandrostane tetraacetate (3.38).10 This
demonstrated the feasibility of oxygenation of the C-19 position in the
androstane series.
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OAc OAc
o
OAc
OH
OAc
OAc
Scheme 3.10
A number of alternative methods have been reported for the
synthesis of 6~-hydroxy steroids, via the reduction of 6-keto steroids.
Amongst these methods is the nitration-s' of unsaturated steroids followed
by reduction with zinc and acetic acid to afford the 6-keto steroid (3AI).
Also the chromic acid oxidation of boranes has been used to synthesise 6-
keto steroids (3041) (scheme 3.11).21
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Scheme 3.11
A significant advance in the strategy (scheme 3.12) to oxygenate the
C-19 methyl functionality was reported by researchers at Syntex, where
pregnenolone acetate (3.42) was converted into the corresponding
bromohydrin (3.43) by addition of hypobromous acid.U' Treatment of the
5a-bromo-6~-hydroxy pregnane (3.43) with lead tetraacetate afforded the
6~,19-oxido steroid (3.44). The 3~-acetoxy substituent was hydrolysed and
oxidised to the 3-keto functionality to give the 6~,19-oxido-3,20-diketo
steroid (3.46). Reduction of this compound with zinc in isopropyl alcohol
afforded the 19-hydroxypregna-5-ene steroid (3.47).10 The insertion of zinc
in to the carbon bromine bond of the 5a-bromo-6~, 19-oxido pregnane
(3.46) enabled an elimination to take place across the C-5, C-6 carbon bond,
thus affording the 19-hydroxy-5-en-pregenolone (3.49) (scheme 3.13). The
advantage of this methodology was that it was not necessary to remove the
5a-bromo functionality in three synthetic steps before ring cleavage of the
6~,19-oxido ring.
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A further advance in the strategy to oxygenate the C-19 methyl
functionality is the use of the hypoiodite reaction in the intramolecular
transannular step.22 The reaction employs iodine alongside lead tetraacetate
to enhance the formation of the 6~, 19-oxido steroid under photolytic
conditions. In this reaction the alkoxy radical is generated from the
photolytic homolysis of the oxygen-iodine bond of the intermediate
hypoiodite (scheme 3.14).
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Scheme 3.13
As before the alkoxy radical abstracts a hydrogen atom from the C-19
methyl group to form the 19-methyl radical. This intermediate then reacts
with iodine to form the iodohydrin (3.53). The large iodine atom attached to
the C-19 methyl group restricts the free rotation of the methyl group and
locks it in a position where the halogen is directly in line with the C-19 and
the 6p-oxygen atom.23 As before, the 6P-hydroxy group is converted via a
hypoiodite (3.54) into the corresponding 6p-alkoxy radical. The
conformation of the 19-iodomethyl group and the 6p-alkoxy radical is
conducive to cyclisation by homolytic substitution.U
12 + Pb (OAC)4 --.~~ Pb (OAch + AcOI
AcOJ + RO-H -- ..~. ROJ + HOAc
ROI --·~~RO· + I
Scheme 3.14
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~ ~ ~~
,or (3.50) ~ 1xg'51) ~ {
Br Br (3.52)
~~I ~ ~~ ~r~{W.53) {~ (3.54) 1~ (3.55)
Br Br Br
Scheme 3.15
Of interest for our research were publications relating to the synthesis
of 19-hydroxyandrostanes.19-26 In these reports 3f3-hydroxy-6f3,19-
oxidoandrost-17-one 3-acetate (3.58) was a common intermediate, which
could be synthesised from dehydroisoandrosterone 3f3-acetate (3.14) via the
bromohydrin followed by an intramolecular transannular oxygenation as
previously described (scheme 3.16).
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Scheme 3.16
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Researchers in Romania= were able to convert this intermediate
(3.58) to 19-hydroxy-5-en-3,17-dione (3.61) by hydrolysis of the 3~-acetate
(3.58), oxidation of the resulting alcohol (3.59), cleavage of the 6~, 19-oxido
ring followed by conjugation under acidic conditions (scheme 3.17).
BrBr
o
o
Br
Scheme 3.17
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Protection of the C-3 and C-17 positions of 19-hydroxyandrostan-
3,17-dione (3.61) with a suitable leaving group at position C-19 would
afford a steroid which would fulfill all of the structural criteria required for
the key intermediate (3.2) in the previously described strategy.
Researchers at Syntex (1966) described the preparation of 10J3-
angular hydroxymethyl, formyl, carboxyl, chloromethyl, vinyl, ethyl, N,N-
dimethyl carboxamide and N,N-diethyl aminomethyl analogues of various 4-
ene and 5-ene androstenes.J> The synthesis began with 3J3-hydroxy-6J3,19-
oxidoandrost-17-one (3.58).
o o
(3.62)
Br
(3.58)AeO
o o
(3.64) X = Cl
(3.65) X = Br
AeO (3.63) AeO
Scheme 3.18
The features in this report that were particularly interesting for our
research are the synthesis of a 19-tosyl steroid (which subsequently
underwent nucleophilic displacement with both Li'Cl and LiBr) and the
synthesis of the 17-ketal-19-formyl-3J3-acetate (3.68) which was prepared
from the 6J3,19-oxidosteroid (3.58) by ketalization of the 17-ketone to afford
the corresponding ketal (3.66). The 6J3,19-oxido bridge was then cleaved
with zinc in ethanol to afford the 19-hydroxy ketal (3.67) which was
oxidised with Cr03 to afford the 19 formyl steroid (3.68).
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0'1o
AeO
0'1o
AeO (3.67)
Scheme
Given the Syntex publication, it was considered that 19-tosyl and 19-
mesyl functionalities would be ideally suited for nucleophilic substitution at
the C-19 methyl group. Therefore an appropriately protected 19-tosylated
steroid would fulfill all of the structural criteria considered to be essential for
the key intermediate in the previously described strategy.
o
Scheme 3.20
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It was proposed that 3,3:17,17-bisethylenedioxyandrost-5-ene 19-
tosylate (3.70), or 3B,19-dihydroxy-17,17-ethylenedioxyandrost-5-ene 3-
acetate 19-tosylate (3.71)26 would be ideal candidates for the key
intermediate of our synthetic strategy and could be synthesised from the
steroids (3.61) and (3.67).
'0./
11'0o..
Scheme
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Chapter 4 Synthetic approach to C-19 aryl androstanes.
U Introduction.
In line with the synthetic strategy (scheme 3.1) attempts were made to
synthesise a differentially protected steroid at C-3 and C-17, bearing a
leaving group at C-19 as the key intermediate for nucleophilic substitution.
This was to be synthesised from 3p-hydroxyandrost-5-en-17-one 3-acetate
(3.14). The IH NMR (table 4.1) and 13CNMR (table 4.2) of (3.14) were run
in order to follow the reaction.
Table 4.1
400 MHz IH NMR of 3p-hydroxyandrost-5-en-17-one 3-acetate (3.14)
multiplicity chemical shift coupling constant assignment
1 H (d) 5.35 5.0 Hz C-6 H
1 H (t.t) 4.54 5.5 Hz, 11.0 Hz C-3a H
3 H (s) 1.97 acetate methyl
3 H (s) 0.99 Me
3 H (s) 0.78 Me
methylene 2.50-0.90
envelope
Table 4.2
400 MHz 13CNMR of 3p-hydroxyandrost-5-en-17-one 3-acetate (3.14)
chemical shift assignment dept
220.7 17 (C)
170.2 acetate carbonyl (C)
139.7 5 (C)
121.6 6 CH
73.4 3 CH
51.4 9/14 CH
49.9 9/14 CH
47.3 13 C
37.9 CH2
36.2 CH2
36.0 10 C
35.6 CH2
31.3 8 CH
31.2 CH2
30.5 CH2
27.4 CH2
22.6 15(11) CH2
21.1 acetate methyl CH3
20.1 11(15) CH2
19.0 19 CH3
13.5 18 CH3
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4.2 Results and Discussion
o o
Scheme 4.1
In accordance with the literature, I 3f3-hydroxyandrost-5-en-17 -one 3-
acetate (3.14) was stirred at room temperature for 30 minutes with N-
bromoacetamide, perchloric acid and distilled water in dioxane to afford
3f3,6f3-dihydroxy-5a-bromoandrost-17-one 3-acetate (3.57). The product
could not be purified by column chromatography as this facilitated the
formation of the by-product, 3~-hydroxy-5~,6~-oxidoandrost-17-one 3-
acetate (4.1).2 The product was purified by suspension in chloroform at DoC
followed by filtration, this method improved the yield over that cited in the
literature! which employed recrystallisation. The product was identified by
its spectra. The !H NMR (table 4.3) indicated a shift in the position of the C-
6 H doublet from 5.358 to give a triplet at 4.228 with a reduction in the
coupling constant from 5.0 Hz to 2.94 Hz due to the electron withdrawing
nature of the Sa-bromo and 6f3-hydroxy functionalities. The 13CNMR (table
4.4) indicated a shift in the position of C-5 signal from 139.78 to 86.028 and
a shift in the position of C-6 signal from 121.68 to 75.298. The infrared
spectrum provided further evidence for the structure with the appearance of
a free 0-H stretch at 3479 cm! and C-O stretch at 1729 cm+, The mass
spectra showed signals consistent with the structure, the El-MS exhibited
signals at 428, 426 both corresponding to the two molecular ions. The CI-
MS(NH4+) exhibited signals at 446, 444 corresponding to the two (MNfLt+)
IOns.
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Table 4.3
400 MHz 1H NMR of 3~,6~-dihydroxy-5a-bromoandrost-17-one 3-acetate
(3.57)
multiplicity
1 H (t,t)
1H (t)
3 H(s)
3 H (s)
3 H (s)
methylene
envelope
chemical shift coupling constant assignment
5.45
4.22
2.02
1.34
0.87
1.00-2.55
5.48 Hz, 10.96 Hz C-3a H
2.94 Hz C-6a H
acetate methyl
C-19 Me
C-18 Me
Table 4.4
400 MHz l3C NMR of 3~,6~-dihydroxy-5a-bromoandrost-17-one 3-acetate
(3.57)
chemical shift Dept
220.68
170.36
86.02
75.29
71.85
50.68
47.72
47.49
40.41
38.21
35.70
34.94
33.35
31.21
30.21
26.17
21.56
21.23
20.47
17.75
13.82
assignment
17
acetate carbonyl
5
6
3
9/14
13
9/14
10
8
15/(11)
acetate methyl
11/(15)
19
18
(C)
(C)
(C)
CH
CH
CH
C
CH
C
CH2
CH2
CH2
CH2
CH2
CH
CH2
CH2
CH3
CH2
CH3
CH3
Following the original method for oxygenation of the C-19 methyl
groups.I 3~,6~-dihydroxy-5a-bromoandrostan-17-one 3-acetate (3.57) was
refluxed with lead tetraacetate in benzene. The product was purified by
silica gel column chromatography to give 3~-hydroxy-5a-bromo-6~,19-
oxidoandrost-17-one 3-acetate (3.58). Unfortunately however the yield by
this procedure was unsatisfactory (23%) for a long synthetic strategy.
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In accordance with the Iiterature.t 3~,6~-dihydroxy-5a-bromo
androstan -17-one 3-acetate (3.57) was refluxed with lead tetra acetate and
iodine in carbon tetrachloride and irradiated with light from halogen lamps, to
afford 3~-hydroxy-5a-bromo-6~,19-oxidoandrost-17-one 3-acetate (3.58) in
quantitative yield. The product was purified by silica gel column
chromatography (acetonitrile/dichloromethane) and identified by its spectra.
The 1H NMR (table 4.5) indicated the loss of the C-19 methyl signal that was
present at 1.348 in the precursor (3.57). This was accompanied by the
appearance of two doublets (each integrating to 1 H), one at 4.098 and the
other at 3.948 with a geminal coupling constant of 8.50 Hz. This
corresponding to the two chemically different C-19 hydrogens. The infrared
spectrum provided further evidence for the structure with the absence of any
free O-H stretch. The El-MS exhibited signals at 426 and 424 both
corresponding to the two molecular ions. The CI-MS(NH4+) exhibited
signals at 444, 442 both corresponding to two (MNH4+) ions.
Table 4.5
400 MHz 1H NMR of 3~-hydroxy-5a-bromo-6~, 19-oxidoandrost-17 -one 3-
acetate (3.58)
multiplicity chemical shift coupling constant assignment
1H (t.t)
1H(d)
1H(d)
1 H(d)
3 H(s)
3 H (s)
methylene
envelope
5.16
4.09
3.94
3.72
2.01
0.88
1.01-2.47
5.28 Hz, 10.56 Hz
4.28 Hz
8.52 Hz
8.48 Hz
C-3a. H
C-6aH
C-19 H
C-19H
acetate methyl
C-18 Me
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Table 4.6
400 MHz BC NMR of 3~-hydroxy-5a-bromo-6~,19-oxidoandrost-17-one
3-acetate (3.58)
chemical shift assignment
219.70
170.00
81.73
74.06
69.54
67.35
50.88
49.18
48.57
48.00
45.80
41.04
35.51
32.84
31.66
31.16
26.62
23.09
21.68
21.13
14.01
17
acetate carbonyl
18
In accordance with the literarure.> 3~-hydroxy-5a-bromo-6~,19-
oxidoandrost-17-one 3-acetate (3.58) was hydrolysed with sodium
hydroxide solution in methanol to give 3~-hydroxy-5a-bromo-6~, 19-
oxidoandrost-17-one (3.59). The product was purified by recrystallisation
and identified by its spectra. The IH NMR (table 4.7) indicated a shift in the
position of the C-3aH signal from 5.16b to 4.14b. The l3C NMR (table 4.8)
indicated the presence of 19 signals with the loss of the acetate signal from
170.00b. The infrared spectrum showed the appearance of a free OH
adsorption signal at 3439 cm+, El-MS exhibited signals at 384 and 382
corresponding to the two molecular ions. CI-MS(NH4+) exhibited signals at
402 and 400 corresponding to the two (MNH4+) ions.
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Table 4.7
400 MHz 1H NMR of 3~-hydroxy-5a-bromo-6~, 19-oxidoandrost-17 -one
(3.59)
multiplicity chemical shift coupling constant assignment
1H (t.t)
1H(d)
1H(d)
1 H(d)
3 H (s)
methylene
envelope
4.14
4.12
3.96
3.73
0.91
1.14-2.50
4.85 Hz, 10.49
4.07 Hz
8.45 Hz
8.47 Hz
C-3aH
C-6H
C-19 H
C-19 H
C-18 Me
Table 4.8
400 MHz BC NMR of 3~-hydroxy-5a-bromo-6~, 19-oxidoandrost-17-one
(3.59)
chemical shift
220.38
81.89
75.08
67.55
66.61
49.29
48.75
48.16
45.82
44.81
35.64
32.92
31.76
31.32
30.41
23.46
21.80
21.22
14.01
assignment
17
18
In accordance with the literature.t 3~-hydroxy-5a-bromo-6~, 19-
oxidoandrost-17-one (3.59) was oxidised with chromium trioxide in pyridine
to give 5a-bromo-6~,19-oxidoandrost-3,17-dione (3.60), which was then
reduced by reflux with zinc dust in ethanol and treated with dilute sulphuric
acid to afford 19-hydroxyandrost-4-en-3,17-dione (3.61).5 The product was
purified by silica gel chromatography (acetonitrile/dichloromethane) and
identified by its spectra. The 1H NMR (table 4.9) exhibited a 1 hydrogen
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singlet at 5.890 corresponding to the C-4 olefinic hydrogen which shows no
coupling. This was accompanied by a shift in the position of the two
chemically different geminally coupled C-19 hydrogens to 4.030 and 3.890
with an increase in the 2J coupling constant from 8.50 Hz to 11.75 Hz. The
infrared spectrum provided further evidence for the structure with the
reappearance of a free OH stretch at 3494 cm-! and three double bond
stretches at 1738 cm+, 1658 crrr! and 1618 cm+. El-MS exhibited a signal at
302 corresponding to the molecular ion. Cl-MS(N~+) exhibited signals at
320 and 303 corresponding to the (MN~+) and (MH+) ions.
Table 4.9
400 MHz IH NMR of 19-hydroxyandrost-4-en-3,17-dione (3.61)
multiplicity chemical shift coupling constant assignment
1H (s) 5.89 C-4 H
1H (d) 4.03 11.5Hz C-19 H
1H (d) 3.89 12.0Hz C-19 H
3 H (s) 0.87 C-18 Me
methylene 1.00-2.77
envelope
Unfortunately, attempts to synthesise 3,3:17,17-bisethylenedioxy
androst-5-ene (3.69) by ketalisation of 19-hydroxyandrost-3,17-dione (3.61)
were unsuccessful due to the instability of the neopentyl 5-ene system. This
problem could theoretically be overcome by altering the sequence of
reactions in the synthetic strategy (scheme 4.2). Ketalisation of 5a-bromo-
6~,19-oxidoandrostan-3,17-dione (3.60) would furnish 3,3:17,17-
bisethylenedioxy-5a-bromo-6~, 19-oxidoandrostane (4.2) which could be
reduced by reflux with zinc in ethanol to afford 3,3:17,17-bisethylenedioxy-
19-hydroxyandrost-5-ene (3.69). Tosylation of this product would afford
the desired key intermediate 3,3:17,17-bisethylenedioxy-19-hydroxyandrost-
5-ene 19-tosylate (3.70) (scheme 4.2).
Although this is a viable strategy, the route was not pursued as a
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differentially protected intermediate (e.g. 3~, 19-dih ydroxy-17, 17-ethylene
dioxyandrost-5-ene 3-acetate 19-tosylate (3.71» was considered to offer a
synthetic advantage in the strategy as the C-3 and C-17 positions could be
selectively chemically manipulated.
0'1
o
o
o
Br Br
Scheme 4.2
At this point a route from 3~, 19-dihydroxyandrostan-5-en-17-one 3-
acetate (3.62) was explored. This compound could be synthesised by the
reduction of 3~-hydroxy-5a-bromo-6~,19-oxidoandrostan-17-one 3-acetate
(3.58).6 The idea of this strategy being that a leaving group could be
introduced at C-19 and the C-17 carbonyl functionality could be protected
(scheme 4.3).
In accordance with the Iiterature.f 3~-hydroxy-5a-bromo-6~, 19-
oxidoandrostan-17-one 3-acetate (3.58) was reduced by reflux with zinc
dust in ethanol to afford 3~, 19-dihydroxyandrostan-5-en-17-one 3-acetate
(3.62). The product was purified by recrystallisation and identified by its
spectra. The IH NMR (table 4.10) indicated the shift of the C-6aH from
4.090 to the olefinic region at 5.770. The infrared spectrum exhibited a free
OH absorption signal at 3463 cm'. CI-MS(Nf14+) exhibited signals at 364
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and 347 corresponding to the (MN~+) and (MH+) ions respectively
o 0
AeO
o
Scheme 4.3
Table 4.10
250 MHz IH NMR of 3~,19-dihydroxyandrostan-5-en-17-one 3-acetate
(3.62).
multiplicity chemical shift coupling constant assignment
1H(m)
1B (t.t)
1B(d)
1B(d)
3 H(s)
3 H (s)
methylene
envelope
5.78-5.76
4.61
3.86
3.60
2.00
0.90
2.46-1.06
4.80 Hz, 11.50 Bz
11.52 Hz
11.48 Hz
C-6B
C-3uB
C-I9 B
C-19 H
acetate methyl
C-18 Me
In accordance with the literature." 3B.19-dihydroxyandrostan-I7-one
3-acetate (3.62) was stirred with tosyl chloride in dry pyridine to afford
3B,19-dihydroxyandrostan-5-en-17-one 3-acetate 19-tosylate (3.63). The
product was purified by silica gel column chromatography and identified by
its spectra. The IH NMR (table 4.11) indicted the appearance of two pairs of
doublets in the aromatic region at 7.408 and 7.768 with a vicinal coupling
constant of 7.5 Hz. This was accompanied by a reduction in the geminal
coupling constant between the two C-19 hydrogens from 11.50 Hz to 10.00
Hz. The l3C NMR (table 4.12) exhibited 24 chemically different signals. The
signal at 21.508 resulted from the coincidence of 2 signals. The infrared
spectrum provided further evidence for the structure with a carbonyl stretch
at 1733 cm-I. The CI-MS(NH4+) exhibited a peak at 518 corresponding to
the (MN~+) ion.
Table 4.11
250 MHz IH NMR of 3~,19-dihydroxyandrostan-5-en-17-one 3-acetate 19-
tosylate (3.63).
multiplicity chemical shift assignment
2H(d)
2H(d)
1H(m)
1H (t.t)
1H(d)
1H(d)
3 H (s)
3 H(s)
methylene
envelope
7.76
7.40
5.64-5.61
4.56
4.15
3.88
2.44
0.75
2.2-0.75
coupling constant
7.4
7.6
aromatic H
aromatic H
C-6H
C-3aH
C-19H
C-19H
5.0 Hz, 11.0 Hz
10.0
10.0 Hz
acetate methyl
C-18 Me
Table 4.12
400 MHz l3C NMR of3~,19-dihydroxyandrostan-5-en-17-one 3-acetate 19-
tosylate (3.63).
chemical shift assignment
220.46
170.25
144.82
133.34
132.62
129.74
127.74
127.02
72.60
69.44
51.91
49.75
47.36
39.91
37.65
35.56
32.61
31.98
31.33
29.95
27.46
21.50
21.16
20.69
13.42
17
acetate carbonyl
1'/4'
1'/4'/5
1'/4'/5
2'/3'
6
18
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Attempts were made to synthesise 3~, 19-dihydroxy-17, 17-ethylene
dioxyandrostan-5-ene 3-acetate 19-tosylate (3.71) by the reflux of 3~,19-
dihydroxyandrostan-5-en-17-one 3-acetate 19-tosylate (3.63) with p-
toluenesulphonic acid, ethylene glycol and dry benzene in a Dean and Stark
apparatus (scheme 4.3). The steroid was not stable under these conditions
and so the product could not be isolated.
AeO
o
AeO
(3.71)
Scheme 4.4
An alternative strategy (scheme 4.4) via the ketalisation of 3~, 19-
dihydroxyandrostan-5-en-17-one 3-acetate (3.62) and subsequent
introduction of a leaving group was considered to offer a suitable route to
3~,19-dihydroxy-17, 17-ethylenedioxyandrostan-5-ene 3-acetate 19-tosylate
(3.71). Attempts were made to ketalise 3~,19-dihydroxyandrostan-5-en-17-
one 3-acetate (3.62) by reflux with p-toluenesulphonic acid, ethylene glycol
and dry benzene in a Dean and Stark apparatus. The product could not be
isolated due to the instability of the neopentyl hydroxy 5-ene system under
these reaction conditions. This meant that protection of the C-17
functionality was necessary prior to the reductive cleavage of the 6~, 19-
oxido ring.
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A strategy was explored via the ketalisation of 3J3-hydroxy-5a-
bromo-6J3,19-oxidoandrost-17-one 3-acetate (3.58) by refluxing for four
hours with ethylene glycol, p-toluenesulphonic acid and dry benzene in a
Dean and Stark apparatus to give 3J3-hydroxy-5a-bromo-6J3,19-oxido-17,17-
ethylenedioxyandrostane 3-acetate (3.66). These reaction conditions also
caused concomitant partial hydrolysis of the 3J3-acetate and therefore a low
yield. This would cause a serious problem for the overall yield in the
synthetic strategy.
Br
o
Br
Scheme 4.5
We also explored an alternative strategy (scheme 4.6) which involved
the ketalisation of 3J3-hydroxy-5a-bromo-6J3, 19-oxidoandrost-17-one (3.59),
followed by an acetylation of the 3J3-a1cohol (4.3) to assess whether this
would provide a more suitable route to 3J3-hydroxy-5a-bromo-6J3,19-oxido-
17,17-ethylenedioxyandrostane 3-acetate (3.66).
BrBr
IBr
Scheme 4.6
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3f3-Hydroxy-5a-bromo-6f3,19-oxidoandrost-17-one (3.59) was
refluxed for 4 hours with ethylene glycol, p-toluenesulphonic acid and dry
benzene in a Dean and Stark apparatus to afford 3f3-hydroxy-5a-bromo-
6f3,19-oxido-17,17-ethylenedioxyandrostane (4.3). The product was purified
by silica gel column chromatography (acetonitrile/dichloromethane) and
identified by its spectra. The IH NMR (table 4.13) exhibited a 4 H multiplet
in the region 3.738 -3.888 corresponding to the C-17 ketal functionality.
The l3C NMR (table 4.14) indicated the presence of 21 signals with the shift
of the position of the C-17 signal from 220.388 to 118.918 and the
appearance of two ketal signals at 65.068 and 64.428. The infrared spectrum
exhibited no carbonyl absorption signal. The CI-MS(NH4+) exhibited signals
at 444 and 446 corresponding to the two (MNH4+) ions and signals at 426
and 428 corresponding to the (MH+) ions. This was accompanied by a new
signal at 99 which corresponds to the ketal ion fragment.
Table 4.13
250 MHz IH NMR of 3f3-hydroxy-5a-bromo-6f3,19-oxido-17,17-
ethylenedioxyandrostane (4.3).
multiplicity chemical shift coupling constant assignment
I H (t.t) 4.06
IH (d) 3.09
4 H (m) 3.88 - 3.73
1H (d) 3.83
I H (d) 3.64
3 H (s) 0.81
methylene 2.30-1.02
envelope
4.54 Hz, 10.80 Hz
4.53 Hz
C-3aH
C-6aH
ketal H's
C-19 H
C-19 H
C-18 Me
8.45 Hz
8.32 Hz
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Table 4.14
400 MHz l3e NMR of3~-hydroxy-5a-bromo-6~,19-oxido-17,17-
ethylenedioxyandro;;_;;s~ta~n~e~()....4~.3~)~.:;--__ -:-- _
chemical shift assignment
118.91 17
82.10 5
75.03 6
67.48 3
66.80 19
65.06 ketal
64.42 ketal
48.48
48.25
46.35
45.72
44.91
34.15
33.45
32.14
30.85
30.44
23.52
22.00
21.84
14.53
15
11
18
3P- Hydrox y-Su-bromo-ojl, 19-oxido-17, 17-ethylenedioxyandrostane
(4.3) was re-acetylated by stirring with freshly distilled acetic anhydride in
dry pyridine to give 3P- hydroxy-Sa- bromo-ob, 19-oxido-17, 17 -ethylene
dioxyandrostane 3-acetate (3.66). An easier synthesis of 3~-hydroxy-5a-
bromo-Sjl, 19-oxido-17, 17-ethylenedioxyandrostane 3-acetate (3.66) was by
ketalisation of 3p-hydroxy-5a-bromo-6p,19-oxidoandrost-17-one 3-acetate
(3.58) followed by acetylation. In accordance with the literature 3P-
hydroxy-5a-bromo-6~,19-oxidoandrost-17-one 3-acetate (3.58) was
refluxed for four hours with ethylene glycol, p-toluenesulphonic acid and dry
benzene in a Dean and Stark apparatus to afford 3p-hydroxY-5a-bromo-
6~,19-oxido-17,17-ethylene dioxyandrostane 3-acetate (3.66). These
reaction conditions also caused concomitant partial hydrolysis of the 3P-
acetate. In order to maximise the final yield, the crude mixture was re-
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acetylated by stirring with freshly distilled acetic anhydride in dry pyridine.
In both reactions the product was purified by silica gel column
chromatography (acetonitrile/dichloromethane) and identified by its spectra.
The IH NMR (table 4.15) exhibited a 4 H multiplet in the region 3.770 - 3.900
(beneath which was concealed one of the C-19 H doublets giving a total
integral over this region of 5 H). The l3C NMR (table 4.16) indicated the
presence of 23 signals with the shift of the position of C-17 signal from
219.700 to 118.830 and the appearance of two ketal signals at 65.070 and
64.420. The infrared spectrum exhibited an absorption signal at 1733 cm-l
corresponding to the 3~-acetate carbonyl group. The El-MS exhibited
signals at 470 and 468 corresponding to the two molecular ions. This was
accompanied by a signal at 99 which corresponds to the ketal ion fragment.
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Table 4.15
250 MHz IH NMR of 3~-hydroxy-5a-bromo-6~, 19-oxido-17 ,17-
ethylenedioxyandrostane 3-acetate (3.66).
multiplicity chemical shift coupling constant assignment
1H (t.t) 5.11 5.12 Hz, 10.24 Hz
1H (d) 3.99 4.43 Hz
5 H 3.90 - 3.77
(4 H(m) + 1H
(d)
1H(d)
3 H (s)
3 H (s)
methylene
envelope
3.66
1.95
0.81
2.30-0.99
8.40 Hz
C-3aH
C-6aH
ketal H'S +
C-I9 H
C-I9H
acetate methyl
C-18 Me
Table 4.16
400 MHz l3C NMR of 3~-hydroxy-5a-bromo-6~,19-oxido-17,17-
ethylenedioxyandrostane 3-acetate (3.66).
chemical shift assignment
170.22 acetate carbonyl
118.83 17
80.03 5/6/19
74.05 3/5/6/19
69.81 3/5/6/19
67.37 5/6/19
65.07 Ketal
64.42 Ketal
48.32
48.18
46.32
45.75
41.15
34.12
33.43
32.10
30.37
26.73
23.18
21.93
21.82
21.20
14.51 18
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In accordance with the literature? 3~-hydroxy-5a-bromo-6~,19-oxido-
17,17-ethylenedioxyandrostane 3-acetate (3.66) was refluxed for 3 hours
with zinc dust (freshly activated with acetic acid) in ethanol (with the
apparent pH adjusted to 5.5 with glacial acetic acid) in order to cause
elimination across the 5 - 6 C-C bond to give 3~,19-dihydroxy-17,17-
ethylenedioxyandrost-5-ene 3-acetate (3.67). The careful adjustment of pH
of the solvent was important as otherwise concomitant partial hydrolysis of
the 3~-acetate occurred. The re-acetylation of the 3~-hydroxy functionality
was not suitable at this stage as it would also bring about the acetylation of
the newly formed 19-hydroxy functionality. The product was purified by
recrystallisation from acetone/hexane and identified by its spectra. The 1H
NMR (table 4.17) indicated a shift of the C-6 H doublet from 3.99~ to the
olefinic region at 5.74~. The position of the two chemically different,
geminally coupled C-19 hydrogens changed to 3.82~ and 3.58~ with an
increase in the 2J coupling constant from 8.40 Hz to 11.0 Hz. The 13C NMR
(table 4.18) indicated the presence of 23 signals with the disappearance of 3
signals from 80.03, 69.81,67.37, the reappearance of a C-5 olefinic signal at
134.39~, C-6 olefinic at 127 .84~ and a new signal for C-19 at 62.59~. The
infrared spectrum provided further evidence for the structure with the
reappearance of a free O-H stretch at 3494 cm-1 and two double bond
stretches at 1732 and 1712 cm-1 corresponding to the acetate C=O double
bond stretch and the C-5 C-C double bond stretch. The El-MS exhibited
signals at 390 and 99 corresponding to the molecular ion and ketal ion
fragment.
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Table 4.17
400 MHz IH NMR of 3~,19-dihydroxy-17,17-ethylenedioxyandrost-5-ene 3-
acetate (3.67).
multiplicity chemical shift coupling constant assignment
1H(d)
1H (t.t)
4H(m)
1 H (d)
1 H (d)
3 H(s)
3 H (s)
methylene
envelope
5.74 4.96 Hz
4.61 5.41 Hz, 10.42Hz
3.93-3.82
3.82
3.58
2.00
0.88
0.99- 2.46
10.6Hz
1l.4 Hz
C-6H
C-3aH
ketal H'S
C-19 H
C-I9H
acetate methyl
C-18 Me
Table 4.18
400 MHz 13CNMR of3~,19-dihydroxy-17,17-ethylenedioxyandrost-5-ene
3-acetate (3.67). --:-_':'"""""'::--:-':"';:':-"__ --:-_~---
chemical shift assignment
170.38 acetate carbonyl
134.39 5
127.84 6
119.25 17
73.21 3
65.03 ketal
64.39 ketal
62.59 19
51.23
49.97
45.76
41.44
38.03
34.04
33.41
33.00
30.67
30.42
27.91
22.40
21.23
21.00
14.45
15
11/ acetate methyl
11/ acetate methyl
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p-Toluenesulphonyl chloride was stirred with 3~,19-dihydroxy-17.17-
ethylenedioxyandrost-5-ene 3-acetate (3.67) in dry pyridine, to afford 3~.l9-
dihydroxy-17,I7-ethylenedioxyandrost-5-ene 3-acetate 19-tosylate (3.71 ).8
The product was purified by silica gel chromatography (acetonitrile/
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dichloromethane) and identified by its spectra. The 1H NMR (table 4.19)
exhibited two chemically different doublets in the aromatic region, each
integrating to 2 hydrogens at 7.12(5 and 7.55(5 with a coupling constant of
7.88 Hz. This was accompanied by the appearance of a new 3 hydrogen
singlet at 1.78(5 corresponding to the aromatic methyl substituent. The
infrared spectrum showed the disappearance of the free OH stretch signal.
The CI-MS(NfI4+) exhibited signals at 568, 545 and 99 corresponding to the
(MNfI4+), (MH+) ion peaks and ketal ion fragment.
Table 4.19
250 MHz IH NMR of3~,19-dihydroxy-17,17-ethylenedioxyandrost-5-ene 3-
acetate 19-tosylate (3.71).
multiplicity chemical shift assignment
IH(d) 7.55
1H (d) 7.12
1H(m) 5.37
1H (t.t) 4.35
1H (d) 3.87
1 H (d) 3.76
4 H (m) 3.75-3.44
3 H (s) 2.22
3 H (s) 1.78
3 H (s) 0.46
methylene 0.15-0.80
envelope
coupling constant
7.98 Hz
7.78 Hz
.aromatic H
aromatic H
C-6H
C-3aH
C-19H
C-19H
ketal H's
acetate methyl
tosyl methyl
C-18 Me
5.25 Hz, 12.01 Hz
10.18 Hz
10.08 Hz
.ia.J Nucleophilic substitution reaction at neopeptyl sites.
Attempts were made to introduce a phenyl substituent at the C-19
neopentyl methyl group by nucleophilic displacement of the C-19 tosyl
leaving group from 3~, 19-dihydroxy-17, 17-ethylenedioxyandrost-5-ene 3-
acetate 19-tosylate (3.71), with phenyl lithium or phenyl magnesium bromide
in ether or tetrahydrofuran.? The nucleophilic substitution did not proceed,
even when the chelating agent N,N,N',N'-tetramethylethylenediamine was
used to increase the nuc1eophilicity of the phenyl anion.
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PhLi/PhMgBr
ether /
tetrahydrofuran II"...r=;
-N N-
\ /
AeO
Scheme 4.7
Although nucleophilic substitution of the tosyl leaving group from the
C-19 neopentylic site had been reported with lithium chloride and lithium
bromide." when we used phenyl lithium, the displacement of the tosylleaving
group did not occur. It is considered that the level of steric hindrance in the
reaction is sufficient to prevent substitution from occurring. The effect of
steric hindrance may be minimised by reducing the size of the leaving group
and nucleophile. Since the aromatic functionality is an essential feature in
the desired compound, only the leaving group was changed. In order to
minimise the effects of steric hindrance we synthesised the corresponding C-
19 mesyl steroid (4.5) (scheme 4.8).
O/j
o
Mesyl chloride,
pyridine, rt.
AeO
PhLi/PhMgBr
ether/tetrahYdrOfur~
r=;
-N N-
\ /
Scheme 4.8
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Methanesulphonyl chloride was stirred with 3~,19-dihydroxy-17,17-
ethylenedioxyandrost-5-ene 3-acetate (3.67) in dry pyridine, to afford 3~, 19-
dihydroxy-17,17-ethylenedioxyandrost-5-ene 3-acetate 19-mesylate (4.5).8
The product was purified by silica gel chromatography (acetonitrile/
dichloromethane) and identified by its spectra. The IH NMR (table 4.20)
indicated the appearance of a new three hydrogen singlet at 1.37S
corresponding to the mesyl methyl group. The l3C NMR (table 4.21)
indicated the presence of 24 signals. The infrared spectrum exhibited a
carbonyl stretch at 1734 cm+. El-MS exhibited peaks at 468 and 99
corresponding to the molecular ion and ketal ion fragment.
Attempts to introduce a phenyl group at the C-19 position by the
nucleophilic attack of the C-19 mesyl leaving group by phenyl lithium or
phenyl magnesium bromide in ether or tetrahydrofuran failed. When a
chelating agent was used, the substitution reaction still did not proceed.
Interestingly the researchers at Roussel-Uclaf have also tried to
develop a synthetic route to C-19 substituted steroids from C-19
hydroxyandrostanes.I" but reported that they encountered extreme difficulty
when working at the hindered C-19 neopentylic site.lO
Table 4.20
400 MHz IH NMR of3~,19-dihydroxy-17,17-ethylenedioxyandrost-5-ene 3-
acetate 19-mesylate (4.5).
multiplicity chemical shift coupling constant assignment
1H(m) 5.71-5.69
1H (t,t) 4.58
5 H (m) 3.97 - 3.76
(4 H (m)+ 1 H (d))
1H(d)
3 H (s)
3 H (s)
3 H (s)
methylene
envelope
4.78 Hz, 11.44 Hz
3.56
1.97
1.37
0.85
l.01-2.49
11.48 Hz
C-6H
C-3aH
ketal H's +
C-19 H
C-19 H
acetate methyl
mesyl methyl
C-18 Me
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Table 4.21
400 MHz l3C NMR of 3~,19-dihydroxy-17,17-ethylenedioxyandrost-5-ene
3-acetate 19-mes)',~la~t~e~(4~.5;;....:)~'~ __ ---: _
chemical shift assignment
170.30 acetate carbonyl
134.43 6
127.57 5
119.17 17
73.18 3
64.94 ketal
64.30 ketal
62.50 19
51.14
49.91
45.68
41.34
37.97
33.96
33.30
32.92
30.60
30.38
27.84
26.68
22.34
21.14
20.93
14.37
15
11/ acetate methyl
11/ acetate methyl
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X
OTosyl (4.6)
OMesyl (4.7)
Cl (4.8)
Br (4.9)
I (4.10)
PhLi/PhMgBr '?
X 1 ether or ~
-':; tetrahydrofuran
3~1 1/.
r=;
-N N-
\ I
(4.11)
Scheme 4.9
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The problem of displacing C-I9 leaving groups was further
investigated using neopentyl derivatives as model systems. p- Toluene
sulphonyl chloride was stirred with neopentyl alcohol in dry pyridine, to
afford 2,2-dimethylpropan-I-ol I-tosylate (4.6). The product was purified by
silica gel chromatography (acetonitrile/ dichloromethane) and identified by its
spectra. The IH NMR (table 4.22) exhibited two chemically different
doublets in the aromatic region, each integrating to 2 hydrogens at 7.30D and
7.73D with a coupling constant of 8.00 Hz. This was accompanied by a new
3 hydrogen singlet at 2.4ID corresponding to the aromatic methyl
substituent. The l3C NMR (table 4.23) indicated the appearance of four
signals in the aromatic region and a signal for the benzylic alcohol at 79.38D.
El-MS exhibited a peak at 242 corresponding to the molecular ion.
Attempts to displace the tosylleaving group from 2,2-dimethylpropan-
1-01 l-tosylate (4.6) by nucleophilic attack with phenyl lithium or phenyl
magnesium bromide in ether or tetrahydrofuran failed. When N,N,N',N'-tetra
methylethylenediamine was used as a chelating agent the C-I9 tosyl group
was not displaced.
Table 4.22
400 MHz IH NMR of 2,2-dimethylpropan-l-0Il-tosylate (4.6).
multiplicity chemical shift coupling assignment
2 H (d) 7.75 13.24 Hz C-2' H
2 H (d) 7.32 12.48 Hz C-3' H
I H (s) 3.62 C-I H
3- H (s) 2.41 C-5' methyl
9 H (s) 0.86 C-3 methyl
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Table 4.23
400 MHz 13CNMR of 2,2-dimethylpropan-l-ol I-tosylate (4.6).
chemical shift assignment
144.57 1'/4'
132.83 1'/4'
129.71 2'/3'
127.74 2'/3'
79.38 I
31.48 2
25.86 3
21.48 5'
Neopentyl alcohol was stirred at room temperature with mesyl chloride
in pyridine to afford 2,2-dimethylpropan-l-01 l-rnesylate (4.7). Nucleophilic
displacement of the mesyl leaving group by phenyl lithium or phenyl
magnesium bromide in ether or tetrahydrofuran from the 2,2-dimethylpropan-
1-01 l-mesylate (4.7) was attempted but also failed. When N,N,N',N'-tetra
methylethylenediamine was used as a chelating agent the C-19 mesyl group
was not displaced.
Following these unsuccessful attempts, displacements on neopentyl
chloride, bromide and iodide were also tried using phenyl lithium and phenyl
magnesium bromide. The desired nucleophilic substitution again did not
proceed, even when the chelating agent N,N,N',N'-tetramethylethylene-l,2-
diamine was used to increase the nucleophilicity of the phenyl anion. The
nucleophilic displacement did not occur in any of the above sp3 hybridised
neopentyl systems.
O~
~I
(4.12)
PhLi I PhMgBr
ether or HO
tetrah ydrfuran ..
(4.13)
Scheme 4.10
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A nucleophilic addition with phenyl lithium+ was also tried on the
neopentyl aldehyde 2,2-dimethylpropanal (4.12) (scheme 4.10). Phenyl
lithium solution was slowly added to a solution of 2,2-dimethylpropanal
(4.12) in dry tetrahydrofuran? to afford I-phenyl-2,2-dimethylpropan-l-01
(4.13). The same product was also synthesised when the Grignard reagent of
bromo benzene was used as the nucleophile. The product in both reactions
was purified by silica gel preparative thin layer chromatography and
identified by its spectra. The IH NMR (table 4.24) exhibited a 5 hydrogen
multiplet in the aromatic region 7.26b -7.65b corresponding to 5 aromatic
hydrogens. This was accompanied by the shift of the aldehydic proton to
4.41b. The 13e NMR (table 4.25) indicated the presence of 4 new chemically
different signals at 142.11b, 127.54b, 127.47b and 127.19b corresponding to
the aromatic carbon signals. There was a shift in the position of the
aldehydic carbon singlet to 82.28b. El-MS exhibited signals at 164 and 107
corresponding to the molecular ion and a substituted tropylium ion fragment.
In contrast to the lack of nucleophilic substitution reactions occurring
with the Sp3 hybridised neopentyl systems bearing the mesyl, tosyl, chloro,
bromo, or iodo leaving groups, an sp2 hybridised system, 2,2-dimethyl
propanal (4.12), smoothly reacted with phenyl lithium or phenyl magnesium
bromide to give the addition product of I-phenyl-2,2-dimethylpropan-l-01
(4.13). The product was identified by its spectra.
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Table 4.24
250 MHz IH NMR of I-phenyl-2,2-dimethylpropan-l-01 (4.13).
multiplicity chemical shift assignment
5 H (m) 7.65 - 7.26 aromatic H
1H(s) 4.41 C-I H
9 H (s) 0.95 methyl groups
Table 4.25
250 MHz l3C NMR of I-phenyl-2,2-dimethylpropan-l-01 (4.13).
chemical shift assignment
142.11 l'
127.54 2'/3'
127.47 2'/3'
127.19 4'
82.28 1
35.53 2
25.85 3
(4.14) \ON,
\, ~:gneSiUm .:
(4.12) tetrahydrofuran
I
N........
"1, LiAlH4' Alel3,
(4.15) ether
Scheme 4.11
(4.16)
In order to assess whether the amino substituent would interfere with
the nucleophilic addition, the reaction was tried between p-N,N-dimethyl
aminophenyl magnesium bromidel ! and 2,2-dimethylpropanal (4.12). To a
stirred solution of p-N,N-dimethylaminophenyl magnesium bromide in dry
terahydrofuan was added 2,2-dimethylpropanal (4.12), to afford l-(p-N,N-
dimethylaminophenyl)-2,2-dimethylpropan-l-01 (4.15), which was purified by
silica gel preparative thin layer chromatography (acetonitrile/
dichloromethane) and identified by its spectra. During this nucleophilic
addition reaction, a benzylic hydroxy functionality was also generated. The
1H NMR (table 4.26) indicated the presence of two doublets, each
integrating to two hydrogens at 7.178 and 6.698 with a coupling constant of
8.74 Hz corresponding to the p- substituted aromatic system. This was
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accompanied by the shift of the aldehydic proton signal to 4.308. The l3C
NMR (table 4.27) indicated the presence of eight chemically different carbon
signals, with a shift of the aldehydic carbon signal to 82.108. The infrared
spectrum provided further evidence for the structure with a free O-H stretch
at 3612 cm+, CI-MS(Nf4+) exhibited peaks at 208 and 151 corresponding
to the (MH+) ion and a substituted tropylium ion. The nucleophilic addition
at the Sp2 hybridised carbon atom had occurred, showing that the amino
substituent did not interfere with the nucleophilic addition reaction.
Table 4.26
250 MHz IH NMR of 1-(p-N,N-dimethylaminophenyl)-2,2-dimethylpropan-l-
01 (4.15).
multiplicity chemical shift coupling
2 H(d)
2 H (d)
1H (s)
6 H (s)
9 H(s)
7.17
6.69
4.30
2.93
0.92
8.55 Hz
8.93 Hz
assignment
C-2'H
C-3'H
C-l H
C-5' methyl
C-3 methyl
Table 4.27
250 MHz 13CNMR of 1-(p-N,N-dimethylaminophenyl)-2,2-dimethylpropan-
1-01 (4.15).
chemical shift
149.81
130.39
128.25
111.71
40.62
82.10
35.71
25.92
assignment
4'
l'
2'
3'
5'
1
2
3
In the previous two examples, a hydroxy functionality is also
generated when 2,2-dimethylpropanal (4.12) is attacked by a nucleophile. If
an aryl nucleophile were to attack a steroid bearing a C-IO~ formyl group, a
C-19 hydroxy group would also be generated. When the structure of the
target compound is considered, a strategy must be developed to remove the
C-19 hydroxy functionality. In this regard a benzylic reduction l2 was
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undertaken in the model neopentyl system. l-(p-N,N-dimethylaminophenyl)-
2,2-dimethylpropan-l-ol (4.15) was refluxed with lithium aluminium hydride
and aluminium chloride in dry ether, to furnish l-(p-N ,N-dimethyl
aminophenyl)-2,2-dimethylpropane (4.16), the product was identified by its
spectra. The 1H NMR (table 4.28) exhibited a 2 hydrogen singlet at 3.420.
The infrared spectrum showed the disappearance of the free OH signal from
3612 cm+, The CI-MS(NfI4+) exhibited a peak at 192 corresponding to the
(MH+) ion.
Table 4.28
250 MHz IH NMR of 1-(p-N,N-dimethylaminophenyl)-2,2-dimethylpropane
(4.16).
multiplicity chemical shift coupling
2 H(d)
2 H (d)
2 H(s)
6 H (s)
9 H(s)
6.87
6.66
3.42
2.89
0.89
8.62 Hz
8.65 Hz
assignment
C-2'H
C-3'H
C-l H
C-5' methyl
C-3 methyl
In view of the investigation of the nucleophilic substitution reactions
of neopentyl systems, it was considered that 3p-hydroxy-17,17-
ethylenedioxyandrost-5-en-19-one 3-acetate (3.68) would be a suitable
candidate for the nucleophilic introduction of a C-19 aryl functionality. The
19-alcohol (3.67) needed to be oxidised to the corresponding aldehyde 3~-
hydroxy-l Oll-formyl-L? ,17-ethylenedioxy-19-norandrost-5-ene 3-acetate
(3.68).
In accordance with the literature,7,13,14 chromium trioxide was stirred
at room temperature with pyridine in dichloromethane for 15 minutes. To this
solution was added 3~, 19-dihydroxy-17 ,17-ethylenedioxyandrost-5-ene 3-
acetate (3.67) and stirred for 15 minutes. The product was filtered through a
bed of celite and purified by recrystallisation from acetone/hexane and
identified by its spectra. The 1H NMR (table 4.29) indicated the loss of the
geminally coupled C-19 hydrogens from 3.828 and 3.588 and the appearance
115
of an aldehydic doublet at 9.638 with a 4J coupling constant of 1.36 Hz (to
the C-Ia H or C-9a H). The l3C NMR (table 4.30) indicated the presence of
23 signals, with a shift in position for the C-19 signal from 62.598 to 204.758.
The infrared spectrum provided further evidence for the structure with the
absence of the OH stretch that was present in 3f3,19-dihydroxy-17,17-
ethylenedioxyandrost-5-ene 3-acetate (3.67) at 3494 em-I. Also two
absorption signals were observed at 1730 cm-! and 1712 cm-! corresponding
to the acetate carbon oxygen double bond stretch and the C-19 carbonyl
stretch. El-MS exhibited signals at 388 and 99 corresponding to the
molecular ion and ketal fragment.
Table 4.29
400 MHz IH NMR 3f3-hydroxy-17, 17-ethylenedioxyandrost-5-en-19-one 3-
acetate (3.67).
1 H(d) 9.63 1.36 Hz C-19 aldehyde H
(couples to 9a H)
C-6H
C-3aH
ketal H's
C-19 H
C-19 H
acetate methyl
C-18 Me
multiplicity
1H(d)
1H (t.t)
4H(m)
1H(d)
1H(d)
3 H (s)
3 H (s)
methylene
envelope
chemical shift coupling constant assignment
5.85
4.57
3.94-3.76
3.94
3.72
2.01
0.87
1.01-2.47
5.48 Hz
4.50 Hz, 11.55 Hz
8.52 Hz
8.48 Hz
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Table 4.30
400 MHz 13CNMR 3~-hydroxy-17,17-ethylenedioxyandrost-5-en-19-one 3-
acetate (3.67).
chemical shift assignment
204.75
170.35
131.32
128.14
118.91
72.47
65.08
64.40
53.36
50.14
48.39
45.38
39.33
33.88
33.00
30.43
30.28
30.06
28.53
22.26
21.53
21.20
13.98
19
acetate carbonyl
5/6
5/6
17
3
ketal
ketal
15
II/acetate methyl
II/acetate methyl
18
0/1o
PhLi/
PhMgBr,
ether
+
Scheme 4.12
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To a stirred solution of 3~-hydroxy-17,17-ethylenedioxyandrost-5-en-
19-one 3-acetate (3.68), in dry tetrahydrofuran was slowly added excess
phenyl lithium solution (in ether/hexanej.? which reacted with both of the
functionalities at position C-3 and C-19, to afford 3~,19-dihydroxy-17,17-
ethylenedioxy-19-phenylandrost-5-ene (4.17). The same product was
synthesised when the Grignard reagent of bromobenzene was used as the
nucleophile.U During the course of the nucleophilic addition reaction at the
10~-formyl group, a C-19 benzylic hydroxy functionality was generated and
the 3~-acetate functionality was removed by reaction with two equivalents
of phenyl lithium or phenyl magnesium bromide to furnish a by-product of
l,l-diphenylethanol (4.18). In both reactions the mixtures were purified by
silica gel preparative thin layer chromatography (acetonitrile/
dichloromethane) and identified by their spectra. The 1H NMR (table 4.31)
indicated a shift in the position of the C-19 hydrogen from the aldehydic
position from 9.630 to 4.950. This was accompanied by a 5 hydrogen
multiplet in the region of 7.200 -7,430 corresponding to the aromatic
hydrogens and the disappearance of the acetate methyl signal from 2.010.
The 13C NMR (table 4.32) indicated the presence of 25 chemically different
signals and a shift of the C-19 aldehydic signal from 204.750 to 75.750, with
the appearance of 4 new signals in the aromatic region. The infrared
spectrum provided further evidence for the structure with the appearance of
a free O-H stretch at 3420 cm+. CI-MS(NH4+) exhibited signals at 425 and
99 corresponding to the (MH+) ion and ketal ion fragment. This was
accompanied by a peak at 107 corresponding to the fragmentation of the 10
benzyl functionality which forms a substituted tropylium ion fragment.
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Table 4.31
250 MHz 1H NMR of 3~, 19-dihydroxy-17, 17-ethylenedioxy-19-
phenylandrost-5-ene (4.17).
5 H (m) 7.43 - 7.20 1.36 Hz
multiplicity chemical shift coupling constant assignment
1 H (t)
1H (s)
4H(m)
1H (t.t)
3 H(s)
methylene
envelope
5.55
4.95
3.90-3.71
3.56
0.78
2.69 - 0.80
2.00 Hz
aromatic
hydrogens
C-6H
C-19H
ketal H's
C-3aH
C-18 Me
5.22 Hz, 10.44 Hz
Table 4.32
250 MHz l3C NMR of 3~,19-dihydroxy-17,17-ethylenedioxy-19-
phenylandrost-5-en:::.e~(..:.:4.:..:..17;.../.):.:.,.~, ,..._ __ ~ _
chemical shift assignment
143.45 4'/5
137.55 4'/5
127.60 2'/3'
127.43 2'/3'
127.11 1'/6
126.56 1'/6
119.23 17
75.75 (19)
71.00 (3)
65.03 Ketal
64.44 Ketal
51.96 9/14
51.83 9/14
45.73
45.03
43.52
34.02
33.48
32.45
32.01
31.12
31.01
22.42
20.98
14.53
15(11)
11(15)
18
11 Q
Butyllithium
Scheme 4.13
The researchers at Syntex were able to introduce a C-I9 methylene
group by a Wittig reaction with 3~-hydroxy-17, I7-ethylenedioxy androstan-
5-ene-I9-one 3-acetate (3.68).7 In line with this strategy we attempted to
introduce a benzyl group at position C-I9 via a Wittig reaction between
benzyltributylphosphonium bromide and 3p-hydroxy-17,17-ethylenedioxy
androstan-5-en-19-one 3-acetate (3.68), Unfortunately the product 3~-
hydroxy-I7, 17-ethylenedioxy-I9-benzylandrostan-5, 19-diene (4.20) could
not be isolated from the reaction mixture. It is considered that steric
hindrance between the large Wittig reagent and the hindered C-19 aldehydic
site prevented the reaction from occurring.
5'
Io/i ,.."N
o
Magnesium,
tetrahydrofuran..
AeO
I
(3.68) ON, HO
'.&Br
(4.14)
+
(4.22)
Scheme 4.14
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Having successfully introduced a phenyl group at the hindered C-19
neopentyl site attempts were made to introduce a substituted aryl
functionality. p-Bromo-N,N-dimethylaniline (4.14) was converted by
reaction with magnesium turnings in tetrahydrofuran to the corresponding
Grignard reagent.U To this stirred solution was added 3p-hydroxy-17, 17-
ethylenedioxyandrost-5-en-19-one 3-acetate (3.68) in tetrahydrofuran, to
give a diastereomeric mixture of 3p,19-dihydroxy-17,17-ethylenedioxy-19-(p-
(N,N-dimethylaminophenyl»androst-5-ene (4.21). During the course of the
reaction nucleophilic addition of the p-N,N-dimethylaminophenyl substituent
occurred at the lOp-formyl group generating a C-19 benzylic hydroxy
functionality and the 3p-acetate functionality was removed by nucleophilic
attack by two equivalents of Grignard reagent, to give a by-product of 1,1-
di(p-(N,N-dimethylaminophenyl)ethanol (4.22). The crude product was
dissolved in a minimum of dichloromethane and treated with hexane, this
reduction in polarity of solvent caused the steroid to come out of solution as
an oil, leaving the by-product in solution. The product was further purified
by silica gel preparative thin layer chromatography (acetonitrile/
dichloromethane) and the major and minor diastereomeric components were
identified by their spectra. The IH NMR (table 4.33) indicated the presence
of two doublets, each integrating to two hydrogens at 7.238 and 6.658 with
a vicinal coupling constant of 8.84 Hz, corresponding to the p-substituted
aromatic system. This was accompanied by the shift of the aldehydic proton
signal to 4.308. The 13C NMR (table 4.35) indicated the presence of 26
chemically different carbon signals, with a shift of the aJdehydic carbon
signal from 204.758 to 75.758. The infrared spectrum provided further
evidence for the structure with a free O-H stretch at 3605 cnr+, FAB-MS
exhibited signals at 468, 150 and 99 corresponding to the (MH+) ion,
substituted tropylium ion fragment and ketal ion fragment. The ratio of the
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major to minor diastereomers synthesised in this reaction was estimated by
comparison of the 1H NMR signal integrals of the hydrogens at C-6, C-18
and C-19 and calculated to be 78% to 22%.
Table 4.33
400 MHz IH NMR 3~,19-dihydroxy-17,17-ethylenedioxy-19-(p-(N,N-
dimethylaminophenyl»androst-5-ene (4.21).
multiplicity chemical shift coupling constant assignment
2 H (d) major 7.23 8.76 Hz aromatic 2' H
(minor) (7.20) (8.68 Hz)
2 H (d) major 6.65 8.88 Hz
(minor) (6.66) (8.88 Hz)
1H (m) 5.52 - 5.56
1H (s) major 4.89,
(minor) (5.02)
4 H (m) 4.00 - 3.75
1H (t.t) 3.55
6 H (s) major 2.91
(minor) (2.89)
3 H (s) 0.76
methylene 0.80 - 2.60
envelope
aromatic 3' H
C-6H
C 19H
ketal H's
5.20 Hz, 10.40Hz C-3a H
5'
C-18 Me
Table 4.34
400 MHz BC NMR signals in diastereomeric mixture attributed to the minor
isomer of 3P, 19-dihydroxy-17, 17-ethylenedioxy-19-(p-(N ,N -dimethyl
aminophenyl»androst-5-ene (4.21).
chemical shift assignment dept
149.5 4' (C)
136.6 5 (C)
127.5 2' CH
126.7 6 CH
112.2 3' CH
72.0 19 CH
71.3 3 CH
52.2 CH
45.1
43.4
40.4
34.4
31.5
31.4
31.3
30.8
22.2
22.0
14.6
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Table 4.35
400 MHz l3C NMR 3~,19-dihydroxy-17,17-ethylenedioxy-19-(p-(N,N-
dimethylaminophenyl)androst-5-ene (4.21). (major isomer)
chemical shift assignment dept
149.68 4' (C)
137.93 5 (C)
131.65 l' (C)
128.21 2' CH
125.99 6 CH
119.30 17 C
111.97 3' CH
75.97 19 CH
71.09 3 CH
64.99 Ketal CH2
64.41 Ketal CH2
52.13 9/14 CH
51.97 9/14 CH
45.78 10/13 C
44.77 10/13 C
43.74 CH2
40.63 5' CH3
34.03 CH2
33.96 CH2
32.63 CH2
31.90 8 CH
31.25 CH2
31.03 CH2
22.42 15(11) CH2
20.97 11(15) CH2
14.57 18 CH3
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I
......N
5'
I
,......N
Scheme 4.15
Following the successful introduction of the substituted and
unsubstituted aryl functionalities into the C-19 position, it was necessary to
find a suitable method to remove the C-19 alcohol.
Alternative methods to do this were considered.
a) Oxidation of the 19-hydroxy functionality to the ketone, followed by
a Wolf Kishner (Huang MinIon modification) reduction to the alkane.
b) Benzylic reduction.I?
The conditions for oxidation of the C-19 hydroxy group would also
oxidise the 3B-alcohol. Protection of the 3B-hydroxy functionality and a
later deprotection would increase the length of the synthetic sequence by
two steps. It was therefore considered that the second method of benzylic
reduction was most suitable.
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The benzylic reductionl! of3p,19-dihydroxy-17,17-ethylenedioxy-19-
(p-N,N-dimethylaminophenyl)androst-5-ene (4.21) was then examined, by
reflux with lithium aluminium hydride and aluminium chloride in dry ether.
The product was purified by silica gel preparative thin layer chromatography
(acetonitrile/dichloromethane) and identified by its spectra. The reduction of
the benzylic C-19 hydroxy functionality occurred smoothly, but
unfortunately there was an unexpected cleavage of the C-17 ketal protecting
group as well, affording the product of 3fj-hydroxy-17-(2-hydroxyethoxy)-
19-(p-N,N-dimethyl aminophenyl)androst-5-ene (4.24). The IH NMR spectra
(table 4.36) indicated the loss of the C-19 1 hydrogen singlet from 4.89B and
the appearance of two geminally coupled C-19 1 hydrogen doublets at 2.90B
and 2.37B with a 2J coupling constant of 14.41 Hz. This was accompanied
by a change in the pattern observed for the ketal multiplet with a shift in the
position to 3.72-3.34B. This was accompanied by a new 1 hydrogen triplet at
3.24B. The l3C NMR spectra (table 4.37) indicated the presence of 26
chemically different signals with a shift in the position of the C-19 signal from
75.97B to 36.66B. This was accompanied by the loss of the C-17 and ketal
signals from 119.30B, 64.99B and 64.41B. El-MS exhibited a peak at 453 and
134 corresponding to the molecular ion and substituted tropylium ion
fragment. Cl-MS exhibited signals at 454 and 134 corresponding to the
(MH+) ion and substituted tropylium ion fragment. The tropylium ion
fragment possess a mass that is 16 less than the corresponding fragment in
the precursor due to the loss of an hydroxy functionality in the reaction.
There was no evidence for the signal at 99 for the ketal ion fragment.
The ketal functionality is normally chemically resistant to lithium
aluminium hydride or aluminium chloride. The combination of these two
reagents was however able to bring about the partial cleavage of the C-17
ketal protecting group furnishing 3p-hydroxy-17-(2-hydroxyethoxy)-19-(p-
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(N,N-dimethylaminophenyl))androst-5-ene (4.24). The cleavage can be
explained in the following manor. During the course of the reaction,
oxonium ions are formed when a lone pair of electrons from an oxygen atom
is accepted by a vacant orbital in an aluminium species. In the ketal
functionality this will raise the electrophilic nature of the C-17 carbon atom
A new oxonium ion is formed when a lone pair of electrons from the second
oxygen atom attacks the electrophilic C-17 carbon atom, which causes the
heterolytic cleavage of the bond that exists between the C-17 carbon atom
and the original oxonium ion. The new oxonium ion is then reduced by
lithium aluminium hydride to afford 3~-hydroxy-17-(2-hydroxyethoxy)-19-
(p-(N,N-dimethylaminophenyl))androst-5-ene (4.24).
Table 4.36
250 MHz IH NMR 3~-hydroxy-17-(2-hydroxyethoxy)-19-(p-(N,N-
dimethylaminophenyl) )androst-5-ene (4.24).
multiplicity chemical shift coupling constant assignment
2 H (d) 7.01 8.65 Hz
2 H (d) 6.60 8.70 Hz
1H(m) 5.53 - 5.27
5 H (m) 3.72 - 3.42
14.35 Hz
aromatic 2' H
aromatic 3' H
C-6H
ethoxy H's +
C-3aH
C-17 H
C-19H
C-5' Me
C-19 H
C-18 Me
1H (t)
1 H (d)
6 H (s)
1 H (d)
3 H(s)
methylene
envelope
3.24
2.90
2.85
2.37
0.50
0.80 - 2.40
8.35 Hz
14.47 Hz
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Table 4.37
250 MHz BC NMR 3p,I9-dihydroxy-I7-(2-hydroxyethoxy)-I9-(p-(N,N-
dimethylaminophenyl))androst-5-ene (4.24).
chemical shift assignment
148.56 4'
137.94 5
130.78 2'
129.23 I'
124.54 6
113.05 3'
89.23
71.63
70.85
61.89
52.86
51.81
42.84
42.78
41.23
41.06
38.70
38.37
36.66
31.64
31.26
30.93
27.80
22.84
20.99
11.74
5'
19
15(11)
11(15)
18
An alternative route had to be found to overcome this problem. The
options at this point were:
a) The use of an alternative protecting group for the C-17 ketone
functionality.
b) Alter the sequence of events of manipulation of the C-3, C-17 and
C-I9 positions.
The option to use a different protecting group was not considered to
be an attractive proposition, as it would mean its introduction at a much
earlier step in the synthetic sequence The alternative idea, of rearranging the
sequence of chemical modifications of positions C-3, C-17, C-19 was
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considered to be most suitable for our purpose. The next logical step was to
deprotect the C-17 functionality of 3p-hydroxy-17, 17-ethylenedioxy-19-(p-
N,N-dimethylaminophenyl)androst-5-ene (4.21) before manipulating the C-19
group.
I
.....N
LiAIH4, AICI3, ~
ether
(4.26)
Scheme 4.16
To a stirred solution of 3P,19-dihydroxy-17,17-ethylenedioxy-19-(p_
(N,N-dimethylaminophenyl))androst-5-ene (4.21) in acetone was added
aqueous hydrochloric acid, II to cause deketalisation and to furnish 3~, 19-
dihydroxy-19-(p-(N,N-dimethylaminophenyl))androst-5-en-17-one (4.25),
which was purified by silica gel preparative thin layer chromatography and
identified by its spectra. The IH NMR (table 4.38) indicated the
disappearance of the 4 H ketal multiplet from 4.000 - 3.750. The l3C NMR
(table 4.39) indicated the shift of the C-17 signal from 119.300 to the
carbonyl position at 201.710 and the loss of the ketal signals from 64.990 and
64.410. The infrared spectrum exhibited an absorption band at 1600 cm!
corresponding to the newly formed C-I7 carbonyl group. The molecular ion,
(MH+) and (MNH4+) fragments were not stable in El-MS, CI-MS(N~+), or
FAB-MS. El-MS did however exhibited signals at 405 and 150
corresponding to molecular ion -18 and substituted tropylium ion fragments.
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Table 4.38
400 MHz IH NMR of 3~,19-dihydroxy-19-(p-(N,N-dimethylamino
phenyljjandrost-f-en-I'r-one (4.25).
multiplicity chemical shift coupling constant assignment
2 H (d) major 7.19 8.93 Hz
2 H (d) major 6.62 8.93 Hz
1H(m) 5.60 -5.50
1H (s) major 4.72
(minor) (4.91)
1 H (t.t) 3.60
6 H (s) major 2.87
(minor) (2.83)
3 H (s) major 0.72
(minor) (0.60)
methylene 0.90 - 2.70
envelope
aromatic 2' H
aromatic 3' H
C-6H
C 19
C-3uH
5'
C-18 Me
Table 4.39
400 MHz 13C NMR of 3~,19-dihydroxy-19-(p-(N,N-dimethylamino
phenyl))androst-5-en-17-one (4.25). (major isomer)
chemical shift assignment
201.71 17
150.42 4'
135.74 5
130.29 2'
129.62 I'
120.85 6
112.34 3'
81.78 19
66.77 3
53.34
52.03
47.82
47.42
40.79
39.43
35.71
35.47
31.82
30.97
29.59
26.85
21.43
19.90
13.17
5'
15/(11)
11/(15)
18
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Since the conditions for benzylic 12 reduction of the C-19 benzylic
alcohol involved reflux with lithium aluminium hydride and aluminium
chloride in ether, the benzylic reduction would also reduce the C-17 keto
group to a 17~-hydroxy functionality. In accordance with the Iiteraturel?
method reported for the benzylic reduction of alcohols, lithium aluminium
hydride was refluxed with aluminium chloride in dry ether for 15 minutes. To
this refluxing solution was slowly added 3~, 19-dihydroxy-19-(p-(N ,N-
dimethylaminophenyl))androst-5-en-17-one (4.25) in dry ether solution, to
afford 3~, 17~-dihydrox y-19-(p-(N ,N-dimethylaminopheny I))androst -5-ene
(4.26), which was purified by recrystallisation from acetone and identified by
its spectra. The IH NMR (table 4.40) indicated the loss of the C-19 H signal
from 4.728 and the appearance of the C-19 methylene group as two 1
hydrogen doublets at 3.128 and 2.408 with a geminal coupling constant of
14.38 Hz. The l3C NMR (table 4.41) was completely assigned (except for
the 2 quaternary carbons) by means of C-H correlation, COSY spectra and
DEPT spectra. The 13C NMR (table 4.41) indicated the shift of the C-19
signal from 81.788 to 36.788. The infrared spectrum provided further
evidence for the structure with two free O-H stretches at 3603 cm-1 and 3435
cm-I. CI-MS(NI-4+) showed signals at 427, 410 and 134 which correspond
to the (MNR4+), (MH+) ions and substituted tropylium ion fragment.
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Table 4.40
400 MHz IH NMR of 3p,17P-dihydroxy-19-(p-(N,N-dimethylamino
phenyl»androst-5-ene (4.26).
assignmentmultiplicity chemical shift
2H(d) 7.03
2 H (d) 6.62
1H (t) 5.54
1H (t.t) 3.60
1H (t) 3.53
1H (d) 3.12
6 H (s) 2.87
1H (d) 2.40
3 H (s) 0.48
methylene 2.08-0.53
envelope
coupling constant
8.64 Hz
8.64 Hz
2.40 Hz
5.35 Hz, 10.70 Hz
8.48 Hz,
14.44 Hz
14.32 Hz
aromatic 2' H
aromatic 3' H
C-6H
C-3aH
C-17aH
C-19 H
C-5'
C-19 H
C-18 methyl
Table 4.41
400 MHz 13CNMR of 3P, 17P-dihydroxy-19-(p-(N,N-dimethylamino
phenyl)androst-5-ene (4.26).
chemical shift assignment dept·
148.83 4'
137.90 5
130.77 2'
128.65 l'
124.65 6
112.88 3'
81.69 17
71.82 3
52.65 14
51.96 9
42.93 4
42.64 10/13
41.08 10/13
40.94 5'
38.79 1
37.03 12
36.78 19
31.75 2
31.49 8
30.96 7
30.31 16
22.22 15
20.95 11
11.10 18
(C)
C
CH
C
CH
CH
CH
CH
CH
CH
CH2
C
C
CH3
CH2
CH2
CH2
CH2
CH
CH2
CH2
CH2
CH2
CH3
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I,....N
3"
Oxidation
(4.28)
i) Propyne,
tetrahydrofurcw..
ii) t-butyl
lithium,
OH I" 2" 3"
HO
Scheme 4.17
The next logical step in the reaction sequence was therefore the
introduction of the 17a-alkynyl substituent (scheme 4.17). Initially this
reaction was assessed in the model compound 3j3-hydroxyandrost-5-en-17-
one (4.29). To a solution of tetrahydrofuran saturated with propyne at O°C
under nitrogen, was added a solution of t-butyllithium in hexane and this was
allowed to stir for 30 minutes. II A solution of 3j3,17j3-dihydroxyandrost-5-
en-17-one (4.29) in tetrahydrofuran was added to this solution, to give 313-
dihydroxy-17 a-(prop-I-yne )androst-5-ene (4.30), a portion of which was
purified by silica gel thin layer chromatography (acetonitrile/
dichloromethane) and identified by its spectra. The 1H NMR (table 4.42)
exhibited a new 3 hydrogen singlet at 1.77(5 corresponding to the propynyl
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methyl group. The 13CNMR (table 4.43) indicated the disappearance of the
C-17 signal from 221.14~. This was accompanied by the appearance of 4
new signals at 79.990, 71.670, 71.500 and 3.600. The signal at 3.600
corresponding to the propynyl methyl group and the remaining 3 signals for
the C-17 and the two alkynyl carbon atoms. El-MS exhibited a peak at 328
corresponding to the molecular ion.
Table 4.42
250 MHz IH NMR of 3~,17~-dihydroxy-17a-(prop-l-yne)androst-5-ene
(4.30)
multiplicity chemical
shift
coupling constant assignment
1H(m)
1H (t.t)
3 H (s)
3 H(s)
3 H (s)
methylene
envelope
5.30 - 5.24
3.42
1.77
0.93
0.75
0.80 - 2.50
4.26 Hz, 11.50 Hz
C-6H
C-3aH
C-3" methyl
C-19 methyl
C-18 methyl
Table 4.43
250 MHz IH NMR of 3~,17~-dihydroxy-17a-(prop-I-yne)androst-5-ene
(4.30)
chemical shift
140.69
121.29
82.67
81.55
79.99
71.67
71.50
50.53
49.69
46.54
42.17
38.91
37.17
36.61
32.45
31.54
31.33
23.11
20.68
19.32
12.65
3.60
assignment
5
6
3/1"/2"
3/1"/2"
3/1"/2"
15(11)
11(15)
19
18
3"
l33
To a solution of tetrahydrofuran saturated with propyne at O°C under
nitrogen was added a solution of t-butyllithium in hexane and this was stirred
for 30 minutes.U A solution of 3p,19-dihydroxy-19-(p-(N,N-dimethyl
aminophenylljandrost-Sven-l t-one (4.25) in tetrahydrofuran was added to
this solution to give 3p,17p,19-trihydroxy-17a-(prop-I-yne)-19-(p-(N,N-
dimethylaminophenyl»androst-5-ene (4.27) a portion of which was purified
by silica gel thin layer chromatography (acetonitrile/ dichloromethane) and
identified by its spectra. The IH NMR (table 4.44) indicated appearance of a
new 3 hydrogen singlet at 1.858 corresponding to the propynyl methyl
group. The l3C NMR (table 4.45) indicated the disappearance of the C-17
signal from 201.718. This was accompanied by the appearance of 4 new
signals at 82.868, 81.238, 79.698 and 3.598 .. The signal at 3.598
corresponding to the propynyl methyl group and the remaining 3 signals for
the C-17 and the two alkynyl carbon atoms. The infrared spectrum showed
absorption bands at 3436 cm-! and 3602 cm! corresponding to free OH
stretches. El-MS exhibited peaks at 463 and 150 corresponding to the
molecular ion and a substituted tropylium ion. CI-MS(NH4+) exhibited peaks
at 464 and 150 corresponding to (MH+) ion and substituted tropylium ion
fragment.
Table 4.44
250 MHz IH NMR of 3P, 17P, 19-trihydroxy-17a-(prop-I-yne )-19-(p-(N ,N-
dimethylaminophenyl»androst-5-ene (4.27)
multiplicity chemical coupling constant assignment
shift
2 H(d)
2 H(d)
1H(m)
1H (s)
1H(m)
6 H (s)
3 H (s)
3 H(s)
methylene
envelope
7.24
6.67
5.63 - 5.58
4.85
3.56 - 3.15
2.93
1.84
0.75
0.65 - 2.50
8.88 Hz
8.73 Hz
aromatic 2' H
aromatic 3' H
C-6H
C 19
C-3aH
C-5' H
C-3" methyl
C-18 methyl
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Table 4.45
250 MHz Be NMR of3~,17~,19-trihydroxy-17a-(prop-l-yne)-19-(p-(N,N-
dimethylaminophenyl»androst-5-ene (4.27). (some of the peaks for major
isomer)
chemical shift assignment
149.68 4'
138.10 5
131.66 l'
128.25 2'
125.88 6
111.99 3'
82.86 17/1"/2"
81.23 17/1"/2"
79.69 17/1"/2"
76.11 19
71.14
60.31
52.17 9/14
51.85 9/14
22.83 15(11)
20.92 11(15)
14.07 18
3.59 3"
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A number of attempts were made to oxidise 3~,17~,19-trihydroxy-17a-
(prop-l-yne )-19-(p-(N,N-dimethylaminophenyl»androst-5-ene (4.27) using
Jones reagent> and chromium trioxide/pyridine.I". 13,14 In none of these
attempts were we able to isolate the desired product. CI-MS(NH4+) of the
crude products showed no evidence for the (MH+) or (MNH4+) ions but
peaks at 446 and 150 were observed. The IH NMR of the crude product
exhibited a pair of doublets at 7.710 and 6.750 with a 3J coupling constant of
8.74 Hz, which correlates with the calculated position of the aromatic signals
expected for 3~, 17 ~ -dihydroxy-l 7 a-(prop-l-yne )-19- (p- (N ,N-
dimethylaminophenyl)androst-4-en-3,19-dione (4.28).
The next logical step was to do a benzylic reduction on the 19-
hydroxy steroid (4.27) (scheme 4.18). In accordance with the general
literature method reported for benzylic reduction of alcohols.t? lithium
aluminium hydride was refluxed with aluminium chloride in dry ether for 15
minutes. To this refiuxing solution was slowly added 3~, 17~, 19-trihydroxy-
17a-(prop-l-yne )-19-(p-(N ,N-dimethyl aminophenyl) )androst -5-ene (4.27) in
ether solution, to afford 3~,17~-dihydroxy-17a-(prop-l-yne)-19-(p_(N,N_
dimethylamino phenyl) )androst- 5-ene (4.31), which was purified by silica gel
thin layer chromatography (acetonitrile/dichloromethane) and identified by
its spectra. The IH NMR (table 4.46) indicated the loss of the C-19 H signal
from 4.850 and the appearance of the C-19 methylene group as two 1
hydrogen doublets at 3.130 and 2.410 with a geminal coupling constant of
14.3 Hz. The 13CNMR (table 4.47) indicated the disappearance of the C-19
signal from 76.110. The infrared spectrum provided further evidence for the
structure wi th a free 0-H stretch at 3604 cnr-' and 3444 cm+. El-MS
exhibited peaks at 447 and 134 corresponding to the molecular ion and
substituted tropylium ion fragments. CI-MS(N~+) exhibited peaks at 448
and 134 corresponding to (MH+) ion and substituted tropylium ion
136
fragments.
Table 4.46
400 MHz IH NMR 3p,17P-dihydroxy-17a-(prop-l-yne)-19-(p-(N,N-
dimethylaminophenyl»androst-5-ene (4.31).
assignmentmultiplicity chemical shift coupling constant
2 H (d) 7.06 8.52 Hz
2 H (d) 6.71 8.04 Hz
1H (t) 5.55 2.18 Hz
1H (t.t) 3.59 5.20 Hz, 10.40 Hz
1 H (d) 3.13 14.4 Hz
6 H (s) 2.89
1 H (d) 2.41
3 H (s) 1.81
3 H (s) 0.54
methylene 2.41 - 0.69
envelope
14.2 Hz
aromatic 2' H
aromatic 3' H
C-6H
C-3aH
C-19H
C-5' methyl
C-19H
C-3" methyl
C-18 methyl
Table 4.47
400 MHz l3C NMR of 3p,17P-dihydroxy-17a-(prop-l,-yne)-19-(p-(N,N_
dimethylaminophenyl»androst-5-ene (4.31 ).
chemical shift assignment dept
148.71 4'
137.81 5
130.57 2'
128.69 l'
124.35 6
112.69 3'
82.81 17/1"/2"
80.99 17/1"/2"
79.57 17/1"/2"
71.50 3
51.79 9/14
51.26 9/14
46.45
42.66
40.88
40.85
40.67
38.62
36.47
33.02
31.82
31.47
30.72
22.47
20.80
12.84
3.44
4
C
C
CH
C
CH
CH
C
C
C
CH
CH
CH
C
CH2
CH33"
(19)
CH2
CH2
CH2
CH
CH2
CH2
CH2
CH2
CH3
CH3
8
15(11)
11(15)
18
3"
137
I
......N
Acetone,
aluminum
isopropoxide
(3.1)
Scheme 4.18
Oppenauer oxidation 15 of 3~, 17~-dihydroxy-17 a-(prop-l- yne )-19-(p-
N,N-dimethylaminophenyl)androst-5-ene (4.31) by reflux with aluminium
isopropoxide in dry acetone gave 17~-hydroxy-17a-(prop-l-yne )-19-(p-
(N,N-dimethylaminophenyl»androst-4-ene-3-one (3.1), which was purified
by silica gel preparative thin layer chromatography (acetonitrile/
dichloromethane) and identified by its spectra. The IH NMR (table 4.48)
indicated the disappearance of the C-3 hydrogen triplet of triplets which was
present in the precursor at 3.59b. This was accompanied by the
disappearance of the olefinic C-6 H triplet from 5.55b and the appearance of
the new olefinic C-4 H singlet at 5.85b. The 13CNMR (table 4.49) indicated
the presence of 27 chemically different signals, with a shift in the C-3 signal
from 71.50S to 200.05S, a shift in the C-5 signal from 137.81b to 168.l7b, the
loss of the C-6 signal from 124.35b and the appearance of a new C-4 signal
at ~ 125b. El-MS exhibited peaks at 445 and 134 which correspond to the
molecular ion and substituted tropylium ion. CI-MS(N14+) exhibited peaks
at 446 and 134 which correspond to (MH+) and substituted tropylium ion
fragments.
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Table 4.48
400 MHz IH NMR 17~-hydroxy-17a-(prop-1-yne)-19-(p-(N,N-
dimethylaminophenyl))androst-4-en-3-one (3.1).
multiplicity chemical shift coupling constant assignment
2 H (d) 6.93 8.64 Hz
2 H (d) 6.55 8.64 Hz
1H (s) 5.85
1H (d) 3.14
6 H (s) 2.87
1H (d) 2.74
3 H (s) 1.85
3 H (s) 0.89
methylene 2.5-1.0
envelope
14.32 Hz
aromatic 2' H
aromatic 3' H
C-4H
C-19H
C-5' methyl
C-19H
C-3" methyl
C-18 methyl
14.32Hz
Table 4.49
400 MHz 13CNMR 17~-hydroxy-17a-(prop-1-yne)-19-(p-(N,N-dimethyl
aminophenyl))androst-4-en-3-one (3.1).
chemical shift assignment
200.05 3
168.17 5
149.30 4'
129.93 2'
126.39 1'/4
125.57 1'/4
112.31 3'
81.82 17/1"/2"
79.68 17/1"/2"
77.10 17/1"/2"
56.29 9/14
50.21 9/14
46.57 10/13/16
43.30 10/13/16
40.40 5'
38.83 10/13/16
37.12
36.00
34.38
33.29
32.75
31.96
29.57
22.96
20.59
12.76
3.58
15(11)
11(15)
18
3"
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4.4 Conclusion and sUl:l:estions for further work.
The work described in this chapter has established a succesful 11 step
route for the synthesis of 17~-hydroxy-17a-(prop-l-yne)-19-(p-(N,N_
dimethylaminophenyl))androst-4-en-3-one (3.1) (scheme 4.19). It would be
of interest to use the strategy established in this chapter to synthesise m-
substituted and p-substituted analogues of 17~-hydroxy-17a-(prop-l-yne)-
19-(p-(N,N-dimethylaminophenyl))androst-4-en-3-one (3.1) with a range of
different substituents; (e.g. RI= NMe2, COCH3); (. Also of interest would be
the synthesis of analogues bearing different functionalities at C-19 (e.g. R2=
H, OH, =0) and at C-17 (e.g. R3=H, Me, CCH, CC-CH3)
RI ==NMe2, COCH3
R2 ==H,OH,=O
R3 ==H, Me, Et,
C::C-H,
C::C-CH3
Figure 4.1
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Chapter 5
Molecular Modellin& + Receptor Specificity.
U Introduction
Receptor binding arises due to the complementary nature of the
steric and electronic architecture of a ligand and its receptor.' Molecular
modelling can be used as a tool to compare the similarities that exist
between those molecules which exhibit a good relative binding affinity
(RBA) for the progesterone and glucocorticoid receptors.2,3 In this way the
features of compounds that are conducive to receptor binding and
antagonism can be assessed.2,3
U Receptor Mappin&.
Whilst investigating the effects of various II ~ substituents on the
RBA of steroids for their receptors, the researchers at Roussel-Uelaf also
embarked upon mapping of the progesterone and glucocorticoid receptor
sites.2-4 A number of ll~ p-substituted phenyl steroids were synthesised
(table 5.1), in order to probe the depth and width of the hydrophobic
pocket.t-' The researchers used the information about compounds (5.1) _
(5.7) (table 5.1) to generate a representation of the hydrophobic pocket by
overlapping the 11~-functionalities of steroids using the 'Script' molecular
modelling program.2-4 The minimum size of the pocket above the C-ring is
represented for the glucocorticoid receptor (fig. 5.3a) and the progesterone
receptor (fig. 5.3b).2-4
The p-phenoxy steroid (5.8) exhibits a good RBA for the two
receptors (table 5.1) and when free rotation is allowed for about the C-O in
this compound, the 'Script' program was reported to generate a much larger
pocket for the glucocorticoid (fig. 5.3c)2 and progesterone (fig 5.3d)2
receptor sites than that shown in the representations (fig. 5.3a and 5.3b),
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although it is unlikely that all of the rotamers are accommodated by the
hydrophobic pocket.
Table 5.1 Relative binding affinity (RBA) for rat thymic
glucocorticoid receptor and rabbit uterus progesterone
receptor determined after 24h of incubation at O°C in rat
thymus and rabbit uterus preparation. Values for
dexamethasone and progesterone are 100 respectively.
(See fig. 5.1 for structure).
Code R
RBA
OR PR
RV 38502
RV
RV 39229
RV 43780
RV
RV 38486
RV 40900
(5.1) but 59 0.7
(5.2) but-phenyl 38 48
(5.3) phenyl-phenyl 160 278
(5.4) phenyl-CC-phenyl 7 8
(5.5) Me 234
(5.6) p-Me2N-phenyl 302 530
(5.7) MeN(EthN-Ehen~1 86 25
RV
RV 25458
(5.8l...£henyl-O-{?henyl 100 177
(5.9) ~~6"""'8'~-Oj'
OH
o
Figure 5.1
When the researchers at Roussel Uclaf compared the RBA of the P:
substituted biphenyl steroid RV 39299 (5.3) and the p-substituted
diphenylacetylene steroid RV 43780 (5.4) (table 5.1), the depth of the
pocket was estimated to be 10-12 A for both receptors. A representation
showing the estimated section of the hydrophobic cavity has been reported
for the glucocorticoid (fig. 5.3e) and progesterone (fig 5.3f) receptors. The
map of the progesterone receptor was further refined when the compound
RV 40900 (5.8) (table 5.1) was taken into account in the 'Script' molecular
modelling program (fig. 5.4 and 5.5).
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On the basis of the RBA of the llf3-t-butyl substituted steroid RU
38502 (5.1) and the 10f3-methyl steroid RU 25458 (5.9) (table 5.1), the
researchers at Roussel-Uelaf suggested that the 10f3-methyl and llf3-t-butyl
groups might both protrude into the hydrophobic pocket of the
glucocorticoid receptor.s-' It was postulated that the low affinity of these
molecules for the progesterone receptor2 (table 5.1), indicated that the
opening of the pocket in the progesterone receptor (3.4 A) was much
narrower than that in the glucocorticoid receptor. When the compound RV
25458 (5.9) was taken into account in the 'Script' program for the
glucocorticoid receptor, the topology of the hydrophobic pocket was
refined (fig 5.6).2,3 A 10f3 functionality will therefore reduce the affinity of
a steroid for the progesterone receptor and increase the specificity for the
glucocorticoid receptor. This is indeed the case for RU 39305 (5.10) and
RU 43044 (5.11) (table 5.2),5 which may explain why the removal of the C-
19 methyl group from a progestational agent increases its affinity for the
progesterone receptor.v-?
Table (5.2) Relative binding affinity (RBA) for rat thymic
glucocorticoid receptor and rabbit uterus progesterone
receptor determined after 24h of incubation at O°C in rat
thymus and rabbit uterus preparation. Values for
dexamethasone and progesterone are 100 respectively.
(See fig. 5.2 for structure)
Code R
RBA
GR PR
RU 39305
RU 43044
RU 45526
RV 43230
(5.10) phenyl
(5.11) pMepheny I
(5.12) Me
(5.13) vinyl
57
130
26
90
0.1
0.2
14
11
OH
o
Figure 5.2
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~ Molecular Modellina:: Results and Discussion.
Alongside the synthetic work undertaken in this project, molecular
modelling was also carried out. The purpose of these studies was:
(i) to compare the steric and electronic features of molecules
which are known to have a high RBA for the progesterone and
glucocorticoid receptors;
(ii) to examine the extent to which the steroid synthesised in our
own work is compatible with these receptor features and thus to predict its
possible spectrum of activity.
The crystal structure of RV 38486 or of any of the other active anti-
hormonal steroids have not been published. However, the crystal structure
of RV 25593 (2.l19) has been reported. The crystallographic parameters
for this steroid were obtained from the S.E.R.C Crystallographic Data Base,
Daresbury Laboratory and imported into the 'Quanta' molecular modelling
program on a Silicon Graphics Machine (Indigo + Elan). All molecular
models of progesterone (1.15), ZK 98.734 (2.43), ZK 98.299 (2.41), Org
31343 (2.42) and the 11~,19-aryl steroid (2.44) were generated by changing
the functionalities of the above crystal structure, followed by energy
minimisation. Minimisations were carried out using Powell, steepest descent
and Newton-Raphson calculations. The structural and electronic
parameters of these molecular models were compared by overlapping the
model of RV 38486 (2.40) with the models of progesterone (LIS) (fig. 5.7),
ZK 98.734 (2.43) (fig. 5.8), ZK 98.299 (2.41) (fig. 5.9), Org 31343 (2.42)
(fig. 5.l0) and the 1l~,I9-aryl steroid (2.44) (fig. 5.11). In (fig. 5.10) the aryl
functionality is oriented above the C-ring.
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Structural comparisons of the molecular model for RV 38486 (2.40)
against the models of 19-norandrost-4,9(11)-dien-3-one steroids (ZK 98.734
(2.43) (fig. 5.8) and ZK 98.299 (2.41) (fig. 5.9)) show that there exists an
extremely good overlap of the steroid skeletons in ring A, B, C, the polar 3-
keto, 17-hydroxy and 11-(p-N,N-dimethylaminophenyl) groups. The
compound ZK 98.299 (2.41) is epimerized at positions C-13 and C-17. The
structural comparison (fig. 5.9) shows little overlap between the D rings,
however despite this difference the 17a-hydroxy group of ZK 98.299
(2.41) shows a surprisingly good overlap with the 17p-hydroxy group in
RV 38486 (2.40).
Structural comparisons between the molecular model of RV 38486
(2.40) and the models of compounds which posses sp3 hybridised carbon
atoms at positions C-9 and C-IO; progesterone (1.15) (fig. 5.7), Org 31343
(2.42) (fig. 5.10), and the l1p,19-aryl steroid (2.44) (fig. 5.11) all show a
good correlation between the positions of C, D rings of the steroid
skeletons, the polar 3-keto and 17p-hydroxy groups. There are however a
number of differences that can be observed in these comparisons. The
carbon atoms at positions C-l, C-2, C-9 and C-IO show some variation in
position to that observed for RV 38486 (2.40).
Progesterone (1.15) is structurally different from RV 38486 (2.40) in
that it possesses a C-19 methyl group and 17p-acetyl group but it does not
have a IIP-(p-N,N-dimethylaminophenyl) group. In the molecular
comparison (fig. 5.7), it can be seen that the polar 17p-hydroxy group of
RV 38486 (2.40) shows a good correlation in position with the polar 17P-
acetyl group of progesterone (1.15).
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The compound Org 31343 (2.42) and the 11~,19-aryl steroid (2.44)
both posses a p-N,N-dimethylaminophenyl substituent, which is attached at
position C-18 in Org 31343 (2.42) and at position C-l1~ in (2.44) with the
aryl group of (2.44) also attached at the ortho position to a C-19 methyl
group. In the structural comparison of the molecular models of these
molecules with that of RV 38486 (2.40) (fig. 5.10 and 5.11) it can be seen
that the orientation of the aryl group is different to that observed for RV
38486 (2.40). Despite this difference the polar dimethyl substituents in Org
31343 (2.42) show a close correlation to their position in RV 38486 (2.40).
A much clearer picture of the topology of the progesterone and
glucocorticoid receptor sites can be obtained by a molecular comparison
between three representative examples of 11~-aryl, 18-aryl and 11~, 19-aryl
steroids (fig. 5.12). In this representation, the C-18 aryl functionality of Org
31343 (2.42) is oriented above the C-ring of the other steroids. It was
postulated that two suitable amino acid residues may be located so that
they form hydrogen bonds with the polar C-3 and C-17 functionalities, thus
facilitating strong receptor binding+ On the basis of the close correlation
that is observed between the polar dimethylamino substituents (fig. 5.12), it
is postulated that within the hydrophobic pocket there exists an amino acid
residue which may enhance receptor binding through the formation of a
hydrogen bond with the polar amino group.
M Predicted Specificity.
A molecular comparison between RV 38486 (2.40) and 17~-
hydroxy-I'Zc-tprop-I- yne )-19-(p-(N ,N-dimethylaminophenyl) )androst- S-
ene (3.1) (fig. 5.13), shows that there is good overlap between the positions
of the respective polar oxygen at 3··keto, 17~-hydroxy groups and amino-
aryl nitrogens. In this representation (fig. 5.13), the C-19 aryl functionality
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of (3.1) is oriented to give the best fit with that of the ll-aryl group in RU
38486 (2.40). The carbon atoms at positions C-l, C-2 and C-IO do not
coincide with those in RU 38486 (2.40), but the polar aryl nitrogen shows a
close correlation of position to that in RU 38486 (2.40). The main
difference between the two molecules is the presence of an additional C-19
methylene group in 17~-hydroxy-17 a-(prop-l-yne )-19-(p-(N ,N-dimethyl
aminophenyl)) androst-S-ene-3-one (3.1).
Taking into account the molecular comparison between RU 38486
(2.40) and 17~-hydroxy-17a-(prop-l-yne)-19-(p-(N,N-dimethylamino
phenyl))androst-S-ene (3.1) (fig. S.13) and the work reported by Roussel-
Uclaf2-5, it is suggested that 17~-hydroxy-17a-(prop-l-yne)-19_(p_(N,N_
dimethylaminophenyl))androst-S-ene (3.1) will theoretically posses an
increased specificity for the glucocorticoid receptor.
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Figure 5.4 Computer generated map of the progesterone receptor
showing the lipophilic pockets above and below the plane of the
steroid; Front view.
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Figure 5.5 Computer generated map of the progesterone receptor
showing the lipophilic pockets above and below the plane of the
steroid; Rear view.
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o
RV 38486 (Mifeprisone) (2.40)
Figure 5.11
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Figure 5.12
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o
RV 38486 (Mifeprisone) (2.40)
o
17f3-hydroxy-17a-propynyl
-19-(P-(N,N-dimethylamino
phenyl»androst-5-ene (3.1)
Figure 5.13
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Chapter 6
6.1 Experimental.
All chemicals and solvents were purchased from Aldrich, Fluka,
Jansens and Sigma. The solvents were of SLR grade and dried where
necessary according to the procedure cited in the literature. I Melting
points were determined on a Gallenkamp Melting point Apparatus and
are uncorrected. Infrared spectroscopy was performed on samples in the
individual methods on a Perkin Elmer instrument (FT-IR 1720X
spectrometer) and recorded as wavenumber (cm+). IH NMR and 13C
NMR were performed on a Bruker AC 250 MHz or a Bruker AC 400
MHz spectrometers in CDCl3 solutions. Chemical shifts are quoted in
ppm (B) and TMS was used as an internal standard. Assignments of NMR
signal were made in accordance with the literature.e-' Low resolution El-
MS, CI-MS(NH4+) and FAB-MS were obtained on a Kratos MS-80 mass
spectrometer. High resolution El-MS and CI-MS(N14+) were obtained
from the SERC Mass Spectrometery Service Centre, University College of
Swansea. Microanalysis was carried out on a Leeman Labs. CE440
Elemental Analyser or obtained from Medac, BruneI University. Thin
layer chromatography was routinely used to follow reactions and
measurements were carried out using DC-Alufolien Kiesclgel 60 F254 (0.2
mm). Column chromatography was carried out using Kieselgel 60
(particle size 40-63 11m). Organic solvents were removed under reduced
pressure on a Buchi rotary evaporator.
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3~.6~·DihydrQxy.5a·brQmQandrQstan.17·Qne
3·acetate (3.57).
Dehydroisoandrosterone 3J3-acetate (3.14) (250 g, 0.76 mols) and
N-bromoacetamide (l57g, 1.33 mols, 1.50 equiv.) were together dissolved
in a solution of 1,4-dioxan (3.80 L), distilled water (450 ml), concentrated
perchloric acid (37 ml, 0.61 mols, 0.81 equiv.) and stirred for 30 minutes at
room temperature. During this period of time the reaction mixture slowly
developed from a pale yellow to a translucent deep orange solution. The
solution was decolourised with saturated sodium hydrogen sulphite
solution, and diluted in excess distilled water (10 L), to cause precipitation
of the steroid. The precipitate was filtered under reduced pressure,
washed with water and dried at room temperature under reduced pressure
over phosphorous pentoxide. The mixture (306.5g, 94%) was suspended
in chloroform (700 ml) at 0-5°C, stirred and filtered to afford (3.57)
(269.8g, 0.63 mols, 83.4%) m.p. 170-171 °c (lit.4-6 173-175°C), I.R. Vmax
(KBr cm+), 3479 (free OH), 1729 (>C=O); IH NMR and 13C NMR data
are shown in table 4.3 and 4.4; found C 58.95, H 7.33 found
(CzIH3104Br requires C 59.2 H 7.31); El-MS m/z; 428(M+), 426(M+), 346,
286; CI-MS(N~+) m/z; 446(MNH4+), 444(MNH4+), 382, 364, 347, 287,
304.
A small quantity of this material was recrystallised from acetone/hexane
furnishing needles m.p. 174 DC (lit.4-6 173-175°C)
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36-Hydroxy-sa-browo-66,19-oxjdoapdrostap_17_ope
3-acetate (3.58),
3~,6~-Dihydroxy-5a-bromoandrostan-17-one 3-acetate (3.57)
(0.53 g, 1.24 mmols) was refluxed for 18 hrs with lead tetraacetate (2.1 g,
3.8 equiv.) in dry benzene (50 ml). The solution was allowed to cool,
before being filtered and washed through with dichloromethane. The
combined organic layers were washed with sodium thiosulphate solution
(3 x 50 ml) and distilled water (50 ml). The organic phase was dried over
anhydrous magnesium sulphate and solvent removed under reduced
pressure. The crude product was purified by silica gel preparative thin
layer chromatography (acetonitrile/dichloromethane) to furnish (3.58)
(121 mg,23 %).
m.p. 185°C (lit.7,8 186-188°C), I.R. Vmax (nujol cm+), 1733 (>C=O); IH
NMR and l3C NMR data are shown in table 4.5 and 4.6; High resolution
El-MS m/z; 426.1182 (C21H2904Br requires 426.1230), 424.1200
(C2IH2904Br requires 424.1250); El-MS m/z; 426 (M+), 424 (M+), 285;
Cl-MS (NH4+) mlz ;444 (M Nl-4+), 442 (M Nl-4+), 364, 304, 285.
36-Hydroxy-sa-browo-66,19-oxjdoapdrostap_17_ope
3-acetate (3.58).
To a refluxing solution of carbon tetrachloride (dry 1 L) was added
lead tetraacetate (l30.7g, 294.79 mmols, 5 equiv.), immediately followed
by 3~,6~-dihydroxy-5a-bromoandrostan-17-one 3-acetate (3.57)
(25.09g, 58.71 mmols) and iodine (29.76g, 117.25 mmols, 2 equiv.). The
solution was allowed to reflux for 2 hrs during which time decolourisation
of the deep red solution occurred. The solution was allowed to cool,
before being filtered and the inorganic residue washed with
dichloromethane. The combined organic layers were washed with sodium
thiosulphate solution (3 x 400 ml) and distilled water (2 x 400 ml), dried
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over anhydrous magnesium sulphate and concentrated under vacuum to
afford a pale yellow solid (3.58) (25.04g, 58.71 mmols, 99.9%)
m.p. 183°C (lit,?,8 186-188C), I.R. Vmax (nujol crrr l), 1733 (>C=O); IH
NMR and l3C NMR data are shown in table 4.5 and 4.6; El-MS m/z; 426
(M+), 424 (M+), 285; Cl-MS (NH4+) m/z ; 444 (M NI-4+), 442 (M NI-4+),
364, 304, 285.
36-Hydroxy-5a-browo-66,19-oxidoapdrostap_17_ope
(3.59),
3~-Hydroxy-5a-bromo-6~, 19-oxidoandrostan-17-one 3-acetate.
(3.58) (l1.12g, 26.24 mmoI) was stirred together with sodium hydroxide
(1.13g, 3 equiv.), distilled water (7 ml), methanol (48 ml) and the
temperature maintained between 10-13aC, until precipitation occurred.
The precipitate was filtered, washed with distilled water and dried under
reduced pressure over phosphorous pentoxide to furnish a white powder
(3.59) (8.96 g, 2.4 mmols, 89.4 %) m.p. 201 -c (lit.? 199-201°C); I.R.
Vmax(nujol cm'); 3439 (free OH), 1721 (C=O);lH NMR and 13C NMR
data are shown in table 4.7 and 4.8; El-MS m/z; 384(M+), 382(M+), 285;
CI-MS(Nl4+) m/z; 402(MNl4+), 4OO(MNI-4+),302, 285.
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19-Hydroxyandrost-4-ene-3,17-djope (3.61)
To a stirred solution of 3p-hydroxy-5a-bromo-6p,19-
oxidoandrostan-17-one (3.59) (0.72g, 1.877 mmols) in acetone (14 ml),
cooled to 0-2°C was added dropwise a solution of chromic anhydride
(0.29g, 2.9 mmols, 1.5equiv.), sulphuric acid (0.5g, 4.70 mmols, 2.5 equiv.)
and distilled water (2.30 ml). After 30 minutes water was added to cause
the precipitation of a crystalline solid, which was then filtered, washed
with distilled water and air dried to give (3.60). 5a-Bromo-6p,19-
oxidoandrostan-3,17-dione (3.60) was without previous purification
refluxed with zinc powder (freshly activated, 1.21g) in ethanol (9 ml) for 3
hrs. The warm suspension was filtered and washed through with hot
ethanol. The combined ethanolic extracts were reduced under vacuum.
The solid was extracted with sulphuric acid 10% (1 ml) and chloroform (3
ml). The organic layer was washed with water (2 x 5 ml), saturated sodium
bicarbonate solution (5 ml), distilled water (5 ml), dried over anhydrous
magnesium sulphate, filtered and concentrated under vacuum. The
mixture was purified by silica gel preparative thin layer chromatography
(acetonitrile/dichloromethane), furnishing a white powder (120.4 mg, 0.40
mmols, 21.2% yield). m.p. 171°C (lit.? 168-170°C);I.R. Vmax (nujol cm+)
3295 (free O-H), 1721, 1688, 1618 ; El-MS m/z; 302(M+), 272; Cl-MS
(N~+) m/z; 320(MN~+), 303(MH+),272.
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36, 19-Djhydroxyandrostan-5-en -17 -ope 3 -acetate
(3.62),
3p-Hydroxy-5a-bromo-6p, 19-oxidoandrostan-17-one 3-acetate
(3.58) (12.8 g, 30.1 mmols), was allowed to reflux with zinc dust (25 g) in
ethanol (130 ml), for 4 hrs. The hot mixture was filtered and washed
through with hot ethanol. The combined ethanolic extracts were
evaporated to dryness under reduced pressure, redissolved in
dichloromethane (150 ml) and washed with distilled water (3 x 100 ml).
The organic layer was dried over anhydrous magnesium sulphate, filtered
and solvent removed under reduced pressure. The crude product was
recrystallised from acetone-hexane furnishing needles (8.16 g, 78.3%)
m.p. 167°C (litY 167-168°C); I.R. Vmax (nujol cm+), 3463 (free OH), 1716
(>C=O) ; IH NMR data is shown in table 4.10; El-MS m/z; 286, 255, 237;
CI-MS(NfI4+) m/z; 364(MNH4+), 347(MH+), 304, 287, 255.
36,19-Djhydroxyapdrost-5-ep_17_ope 3-acetate 19-
tosylate (3.63),
3p,19-Dihydroxyandrost-5-en-17-one 3-acetate (3.62) (9.68 g,
28.0 mmols) was stirred at room temperature for 18 hrs with tosyl chloride
(10.7 g, 2 equiv.), in dry pyridine (lOO ml). The reaction mixture was
poured into distilled water (200 mI) and extracted with dichloromethane
(3 x ISO ml). The combined organic extracts were washed with distilled
water (3 x 300 ml), dilute hydrochloric acid (2 M, 300 ml), aqueous
sodium hydrogen carbonate (300 ml) and water (300 ml). The organic
phase was dried over anhydrous magnesium sulphate, filtered and
evaporated to dryness under reduced pressure. The crude product was
purified by silica gel preparative thin layer chromatography
(acetonitrile/dichloromethane) furnishing a pale yellow solid (3.63)
(11.61 g,83%).
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m.p. 154°C (lit9 155-157°C); I.R. Vmax (nujol cm+), 1733 (>C=O);
IH NMR and 13C NMR data are shown in table 4.11 and 4.12 ; El MS
m/z; 368,329,268; Cl-MS (NJ--4+)m/z; 518(MNJ--4+),346, 329, 269.
36-Hydroxy-Sa-brorno-66,19-oxido-17,17 -ethylene
dioxyandrostane (4.3).
3~-Hydroxy-5a-bromo-6~,19-oxidoandrostan-17_one (3.58) (8.3
g, 21.7 mmols), was allowed to reflux with ethyleneglycol (45 ml), P:
toluenesulphonic acid (0.23 g, catalytic) and dry benzene (l70 ml), for 4
hrs., in Dean and Stark apparatus. The mixture was washed with distilled
water (3 x 100 ml), aqueous sodium bicarbonate (100 ml) and distilled
water (lOO ml). The organic phase was dried over anhydrous magnesium
sulphate, filtered and evaporated to dryness under reduced pressure. The
crude product was recrystallised from ethanol to furnish (4.3) (8.00g,
86.4%) m.p. 215°C (lit.? 216-217°C), I.R. Vmax (KBr crrr I), 3495 (free
OH); IH NMR and 13CNMR data are shown in table 4.13 and 4.14; CI-
MS(N~+) m/z; 444 (MN~+), 446 (MNJ--4+),428 (MH+), 426 (MH+), 329,
99.
36-Hydroxy-Sa-brorno-66,19-oxido-17,17_ethylene
dioxyandrostane 3-acetate (3.66),
3~-Hydrox y-5a- bromo-oji, 19-oxido-17, 17-ethylenediox y
androstane (4.3) (12.43 g, 29.1 mmols), was stirred at room temperature for
20 hrs with freshly distilled acetic anhydride (30 ml) and dry pyridine (60
ml). The solution was poured into distilled water (lOO ml) and extracted
with dichloromethane (3 x 100 ml). The combined organic extracts were
washed with distilled water (3 x 150 ml), aqueous sodium hydrogen
carbonate (150 ml), distilled water (150 ml), dried over anhydrous
magnesium sulphate and concentrated under vacuum to afford a pale
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brown solid which was purified by silica gel column chromatography
(acetonitrile/dichloromethane) (10.18 g, 74.6%) m.p. 166 DC (Iit.? 164-
165°C), I.R. Vmax (KBrcm-1), 1733 (>C=O); IHNMR and I3C NMR data
are shown in table 4.15 and 4.16; El-MS m/z; 470 (M+), 468 (M+), 329,
99.
36-Hydroxy -Sa- browo-66.19-oxjdo-17,17 -ethylene
djoxyandrostane 3-acetate (3.66).
3f3-Hydroxy-5a-bromo-6f3,19-oxidoandrostan_17_one 3-acetate
(3.58) (48.5 g, 114 mmols), was allowed to reflux with ethylene glycol
(240 ml), p-toluenesulphonic acid (1.2 g, 0.06 equiv., catalytic) and dry
benzene (900 ml) for 4 hrs. in Dean and Stark apparatus. The reaction
mixture was then allowed to cool before being washed with distilled
water (2 x 300 ml), sodium bicarbonate solution (2 x 300 ml) and distilled
water (300 ml). The organic layer was dried over anhydrous magnesium
sulphate, filtered under reduced pressure and the solvent removed under
reduced pressure to give a yellow oily residue (49.6g). The residue was
dissolved in dry pyridine (lOO ml) and stirred along with freshly distilled
acetic anhydride (50 ml), at room temperature for 12 hrs. The solution was
poured into distilled water (300 ml) and extracted with dichloromethane
(2 x 200 ml), The combined organic extracts were washed with distilled
water (3 x 250 ml), aqueous sodium hydrogen carbonate (250 ml),
distilled water (300 ml), dried over anhydrous magnesium sulphate and
concentrated under vacuum to give a pale brown solid which was
purified by silica gel column chromatography
(acetonitrile/dichloromethane) to afford (3.66) (25.04g, 58.71 mmols,
99.9%) m.p. 165 DC (lit.? 164-165°C), I.R. Vmax (KBr cm+), 1773 (>C=O);
IH NMR and l3C NMR data are shown in table 4.15 and 4.16; El-MS
m/z; 470 (M+), 468 (M+), 329, 237, 99.
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3~.19-Dibydroxy -17.17 -etbylenedjoxyandrostan -s-
ene 3-acetate (3.67),
3P-Hydroxy-5a-bromo-6p, 19-oxido-17, 17-ethylenedioxy
androstane 3-acetate (3.66) (23.4 g, 49.8 mrnols), was refluxed along with
zinc powder (45 g) and ethanol (100 ml, pH adjusted to 5.5 with glacial
acetic acid), for 3 hrs. The mixture whilst warm was filtered and washed
with hot ethanol, the inorganic residue was further washed with
dichloromethane. Solvent was removed from the combined organic
extract under reduced pressure. The residue was redissolved in
dichloromethane (200 ml) and washed with distilled water (3 x 100 ml).
The organic layer was dried over anhydrous magnesium sulphate and
solvent removed under reduced pressure to afford a pale yellow gum
(19.4 g), which was recrystallised from acetone-hexane furnishing needles
(l4.6 g, 37.4 mmol, 75 %) m.p. 140°C (lit.", 138-140oC); I.R. Vmax (KBr
cm+), 3494 (free OH), 1732 (C=O), 1712(C=O); IH NMR and l3C NMR
data are shown in table 4.17 and 4.18; found C 70.740 H 8.775
(C23H3305requires C 70.59 H 8,69); El MS m/z; 390 (M+), 372, 331, 313,
99; Cl -MS (NJ4+) m/z 408(MNH4+), 391(MH+), 331, 313, 99.
3~.19-DibydroxY-17.17-etbYlenedjoxyandrost_5_ene
3-acetate 19-tosylate (3.71 )L10
3P, 19-Dihydroxy-17, 17-ethylenedioxyandrost_5_ene 3-acetate
(3.67) (l.4g, 3.58 mmol) was stirred along with tosyl chloride (l.4g, 7.34
mmol, 2 equiv.), in dry pyridine (14 rnl), at room temperature for 18 hrs.
The reaction mixture was poured into water (20 ml) and extracted with
ethyl acetate (3 x 30 ml). The combined organic extracts were washed
with water (3 x 50 ml), dilute hydrochloric acid (50 ml), aqueous sodium
hydrogen carbonate (50 ml) and water ( 50 ml). The organic phase was
dried over magnesium sulphate, filtered and evaporated to dryness under
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reduced pressure to afford a yellow oily residue (1.72 g, 88 %) which was
purified by silica gel preparative thin layer chromatography
(acetonitrile/dichloromethane) furnishing a pale yellow gum (1.34 g,
68.7%). I.R. Vmax (KBr cm+), 1733 (>C=O); IH NMR data is shown in
table 4.19; CI-MS(Nf4+) m/z; 562(MNf4+), 545(MH+), 407, 389, 99.
J~,19-Djhydroxy -17,17 -ethylenedjoxyapdrost-5-epe
3-acetate 19-mesylate (4,5), 10
3~, 19-Dihydroxy-17, 17-ethylenedioxyandrost-5-ene 3-acetate
(3.67) (0.90 g, 2.30 mmol), was stirred along with mesyl chloride (O.60g, 1
equiv.), in dry pyridine (12 ml), at room temperature for 18 hrs. The
reaction mixture was poured into water (20 ml) and extracted with ethyl
acetate (3 x 15 ml). The combined organic extracts were washed with
water (3 x 30 ml), dilute hydrochloric acid (30 ml), aqueous sodium
hydrogen carbonate (30 ml) and water ( 30 ml). The organic phase was
dried over magnesium sulphate, filtered and evaporated to dryness under
reduced pressure to afford a yellow oily residue (1.02 g, 94%) which was
purified by silica gel preparative thin layer chromatography furnishing a
pale yellow gum (0.78 g, 72 %). I.R. Vmax (KBr cm+), 1734 (>C=O); IH
NMR and l3C NMR data are shown in table 4.20 and 4.21; El-MS m/z;
468(M+), 408, 309, 99.
2.2-dimethylpropan-1-ol 1-tosylate (4,6),
2,2-dimethylpropan-l-01 (1.10 g, 12.5 mrnol) was stirred at room
temperature for 18 hrs along with tosyl chloride (2.85 g, 1.2 equiv.) in dry
pyridine (30 ml). The reaction mixture was poured into distilled water (60
ml) and extracted with dichloromethane (3 x 40 ml). The combined
organic extracts were washed with water (3 x 70 ml), dilute hydrochloric
acid (2M, 80 ml), aqueous sodium hydrogen carbonate (70 ml) and
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distilled water (70 ml). The organic phase was dried over anhydrous
magnesium sulphate, filtered and evaporated to dryness under reduced
pressure. The crude product was recrystallised from ether (1.66 g, 54.9%).
m.p. 4SoC (lit.U 4S-49°C); I.R. Vmax (KBr crn+), no free OH signal; the IH
NMR and l3C NMR data are shown in table 4.22 and 4.23; El-MS m/z;
242,92.
1-phenyl-2,2-dimethylpropap_l_ol (4.13).
2,2-Dimethylpropanal (1g, 11.6 mmol) was stirred with diethyl ether
(dry, 20 ml) and cooled with dry ice. To this solution was added dropwise
phenyl lithium solution in ether (10 ml, 1.S M, 17.S mmol, 1.5 equiv.) and
was stirred for 1 hour. The solution was quenched with aqueous
ammonia (10 ml) and extracted with dichloromethane (3 x 40 ml). The
combined organic extracts were washed with distilled water (3 x SOml),
aqueous sodium hydrogen carbonate (SOml) and distilled water (SO ml).
The organic phase was dried over anhydrous magnesium sulphate, filtered
and evaporated under reduced pressure to afford a solid (1.23 g, 64.5 %).
m.p. 44°C (lit.I2 43-45°C), the IH NMR and l3C NMR data are shown in
table 4.24 and 4.25; El-MS 164(M+), 107.
1-phenyl-2,2-dimethylpropan_1_ol (4.13).
Dry magnesium turnings (0.34 g, 1.2 equiv.) were placed into a dry
flask equipped with condenser and dropping funnel under nitrogen.
Freshly dried and distilled tetrahydrofuran (15 ml) was added so as to the
flask to just cover the magnesium turnings. A small iodine crystal was
added to the mixture which was stirred and the flask was gently warmed
with an air gun. To this stirred solution was slowly added a solution of
freshly distilled bromo benzene (2.19 g, 1.2 equiv.) dissolved in dry
tetrahydrofuran (40 ml) at a rate sufficient to maintain a steady reflux. At
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the start of addition, the formation of the Grignard reagent was initiated
by warming the flask such that the mixture just began to reflux. The
solution was stirred for 30 minutes. To the stirred solution was added
dropwise 2,2-dimethylpropanal (1.02 g) dissolved in dry tetrahydrofuran
(20 ml) at a rate sufficient to cause the reaction mixture to gently reflux.
The solution was stirred for 45 minutes, before being quenched with
aqueous ammonia (30 ml). The reaction mixture was extracted with
tetrahydrofuran (3 x 30 ml), the combined organic extracts were washed
with distilled water, dried over anhydrous magnesium sulphate and
evaporated to dryness under reduced pressure to give (1.72, 90.2 %). m.p.
42°C (lit.12 43-45°C) The 1H NMR and l3C NMR data are shown in table
4.24 and 4.25; El-MS 164, 107.
1-(p-N.N -dimethylamipophenyJ)_2.2_dj methyl
propan -1-01 (4.15),
Dry magnesium turnings (0.34 g) were placed into a dry flask
equipped with condenser and dropping funnel under nitrogen. Freshly
dried and distilled tetrahydrofuran (20 ml) were added so as to the flask to
just cover the magnesium turnings. A small iodine crystal was added to
the mixture which was stirred and the flask was gently warmed with an
air gun. To this stirred solution was slowly added a solution of p-bromo-
N,N-dimethylaniline (2.79 g, 1.2 equiv.) dissolved in dry tetrahydrofuran
(20 ml) at a rate sufficient to just maintain a reflux, the solution was
stirred for 30 minutes. To the stirred solution was slowly added dropwise
2,2-dimethylpropal (1 g,) dissolved in dry tetrahydrofuran (10 ml) at such
a rate as to only cause the reaction mixture to gently reflux. The solution
was stirred for 45 minutes, before being quenched with aqueous ammonia
(30 ml). The reaction mixture was extracted with tetrahydrofuran (3 x 30
ml). The combined organic extracts were washed with distilled water (3 x
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70 ml), dried over anhydrous magnesium sulphate and evaporated to
dryness under reduced pressure. The crude product was purified by silica
gel column chromatography (acetonitrile/dichloromethane) to afford a
grey solid (1.78g, 74.0 %). I.R. Vmax(nujol cm+) 3612 (free OH); The IH
NMR and l3C NMR data are shown in table 4.26 and 4.27; CI-MS(NIf4+)
m/z; 208, 151.
1-(p-N,N-dimethylamioophenyn-2,2_djmethyl
propane (4.16).
Lithium aluminium hydride (310 mg, 3.3 equiv.) and aluminium
chloride (1.00 g, 3 equiv.) were refluxed with dry diethyl ether (20 ml), for
15 minutes. To this refluxing solution was added l-(p-N,N-
dimethylaminophenyl)-2,2-dimethylpropan_l_o1 (4.15) (0.52 g, 2.5 mmols)
in dry diethyl ether (20 ml). The green mixture was allowed to reflux for
15 minutes and the reaction quenched with aqueous sodium hydrogen
carbonate (20 ml). The mixture was extracted with dichloromethane (3 x
50 ml) and the combined organic extracts were washed with distilled
water (2 x 70 ml). The organic solution was dried over anhydrous
magnesium sulphate, filtered and evaporated to dryness under reduced
pressure to give a gum. The residue was purified by silica gel preparative
thin layer chromatography (acetonitrile/dichloromethane) to give a brown
oil (0.21 mg, 43%). I.R. Vmax (nujol crrr+) (no free OH);IH NMR and data
is shown in table 4.28; CI-MS(NIf4+) m/z; 192 (MH+), 135,91,57.
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3~-Hydroxy-17,17-ethylenedioxyapdrostap-5-ep-19-
ope 3-acetate (3.68).
Chromium trioxide (15.2 g, 38.9 mmol), was slowly added to a
stirred solution of dry pyridine (40 ml) and dry dichloromethane. (820 ml).
The solution was stirred for 15 minutes at room temperature. To this
stirred solution was added 3~, 19-dihydroxy-17, 17 -ethylenedioxy
androstan-5-ene 3-acetate (3.68) (15.2 g), in dry dichloromethane (55 ml).
The solution was stirred for a further 15 minutes after which the organic
layer was decanted and the tarry residue leached with ether (4 x 100 ml)
and dichloromethane (3 x 100 ml). Solvent was removed under reduced
pressure from the combined organic extracts to afford a dark brown oily
residue which was redissolved in dichloromethane and filtered through a
bed of celite to remove any inorganic matter. Solvent was removed under
reduced pressure from the organic filtrate affording a pale yellow gum
(14.8 g, 38.1 mmol). The residue was recrystallised from acetone/hexane
furnishing needles (12.2 g, 31.4 mmol, 84 %). m.p. 150°C (lit.? 148°C);
I.R. Vmax (nujol cm+), 1730 (C=O), 1712 (C=O); IH NMR and l3C NMR
data are shown in table 4.29 and 4.30; found C 71.18 H 8.27 (C24H3204
requires C 71.11 H 8.30); El-MS m/z; 388(MH+), 328, 289, 229, 99.
3~,19-Dihydroxy-17, 17-ethylepedioxy -19-phenyl-
apdrost-5-epe (4.17).
To a stirred solution 3~-hydroxy-17,17-ethylenedioxyandrostan-5-
en-19-one 3-acetate (3.68) (l.33 g, 3.42 mmols) dissolved in dry
tetrahydrofuran was slowly added a solution of phenyl lithium (7.6 ml. 1.8
M, 4 equiv.). The solution was stirred for 3 hrs, before being quenched
with aqueous ammonia. The reaction mixture was decanted and the
inorganic residue was leached with tetrahydrofuran. The combined
organic extracts were washed with distilled water, dried over anhydrous
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magnesium sulphate and evaporated to dryness under reduced pressure.
The crude product was purified by silica gel preparative thin layer
chromatography (acetonitrile/dichloromethane) to give a gum (1.18g, 81
%). I.R Vmax (CHCI3), 3420 (free OH); IH NMR and 13CNMR data are
shown in table 4.31 and 4.32; high resolution CI-MS(NH4 +) m/z;
425.2690(MH+) (C27H3704requires 425.2692); El-MS m/z 318,307,300,
219,201 105,99; CI-MS(NH4+) m/z; 425(MH+), 407,319,238, 107,99.
3~.19-Dihydroxy-17. 17-ethylenedjoxy -19- phenyl-
androst-5-ene (4.17),
Dry magnesium turnings (0.24 g, 5 equiv.) were placed into a dry
flask equipped with condenser and dropping funnel under nitrogen.
Minimum freshly dried and distilled tetrahydrofuran (45 ml) was added to
the flask to just cover the magnesium turnings. A small iodine crystal was
added to the stirred mixture and the flask was gently warmed with an air
gun. To this stirred solution was slowly added freshly distilled
bromobenzene (1.54g) dissolved in dry tetrahydrofuran (30 ml) at a rate
sufficient to just maintain a reflux. The solution was stirred for 30
minutes. To the stirred solution was slowly added 3~-hydroxy-17 ,17-
ethylenedioxyandrostan-5-en-19-one 3-acetate (0.76 g, 2.0 mmols)
dissolved in dry tetrahydrofuran (20 ml) at such a rate as to only cause
the reaction mixture to gently reflux. The solution was stirred for 2 hrs,
before being quenched with aqueous ammonia (80 ml). The reaction
mixture was extracted with dichloromethane (3 x 60 ml) and the
combined organic extracts were washed with distilled water (3 x 100 ml),
dried over anhydrous magnesium sulphate, filtered and evaporated to
dryness under reduced pressure. The residue was purified by silica gel
preparative thin layer chromatography to give a gum (0.57,68.2 %).
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I.R Vmax (CHCI3), 3420 (free OH); 1H NMR and l3C NMR data are
shown in table 4.31 and 4.32; high resolution CI-MS(NH4 +) m/z;
425.2690(MH+) (C27H3704requires 425.2692); El-MS m/z 318,307,300,
219,201 105,99; CI-MS(NH4+) m/z; 425(MH+), 407,319,238,107,99.
3~,19-Dibydroxy-17,17 -etbylepedjoxy-19-(p-N,N-
djmetbylamipopbenynapdrost-S-epe (4.21>'
Dry magnesium turnings (1.41 g) were placed into a dry flask
equipped with condenser and dropping funnel under nitrogen. Minimum
freshly dried and distilled tetrahydrofuran (45 ml) was added to the flask
to just cover the magnesium turnings. A small iodine crystal was added to
the mixture which was stirred and the flask was gently warmed with an
air gun. To this stirred solution was slowly added a solution of p-bromo-
N,N-dimethylaniline (11.59 g) dissolved in dry tetrahydrofuran (40 ml). At
the start of addition the formation of the Grignard reagent was initiated
by warming the flask such that the mixture just began to reflux. The
refluxing of the solution was sustained by the exothermic nature of
formation of the Grignard reagent. The solution was stirred for 30
minutes. To the stirred solution was slowly added 3~-hydroxy-17, 17-
ethylenedioxyandrostan-5-en-19-one 3-acetate (9.02 g, 19.3 mmols)
dissolved in dry tetrahydrofuran (90 ml) at a rate sufficient to cause the
reaction mixture to gently reflux. The solution was stirred for 3 hrs,
before being quenched with aqueous ammonia. The reaction mixture was
decanted and the inorganic residue leached with tetrahydrofuran. The
combined organic extracts were washed with distil1ed water, dried over
anhydrous magnesium sulphate and evaporated to dryness under reduced
pressure affording a dark green oily residue (27.9 g). The oily residue was
redissolved in minimum dichloromethane and treated with minimum
hexane to cause the solution to become permanently cloudy and a green
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residue separated from solution. The organic layer was decanted, the
residue dissolved in warm dichloromethane and stirred with charcoal. The
solution was filtered, evaporated to dryness under reduced pressure
giving a green gum (7.37,68.3 %).
I.R. Vmax (CHCI3 cm') 3605 (free OH); IH NMR and l3C NMR data are
shown in table 4.33, 4.34 and 4.35; high resolution FAB-MS m/z;
468.3092 (C29fI4104N requires 468.3114); El-MS m/z 449,299, 200, 150,
99; CI-MS(NfI4+) m/z; 468 (MfI4+), 450, 329, 236, 150,99; FAB-MS; 468
(MH+), 450, 317,150,99.
3~- Hydroxy -17 -(2-hydroxyethoxy)-19-(p-N,N-
djmethylaminophenynandrost-5-ene (4.24).
Lithium aluminium hydride (33.8 mg, 4 equiv.) and aluminium
chloride (118.6 mg, 4 equiv.) were refluxed with dry diethyl ether (10 ml),
for 15 minutes. To this solution was added 3~,19-dihydroxy-17,17-
ethylenedioxy-19-(p-N,N-dimethylaminophenyl)androst-5-ene (4.21) (104
mg, 0.22 mmols) in dry diethyl ether (5 ml). The green mixture was
allowed to reflux for 15 minutes and the reaction quenched with ethyl
acetate followed by aqueous sodium hydrogen carbonate (20 ml). The
solution was washed with ethyl acetate (3 x 30 ml) and the combined
organic extracts were washed with distilled water (2 x 40 ml), aqueous
sodium hydrogen carbonate (40 ml) and distilled water (40 ml). The
organic solution was dried over anhydrous magnesium sulphate, filtered
and evaporated to dryness under reduced pressure to give an oily residue.
The residue was purified by silica gel preparative thin layer
chromatography (acetonitrile/dichloromethane) to give (15 mg, 15%). 'H
NMR and l3C NMR data are shown in table 4.36 and 4.37; high
resolution CI-MS(NH4+) m/z; 454.3261 (C29H4303N requires 454.3323);
El-MS m/z; 453 (M+), 435, 419, 392, 374, 301, 258, 239, 134; CI-
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MS(N14+) m/z; 454 (MH+), 436, 391, 239,134; FAB-MS(NBA) m/z; 454
(MH+), 436,391,239,134.
J.~,19-Dihydcoxy-19(p-dimethylaminophenyl)
apdcostan-5-en-17 -ope (4.25).
3~,19-Dihydroxy-17, 17-ethylenedioxy-19-(p-N,N-dimethylamino
phenyl)androst-5-ene (4.21) (7.66 g, 16.4 mmols) was dissolved in
acetone (130 ml) and stirred with hydrochloric acid (4M, 35 ml). The
solution was stirred for 10 minutes before being quenched with saturated
sodium hydrogen carbonate solution (100 ml). The aqueous solution was
extracted with dichloromethane (3 x 100 ml), the combined organic
extracts were dried over anhydrous magnesium sulphate and solvent
removed under reduced pressure to afford an oily residue (6.21g) which
was purified by silica gel column chromatography to give a gum (2.93 g,
42.3%)
I.R. Vmax (CHCb crn') 3691, 3606 (free OH), 1600 (>C=O); IH NMR and
l3C NMR data are shown in table 4.38 and 4.39; El-MS m/z 405,150; CI-
MS(NH4+) m/z; 406, 273, 256,273,256,150; FAB-MS m/z; 406,255.
J.~.17 -DihYdco xy -19 -(p -N,N & d imeth y Iamin 0phen y I)
apdcostap-5-ene (4.26),
To a refluxing solution of aluminium chloride (0.94 g, 4 equiv.) and
lithium aluminium hydride (0.27 g, 4 equiv.), in dry ether (30 ml) was
added 3~, 19-dihydroxy-19-(p-N,N-dimethylaminophenyl)androst-5-en-
17-one (4.25) (0.748 g, 1.8 mmols) and refluxed for 15 minutes. The
reaction mixture was slowly quenched with ethyl acetate followed by
distilled water. The aqueous solution was treated with aqueous sodium
hydrogen carbonate solution (40 ml) and extracted with dichloromethane
(4 x 40 ml). The combined organic extracts were dried over anhydrous
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magnesium sulphate and solvent removed under reduced pressure to give
a solid. The solid was recrystallised from acetone furnishing needles (352
mg, 48.76 %). m.p. 234°C; I.R. Vmax (CHCI3 cm+) 3603, 3435 (free OH);
1H NMR and 13CNMR data are shown in table 4.40 and 4.41; found C
78.94, H 7.64 N 3.42 (C27H3902N requires C 79.17 H 7.60 N 3.42); high
resolution CI-MS(N14+) m/z; 410.3059 (C27H4002N requires 410.3060);
El-MS m/z; 409(M+), 274, 256,134; CI-MS(NH4+) m/z; 427, 410(MH+),
392,275,257, 134.
3~.17~-DihydrQxy-17a-(prQP-l-YDe)aDdrQst-5-eDe (4.30).
To a solution of tetrahydrofuran (150 ml) saturated with propyne
at O°C,was slowly added n-butyllithium solution (in hexane/ether 1.2 ml,
8.0 M), without raising the temperature. The solution was stirred for 30
minutes at O°C, before a solution of 3~-hydroxyandrost-5-en-17-one
(4.29) (1.2 g, 4.16 mmol) dissolved in dry tetrahydrofuran (50 ml) was
slowly added. The reaction mixture was stirred for 30 minutes, before
being poured into distilled water (300 ml) and treated with sodium
hydrogen carbonate solution (50 ml). The aqueous solution was
extracted with dichloromethane (3 x 200 ml) and the combined organic
extracts were washed with distilled water (3 x 250 ml), dried over
anhydrous magnesium sulphate, filtered under reduced pressure and
evaporated to dryness under reduced pressure to afford an oily residue
(1.28 g, 93%) which was purified by silica gel preparative thin layer
chromatography (acetonitrile/dichloromethane) to furnish a solid (1.13 g,
82.7%). m.p. 177°C (lit.13 177-179°C), IH NMR and l3C NMR data are
shown in table 4.42 and 4.43; El-MS m/z; 328 (M+), 310; CI-MS(NH4+)
m/z; 328,311.
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3~,17~,19- Tribydroxy-17a-(prop-l-yne)-19-(p-N,N-
djmetbylaminopbenyllandrost-S-ene (4.27).
To a solution of tetrahydrofuran (l50 ml) saturated with propyne
at O°C, was slowly added n-butyllithium solution (in hexane/ether 5 mI,
8.0M), without raising the temperature. The solution was stirred for 30
minutes at O°C, before 3~, 19-dihydroxy-19-(p-N ,N -dimethylamino
phenyl)androst-5-en-17-one (4.25) (2.44 g) dissolved in dry
tetrahydrofuran (lOO ml) was slowly added. The reaction mixture was
stirred for 30 minutes, before being poured into distilled water (400 ml)
and treated with sodium hydrogen carbonate solution (200 ml). The
aqueous solution was extracted with dichloromethane (3 x 300 ml) and
the combined organic extracts were washed with distilled water (3 x 250
ml), dried over anhydrous magnesium sulphate, filtered under reduced
pressure and evaporated to dryness under reduced pressure to afford an
oily residue (2.5 g) which was purified by silica gel preparative thin layer
chromatography (acetonitrile/dichloromethane) to furnish a green gum
(1.43 g, 53.5%).
I.R. Ymax (CRC13 cm') 3436, 3602 (free OR); IR NMR and l3C NMR
data are shown in table 4.44 and 4.45; El-MS m/z; 463 (M+), 445, 405,
295, 150; CI-MS(N1f4+) m/z; 464 (MH+), 446, 406, 337, 314, 313,296,
274,256, 150.
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J~,17~-Dihydroxy-17a-(prop-l-ype)-19-(p-N,N -
djmethylamipophenyllapdrost-5-epe (4.29),
To a refluxing solution of aluminium chloride (1.43 g, 4 equiv.) and
lithium aluminium hydride (0.41 g, 4 equiv.), in dry ether (30 ml) was
added 3P, 17p,19-trihydroxy-17a-(prop-1-yne)-19-(p-N,N-dimethylamino
phenyl)androst-5-ene (4.27) (1.24 g, 2.7 mmols) and refluxed for 15
minutes. The reaction mixture was then slowly quenched with ethyl
acetate followed by distilled water. The solution was treated with
aqueous sodium hydrogen carbonate solution (lOO ml) and extracted
with dichloromethane (3 x 250). The combined organic extracts were
dried over anhydrous magnesium sulphate and solvent removed under
reduced pressure to afford a gum which was purified by silica gel column
chromatography (acetonitrile/dichloromethane) to furnish (4.31) (220 mg,
17.8%).
I.R. Vmax (CHCI3 cm') 3604, 3444 (free OH); IH NMR and l3C NMR
data are shown in 4.46 table and 4.47; high resolution El-MS m/z;
447.3137 (C30H4102N requires 447.3137); El-MS m/z; 447 (MH+), 429,
407, 389,134; CI-MS(N~+) m/z; 448 (MH+), 408, 134; FAB-MS m/z; 448
(MH+), 409, 134.
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J.~,17~-Dibydroxy-17a-(prop-l-yue)-19-(p-N,N -
dimetbylamiuopbeuyllaudrost-4-eue-3-oue (3.1).
3~,17~-Dihydroxy-17a-(prop-l-yne)-19-(p-N,N-dimethylamin0
phenyl)androst-5-ene (4.31) (200 g, 0.45 mmols) was refluxed for 3 hrs
with aluminium isopropoxide (367 g, 4 eqiv) in dry acetone (50 ml). The
solution was treated with aqueous sodium hydrogen carbonate solution
(20 ml) and extracted with dichloromethane (3 x 50ml). The combined
organic extracts were dried over anhydrous magnesium sulphate and
solvent removed under reduced pressure. The crude product was purified
by silica gel preparative thin layer chromatography (acetonitrile/
dichloromethane) to furnish (3.1) (11.2 mg, 5.6%).
1H NMR and l3C NMR data are shown in. table 4.48 and 4.49; high
resolution El-MS m/z; 445.2981 (C30H3902N requires 445.2981); El-MS
m/z; 445 (MH+), 405, 311, 271, 134; CI-MS(NH4+) m/z; 446 (MH+), 406,
312,272, 134; FAB-MS m/z; 448 (MH+), 409, 134.
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